Abstract Funding Sources* AGA Oral and Poster ... · Abstract Funding Sources* AGA Oral and Poster Presentations at DDW® 2019 AGA Institute 4930 Del Ray Avenue Bethesda, MD 20814

Abstract Funding Sources*

AGA Oral and Poster Presentations at DDW® 2019

AGA Institute 4930 Del Ray Avenue Bethesda, MD 20814 301.654.2055 (National Office) 301.654.3978 (Fax) www.gastro.org

* Information contained in this report is current as of April 22, 2019.

http://www.gastro.org/

AGA Oral Presentations

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

1. . . . HUMAN INDUCED PLURIPOTENT STEM CELL-DERIVED MESENCHYMAL… (2*) 2. . . . STEM CELL-DERIVED 3D ORGANOIDS RECAPITULATE FEATURES… (2*) 3. . . . A NEW FORM OF HUMAN ROTAVIRUS… (2*) 4. . . . FIRST LARGE SCALE STUDY DEFINING THE… (4*) 5. . . . MICROBIOTA-DEPENDENT BEHAVIORAL ABNORMALITIES IN THE ZONULIN… (2*) 6. . . . INTESTINAL MICROBIAL FUNCTIONAL CONTENT BETTER DEFINES… (4*)|(2) 7. . . . THE ICON STUDY: INFLAMMATORY BOWEL DISEASE… (6*)|(2) 8. . . . POPULATION-SCALE MICROBIOME ANALYSIS DEFINES A NEW… (2*) 9. . . . PREVALENCE AND PREDICTORS OF GERD AND… (3*)|(Ironwood Pharmaceuticals) 10. . . . EFFECT OF RECENTLY DESCRIBED ADVERSE EVENTS… (5*) 11. . . . THE EFFECT OF REBAMIPIDE IN PATIENTS… (3*)|(Korea Otsuka Pharmaceutical Co., Ltd.) 12. . . . IMPACT OF IW-3718, A NOVEL GASTRIC-RETENTIVE… (3*)|(Ironwood Pharmaceuticals) 13. . . . ANTIREFLUX SURGERY WITHIN SIX MONTHS AFTER… (5*) 14. . . . PANCREATIC AND HEMATOPOIETIC CALCINEURIN INDEPENDENTLY MEDIATE… (2*) 15. . . . SOLUTE TRANSPORTER SLC26A9 LOCALIZES TO THE… (2*) 16. . . . IMMUNE PROFILING OF THE HUMAN PANCREAS… (2*) 17. . . . DYNAMIC ASSOCIATION OF SYSTEMIC INFLAMMATION, GUT… (2*) 18. . . . ROLE OF SONIC HEDGEHOG PATHWAY IN… (2*)|(5) 19. . . . KRÜPPEL-LIKE FACTOR 5 PLAYS AN IMPORTANT… (4*) 20. . . . TRANSCRIPTOME ANALYSIS DURING PROGRESSION OF CHRONIC… (4*)|(Nil)

21. . . . EFFICACY AND SAFETY OF URSODEOXYCHOLIC ACID… (3*)|(Daewoong Pharmaceutical Co., Ltd.) 22. . . . CAN CHOLECYSTITIS BE AN ADVERSE EVENT… (5*) 23. . . . BILIARY DILATION IN PATIENTS WITH NORMAL… (2*)|(4) 24. . . . TIMING OF CHOLECYSTECTOMY AFTER ACUTE BILIARY… (5*) 25. . . . UNDERLYING EATING DISORDER PATHOLOGY IN CHRONIC… (5*) 26. . . . THE EFFECT OF RECREATIONAL MARIJUANA USE… (7*)|(2) 27. . . . TRANSLUMBOSACRAL NEUROMODULATION THERAPY FOR FECAL INCONTINENCE:… (2*) 28. . . . DEFECATORY FUNCTION TESTING IN FI PATIENTS… (2*) 29. . . . RESTORATION OF FECAL CONTINENCE IN A… (6*) 30. . . . NORMAL VALUES FOR ANORECTAL PRESSURES MEASURED… (2*)|(3)|(Medspira Inc) 31. . . . ENDOSOMAL SNX17 SETS THE PLASMA MEMBRANE… (2*) 32. . . . UNIQUE REGULATION OF INTESTINAL EPITHELIAL CELL… (2*) 33. . . . GLP-2 INCREASES ELECTROGENIC ANION SECRETION AND… (2*)|(3)|(Shire Pharmaceuticals) 34. . . . E.COLI HEAT STABLE ENTEROTOXIN (ST) INHIBITION… (2*)|(6) 35. . . . SHIGELLA GASTROENTERITIS TARGETS INTESTINAL URATE TRANSPORTER… (2*) 36. . . . GLUCOCORTICOIDS AND SGK1- POTENT REGULATORS OF… (2*) 37. . . . METHYLATION CHANGES AT THE GNAS IMPRINTED… (7*) 38. . . . ENDOSCOPIC ULTRASOUND-GUIDED FINE NEEDLE BIOPSY HAS… (5*) 39. . . . AGE, OBESITY, DIABETES AND INITIAL CYST… (5*) 40. . . . TRIACYLGLYCEROLS AS A MARKER FOR CHARACTERIZATION… (2*)

41. . . . THE DUTCH AMERICAN RISK STRATIFICATION TOOL… (5*) 42. . . . THIOPURINE METABOLITE LEVELS IN PREGNANT IBD… (4*)|(6) 43. . . . PREGNANCY OUTCOMES IN INFLAMMATORY BOWEL DISEASE… (5*) 44. . . . INFLIXIMAB CLEARANCE IS DECREASED DURING 2ND… (1*) 45. . . . LONG-TERM OUTCOMES OF IN-UTERO EXPOSURE TO… (6*) 46. . . . SAFETY OF FLEXIBLE SIGMOIDOSCOPY IN PREGNANT… (5*) 85. . . . SIRT2 REGULATES INTESTINAL CELL PROLIFERATION AND… (2*) 86. . . . HEAT SHOCK PROTEIN GP96 IS ESSENTIAL… (4*) 87. . . . MIR-181A-5P CONTRIBUTES TO INTESTINAL CELL DIFFERENTIATION… (2*) 89. . . . MULTITARGET STOOL DNA TESTING AS ALTERNATIVE… (6*) 90. . . . POST-COLONOSCOPY MORTALITY IN A FIT-BASED COLORECTAL… (2*) 91. . . . INTERVAL CANCERS AFTER A NEGATIVE FAECAL… (2*) 92. . . . COMPARING THE COST-EFFECTIVENESS OF NEW COLORECTAL… (2*) 93. . . . FACTORS ASSOCIATED WITH THE PROGRESSION OF… (7*)|(4) 94. . . . SYSTEMATIC SCREENING PROTOCOL FOR THE STOMACH… (2*) 95. . . . SERUM PROTEOMIC PROFILING IN ULCERATIVE COLITIS… (4*) 96. . . . INCREASED INTESTINAL PERMEABILITY IS A PREDICTOR… (6*)|(2) 97. . . . INCREASED RISK OF ULCERATIVE COLITIS IN… (5*) 98. . . . HORMONE THERAPY FOR CANCER IS A… (6*)|(The Chemotherapy Foundation, philanthropic organization) 99. . . . INFLAMMATORY BOWEL DISEASE IN UK PRIMARY… (6*) 100. . . . LONGITUDINAL CHANGES IN THE DIRECT COSTS… (6*)|(Crohn's and Colitis Cada)


* = Primary Source



101. . . . INCREASED EXPRESSION OF MELATONIN IN THE… (2*) 102. . . . PHYSIOLOGICAL AND PROTEOMIC CHARACTERIZATION OF CAMPYLOBACTER… (2*)|(NIH K23 DK103911) 103. . . . BENEFICIAL EFFECTS OF A LOCALLY ADMINISTERED… (2*)|(4) 104. . . . ASSOCIATIONS BETWEEN FECAL SHORT CHAIN FATTY… (4*) 105. . . . SACCHAROMYCES BOULARDII, A YEAST PROBIOTIC, REGULATES… (5*) 106. . . . ALTERED GENDER DIFFERENCE IN BRAIN HISTAMINE… (2*) 107. . . . DISCONTINUITY OF CARE AMONG INFLAMMATORY BOWEL… (5*) 108. . . . THE PREVALENCE AND USE OF CANNABIS… (5*) 109. . . . ORAL VANCOMYCIN INDUCES AND MAINTAINS REMISSION… (5*) 110. . . . STOPPING 5-AMINOSALICYLATES IN CROHN'S DISEASE PATIENTS… (6*) 111. . . . INCREASING VACCINATION RATES WITH A PATIENT… (5*) 112. . . . TELEPHONE STRAIGHT-TO-TEST (TSTT) IMPROVES EARLY DIAGNOSIS… (5*) 113. . . . HIGHER RESILIENCE IS ASSOCIATED WITH DECREASED… (5*) 114. . . . TISSUE-ENGINEERED INTESTINES CAN NEO-INNERVATE EXPERIMENTALLY DENERVATED… (2*) 115. . . . TRANSCUTANEOUS AURICULAR VAGAL NERVE STIMULATION IMPROVES… (5*) 116. . . . ELECTROGASTOGRAPHY AT BASELINE AND RESPONSE TO… (5*) 117. . . . SYNDAPIN 2 IS REQUIRED FOR MICROVILLUS… (2*) 118. . . . ACTIVATION OF THE UNFOLDED PROTEIN RESPONSE… (2*) 119. . . . RNA-BINDING PROTEIN HUR REGULATES AUTOPHAGY ACTIVITY… (2*) 120. . . . MITOCHONDRIAL IMPAIRMENT IN CROHN'S DISEASE-LIKE INFLAMMATION… (2*)

121. . . . HIGH CONTENT MORPHOLOGICAL ANALYSES OF ESOPHAGEAL… (2*)|(4) 122. . . . CALPONIN-HOMOLOGY AND MICROTUBULE-ASSOCIATED PROTEIN INTERACTS WITH… (2*) 144. . . . POSTOPERATIVE ENDOSCOPIC AND CLINICAL RECURRENCE AFTER… (6*)|(7) 145. . . . INFLAMMATORY POTENTIAL OF DIET IS NOT… (2*) 146. . . . GUT MICROBIAL DYSBIOSIS CONTRIBUTES TO FATIGUE… (6*)|(3) 147. . . . PEPT1 ENHANCED BACTERIAL PEPTIDE TRANSPORT INTO… (2*) 148. . . . SLC7A5 IS CRUCIAL FOR MAITENANCE OF… (2*) 149. . . . IN-DEPTH CHARACTERIZATION OF HOST-GENETICS AND GUT… (4*)|(2) 150. . . . SINGLE-CELL ANALYSIS OF T CELL PATHOGENESIS… (4*) 151. . . . USING DEEPLEARNING AND GENETIC BIGDATA TO… (2*)|(6) 152. . . . PENTOXIFYLLINE TREATMENT IN ACUTE PANCREATITIS: FEASIBILITY… (2*) 153. . . . CORONIN 1 IS NECESSARY FOR M… (2*) 154. . . . GUT MICROBE-PRODUCED SHORT CHAIN FATTY ACIDS… (2*)|(4) 155. . . . PRIMARY AND PLURIPOTENT STEM CELL DERIVED… (2*)|(4) 156. . . . H. PYLORI INDUCES GASTRIC EPITHELIAL CELL… (2*) 157. . . . THE INTESTINAL MICROENVIRONMENT INDUCES A TRANSCRIPTION… (4*) 158. . . . LEVERAGING HUMAN INTESTINAL ORGANOIDS TO ADVANCE… (3*)|(AbbVie) 159. . . . ALDH1A3 PROMOTES METASTATIC COLONISATION OF PANCREATIC… (2*) 160. . . . DELETION OF NRF2 IN PANCREATIC STELLATE… (5*) 161. . . . PANCREATIC ACINAR CELL REPROGRAMMING INDUCED BY… (2*) 162. . . . GLYCEMIC PROFILE OF SUBJECTS WITH FAMILIAL… (5*)

163. . . . METFORMIN AND BET INHIBITORS REDUCE PROLIFERATION… (2*) 164. . . . ESTABLISHMENT OF A NOMOGRAM COMPRISING OF… (2*)|(4) 165. . . . DEVELOPMENT OF THE EOSINOPHILIC GASTRITIS MOLECULAR… (2*)|(CEGIR (U54 AI117804) is part of the Rare Disease Clinical Research Network, an initiative of the Office of Rare Diseases Research, NCATS, and is funded through collaboration between NIAID, NIDDK, and NCATS. CEGIR is also supported by patient advocacy grou) 166. . . . L-TYPE CALCIUM CHANNEL INHIBITORS (VERAPAMIL AND… (4*) 167. . . . EOE ESOPHAGEAL EPITHELIAL CELLS INDUCE TH2… (4*)|(2) 168. . . . EPIGENETIC ANALYSIS INDICATES ACCELERATED MOLECULAR AGEING… (5*) 169. . . . INTERLEUKIN-13-MEDIATED RELEASE OF MITOCHONDRIAL DNA FROM… (2*)|(3)|(Shire) 202. . . . THE MICROBIAL METABOLITE BUTYRATE PROMOTES GOBLET… (2*) 203. . . . COLONIC MESENCHYMAL STROMAL CELL MYD88-MEDIATED SIGNALING… (2*) 204. . . . SURGERY IN VERY EARLY ONSET INFLAMMATORY… (6*) 205. . . . COLLEGE ADJUSTMENT IN IBD STUDENTS: AGE… (3*)|(Abbvie Inc.) 206. . . . INCREASED EMERGENCY DEPARTMENT VISITS AND HOSPITALIZATIONS… (2*)|(6) 207. . . . INCREASED INCIDENCE OF MALIGNANCY IN PATIENTS… (2*)|(6) 208. . . . SAFETY AND EFFICACY OF ANTI-TNF THERAPY… (5*) 209. . . . EARLY COMBINED IMMUNOSUPPRESSION IS EFFECTIVE AND… (2*) 235. . . . EARLY INFLIXIMAB PHARMACOKINETICS AND WEEK ONE… (6*)|(2)|(Prometheus Labortories, Inc.provided study assay.) 236. . . . ADOLESCENTS' AND YOUNG ADULTS' SATISFACTION WITH… (5*) 237. . . . GEOGRAPHIC ANALYSIS OF PEDIATRIC INFLAMMATORY BOWEL… (5*)


* = Primary Source



238. . . . NUCLEIC ACID AMPLIFICATION FOLLOWED BY ENZYME… (2*) 251. . . . ENDOSCOPIST-RELATED FACTORS INFLUENCING POLYP DETECTION RATE… (5*)|(The first author completed this research during a Newman Fellowship programme, sponsored by Boston Scientific) 252. . . . A PROSPECTIVE RANDOMIZED TANDEM COLONOSCOPY STUDY… (4*)|(Nil) 253. . . . THE POLYP-BASED RESECT-AND-DISCARD STRATEGY: A PROSPECTIVE… (5*) 254. . . . VALIDATION OF BLUE LIGHT IMAGING (BLI)… (5*) 255. . . . ARTIFICAL INTELLIGENCE IMAGE CLASSIFIER BASED ON… (4*) 256. . . . ARTIFICIAL INTELLIGENCE FOR REAL-TIME MULTIPLE POLYP… (5*) 257. . . . HIGHER ABUNDANCE OF BILE ACID-METABOLIZING MICROBIOTA… (5*) 258. . . . INTEGRATED METABOLOMIC AND MICROBIOME APPROACH REVEALED… (6*) 259. . . . INCREASED BACTERIOPHAGE ABUNDANCE AND LOSS OF… (2*)|(4) 260. . . . IDENTIFICATION OF PATHOGENIC BACTERIA IN SEVERE… (2*) 261. . . . PROTEUS IS A KEY CANDIDATE IN… (6*) 262. . . . DIETARY SERINE REGULATE THE INTEGRITY OF… (2*) 263. . . . GUT MICROBIOTA PROFILING IN A PROSPECTIVE… (4*) 264. . . . DIETARY EMULSIFIERS REDUCE THERMOGENESIS IN BROWN… (2*) 265. . . . NEUROTENSIN (NT)-α-DEFENSINS AXIS MEDIATES THE INFLUENCE… (2*) 266. . . . DIETARY INTERVENTIONS AMELIORATE INFECTIOUS COLITIS THROUGH… (2*) 267. . . . EXCLUSIVE ENTERAL NUTRITION (EEN) AND CROHN'S… (2*)|(3) 268. . . . GUT MICROBIOTA MATURATION DURING EARLY LIFE… (2*)|(4) 269. . . . COLONIC EOSINOPHILIA IS ASSOCIATED WITH CURRENT… (4*)

270. . . . ESOPHAGEAL HYPERVIGILANCE AND SYMPTOM ANXIETY ARE… (2*) 271. . . . MANAGEMENT OF SUPRA-GASTRIC BELCHING WITH COGNITIVE… (1*) 272. . . . AVOIDANT/RESTRICTIVE FOOD INTAKE DISORDER AMONG ADULT… (5*) 273. . . . A MULTIDISCIPLINARY INTEGRATED TREATMENT APPROACH IS… (2*) 274. . . . VARIATION IN ADENOMA DETECTION RATE AND… (2*) 275. . . . DETERMINATION OF BENCHMARKS FOR SERRATED POLYP… (5*) 276. . . . EFFICACY AND SAFETY OF HOT AND… (5*) 277. . . . RAPID DEVELOPMENT OF FELLOWS' COGNITIVE AND… (5*) 278. . . . SIMULATION BASED TRAINING IMPROVES CONFIDENCE LEVELS… (5*) 279. . . . VALIDATION OF A NATURAL LANGUAGE PROCESSING… (2*) 280. . . . INHIBITORY SMAD6 REDUCES SOX9 EXPRESSION IN… (2*) 281. . . . ROLE OF ENDOGENOUS AND EXOGENOUS CARBON… (4*)|(Jagiellonian University Medical College, Faculty of Medicine, statutory grant No. 007716) 282. . . . EXPOSURE OF BARRETT’S AND ESOPHAGEAL ADENOCARCINOMA… (2*)|(4) 283. . . . THE ROLE OF ST6GAL-I, A GLYCOSYLTRANSFERASE… (4*)|(2) 284. . . . TRANSGENIC MOUSE MODEL BASED ON VSIG10L,… (2*) 297. . . . DEEP LEARNING ALGORITHM FOR CHARACTERIZATION OF… (5*) 298. . . . ARTIFICIAL INTELLIGENCE FOR DETECTING GASTRIC CANCER… (5*) 299. . . . VIDEO VALIDATION OF SMALL BOWEL CONVOLUTIONAL… (5*) 300. . . . DIFFERENTIATION BETWEEN PANCREATIC CANCER AND NORMAL… (2*) 301. . . . CROHN'S DISEASE EXCLUSION DIET IS EQUALLY… (2*)|(3)|(Nestlé Health Sciences)

302. . . . EARLY CHANGE IN FECAL CALPROTECTIN PREDICTS… (2*)|(4) 303. . . . EFFECT OF A PRACTICE-WIDE ANTI-TNF THERAPEUTIC… (2*)|(4) 304. . . . NEW KEY PLAYERS IN IMPAIRED ANGIOGENESIS… (2*) 305. . . . GENERATION OF STRATIFIED ESOPHAGEAL EPITHELIUM FROM… (6*) 306. . . . CELLS LINEAGE TRACED FROM LGR5+ CELLS… (2*) 307. . . . PROTEOMIC ANALYSIS OF INTESTINAL BRUSH BORDER… (2*) 308. . . . TEDUGLUTIDE IN A REAL WORLD SETTING… (5*) 309. . . . A NOVEL R-SPONDIN 1/POMC NEUROCIRCUIT IN… (2*) 322. . . . PREVENTION OF RECURRENT IDIOPATHIC GASTRODUODENAL ULCER… (2*) 323. . . . RISK OF GASTROINTESTINAL BLEEDING AFTER TREATMENT… (5*) 324. . . . OPTIMAL TIMING OF WARFARIN RESUMPTION AFTER… (5*) 325. . . . DEVELOPMENT AND VALIDATION OF MACHINE LEARNING… (2*) 326. . . . RIVAROXABAN IS ASSOCIATED WITH HIGHER RATES… (1*) 327. . . . FAK ACTIVATORS PROMOTE INTESTINAL MUCOSAL HEALING… (5*) 328. . . . PRECLINICAL DRUG EVALUATION REVEALS INHIBITION OF… (2*) 329. . . . TNFAIP8 IS A CRITICAL REGULATOR OF… (2*) 330. . . . PHARMACOLOGICAL INHIBITION OF THE APICAL SODIUM-DEPENDENT… (2*) 331. . . . THE LONG NON-CODING RNA, IFNG-AS1/NEST, IS… (6*)|(4) 332. . . . TUMOR NECROSIS FACTOR RECEPTOR 2 REGULATES… (2*)|(6) 333. . . . TREM1, THE FIRST ANTI-TNF SPECIFIC BIOMARKER… (4*) 334. . . . DEVELOPMENT AND VALIDATION OF A CLINICAL… (3*)|(Takeda Pharmaceuticals U.S.A., Inc.)


* = Primary Source



335. . . . VEDOLIZUMAB TARGETS LYMPHOID AGGREGATES IN THE… (2*)|(3)|(Takeda Pharmaceuticals) 336. . . . USING DEEP LEARNING FOR AUTOMATED GRADING… (2*) 337. . . . COMPLETE HISTOLOGIC NORMALIZATION IS ASSOCIATED WITH… (5*) 338. . . . LIVER TRANSPLANTATION FOR PRIMARY SCLEROSING CHOLANGITIS… (5*) 347. . . . IS SUCROSE THE SIXTH FODMAP IN… (4*) 348. . . . BMI RATHER THAN SYMPTOMS IS ASSOCIATED… (5*) 349. . . . BASELINE GLP-1 LEVEL CORRELATES WITH DEGREE… (5*) 350. . . . GWAS-IDENTIFIED METABOLIC SYNDROME GENES ARE TIGHTLY… (2*)|(3)|(Pathway Genomics) 357. . . . PROSPECTIVE EVALUATION OF A NOVEL, ENDOSCOPIC… (2*)|(6) 358. . . . CLOSE FOLLOW-UP IS ASSOCIATED WITH FEWER… (2*) 359. . . . EOSINOPHILIC ESOPHAGITIS-LIKE DISEASE WITH LACK OF… (2*) 360. . . . ORAL VISCOUS BUDESONIDE VERSUS SWALLOWED FLUTICASONE… (2*) 361. . . . FUNCTIONAL LUMINAL IMAGING PROBE PROVIDES AN… (6*)|(2) 362. . . . IBD EPIDEMIOLOGY: WHAT IS GOING ON… (5*) 363. . . . DOES RIFAXIMIN OFFER ANY PROMISE IN… (5*) 364. . . . EARLY USE OF AZATHIOPRINE ASSOCIATED WITH… (5*) 365. . . . EFFICACY AND SAFETY OF INFLIXIMAB RETREATMENT… (5*) 366. . . . SURVEILLANCE COLONOSCOPIES IN ULCERATIVE COLITIS: DOES… (4*) 367. . . . VAGUS NERVE STIMULATION REDUCES DISEASE ACTIVITY… (3*)|(SetPoint Medical) 369. . . . TARGETED DELETION OF THE ATP-BINDING CASSETTE… (2*) 370. . . . PREVALENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE… (5*)

371. . . . USING A MACHINE LEARNING PROGRAM -… (2*) 372. . . . ELMO1, A MICROBIAL SENSOR, REGULATES BACTERIAL… (2*) 373. . . . ROLE OF SURFACE POLYSACCHARIDES OF ADHERENT-INVASIVE… (6*) 374. . . . MICRORNA-125A PROTECTS INTESTINAL MUCOSAL INFLAMMATION THROUGH… (2*)|(the tiol tural Science Foundation of Chi (81630017)) 375. . . . HELMINTH EXPOSURE ALTERS TH17 SUBPOPULATION PLASTICITY… (2*) 377. . . . PROTECTIVE AND POTENTIALLY AGGRESSIVE BACTERIAL SPECIES… (2*) 401. . . . EFFICACY AND SAFETY OF COMBINED CPP-1X/SULINDAC… (3*)|(Cancer Prevention Pharmaceuticals, Inc.) 414. . . . A ROLE FOR THE STOMACH IN… (4*) 415. . . . COMBINED BLOCKADE OF α4β7 AND αEβ7… (3*)|(Genentech Inc., South San Francisco, CA) 416. . . . THE ORAL α4β7 INTEGRIN SPECIFIC ANTAGONIST… (3*)|(Protagonist Therapeutics, Inc.) 417. . . . FUNCTIONAL CHARACTERIZATION OF ENTEROCHROMAFFIN CELLS USING… (2*) 418. . . . DEFECTIVE CFTR FUNCTION IN PANCREATIC DUCTAL… (4*)|(2) 419. . . . LACTOBACILLUS REUTERI SECRETES γ-GLUTAMYLCYSTEINE TO SUPPRESS… (2*) 421. . . . PATHOLOGICAL ACTIVATION OF PIEZO1 IS THE… (2*) 422. . . . EPITHELIAL IDO1 MODULATES AHR AND NOTCH… (2*)|(6) 423. . . . IDENTIFYING THE MOST COST-EFFECTIVE TREATMENT ALGORITHM… (5*) 424. . . . A PROSPECTIVE, LONGITUDINAL STUDY OF METABOLOMIC… (2*) 425. . . . DURABLE TRANSFER OF CANDIDATE PROCARCINOGENIC BACTERIA… (2*)

426. . . . MARKED ALTERATIONS IN THE FECAL VIROME… (4*) 427. . . . FECAL MICROBIOTA TRANSPLANTATION REGULATES CIRCULATING MICRORNA… (4*) 428. . . . SOLUTE CARRIER FAMILY 26 MEMBER 3… (3*)|(2)|(Funding: Merck & Company sponsored this study. HWK was supported by NIH R03 DK103964 grant. CP was supported by NIH U01 DK110003-01 and P30 DK 41301-26.) 429. . . . AUTOIMMUNE ANTIBODIES AND SYMPTOMS OF AUTOIMMUNE… (2*) 430. . . . A MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF… (3*)|(Lyric Pharmaceuticals, South San Francisco, CA, USA) 431. . . . ACTIVATION OF NRF2 ATTENUATES DELAYED GASTRIC… (2*) 432. . . . PROTEOMICS IN GASTROPARESIS: UNIQUE AND OVERLAPPING… (2*)|(Study funded by NIDDK grants: U01DK112193, U01DK112194, U01DK073983, U01DK073975, U01DK074035, U01DK074007, U01DK073974, U24DK074008) 433. . . . LOSS OF CX3CR1-POSITIVE GASTRIC MUSCULARIS MACROPHAGES… (2*) 434. . . . CHARACTERIZATION OF PYLORIC TONIC AND PHASIC… (5*) 435. . . . DUAL THERAPY WITH ESOMEPRAZOLE AND AMOXICILLIN… (2*)|(3)|(This study was funded by ‘12th Five-Year’ tiol Science and Technology Support Plan project (2012BAI06B02) and AstraZeneca Investment (Chi) Co., Ltd.) 436. . . . THE EFFICACY OF FOURTEEN-DAYS ESOMEPRAZOLE AND… (4*) 437. . . . AN OPEN-LABEL, MULTI-CENTER, RANDOMIZED, SUPERIORITY TRIAL… (5*) 438. . . . HISTOLOGICAL GASTRITIS IN A COMMUNITY POPULATION… (3*)|(The study was supported by Olympus Sverige AB (Box 1816, 171 23 Sol, Sweden), who supplied study equipment.) 439. . . . RESIDUAL RISK OF GASTRIC CANCER FOLLOWING… (5*) 440. . . . ROBUSTNESS OF ELUXADOLINE FOR THE TREATMENT… (3*)|(This study was supported by Allergan plc, Dublin, Ireland. Writing assistance by Complete


* = Primary Source



HealthVizion, Inc., Chicago, IL, USA with funding by Allergan plc, Dublin, Ireland.) 441. . . . PSYCHOLOGICAL FACTORS HAVE A VARYING EFFECT… (6*) 442. . . . SAFETY PROFILE OF ELUXADOLINE IN PATIENTS… (3*)|(This study was supported by Allergan plc, Dublin, Ireland. Writing assistance by Complete HealthVizion, Inc., Chicago, IL, USA with funding by Allergan plc, Dublin, Ireland.) 443. . . . INTESTINAL BIOFILMS ARE AN ENDOSCOPIC FEATURE… (2*) 444. . . . RIFAXIMIN FOR IMPROVING ABDOMINAL PAIN AND… (3*)|(Funded by Salix Pharmaceuticals.) 445. . . . NT-NTR1 SIGNALING POSITIVELY REGULATES INTESTINAL FATTY… (2*) 446. . . . MODULATION OF BILE ACIDS PATHWAY IN… (2*)|(3)|(Funds and product provided by Satiogen Pharmaceuticals) 447. . . . DIFFERENCES IN PREVALENCE OF METABOLIC CONDITIONS… (5*) 448. . . . CHOLECYSTECTOMY ALTERS GASTROINTESTINAL HEALTH INDICES AND… (4*) 449. . . . HIGH FAT KETOGENIC DIET DECREASES SERUM… (4*) 450. . . . EFFECT OF FARNESOID X RECEPTOR ACTIVATION… (2*) 451. . . . FUNCTIONAL GENOMIC SCREENING USING CRISPR/CAS9 IDENTIFIES… (4*) 452. . . . TRIM67 PREVENTS COLORECTALTUMORIGENESIS IN MICE BY… (2*) 453. . . . THERAPEUTIC DOSE OF PELVIC RADIATION SLOWS… (2*) 454. . . . PD-L1 EXPRESSION REGULATES TUMOR CELL APOPTOSIS… (2*)|(4) 455. . . . DIFFERENTIAL POST-TRANSLATIONAL MODIFICATION OF POLYMORPHIC MSH3… (2*)|(4) 456. . . . DCLK1 MONOCLONAL ANTIBODY-BASED CAR-T CELLS AS… (2*) 457. . . . ON DEMAND VS CONTINUOUS USE OF… (4*) 458. . . . SUCCESSFUL REDUCTION OF OVERALL AND INAPPROPRIATE… (5*)

459. . . . TRENDS IN PRESCRIBING OF ACID-REDUCING THERAPIES… (1*) 460. . . . EFFECTS OF PROTON-PUMP INHIBITORS IN PATIENTS… (5*) 461. . . . ANOTHER FALSE ALARM: NO GOOD EVIDENCE… (5*) 462. . . . CIRCULATING EXTRACELLULAR VESICLES AND SPHINGOLIPIDS CARGO… (2*) 463. . . . SIGNIFICANTLY WORSE FUNCTIONAL STATUS AT TIME… (5*) 464. . . . SIGNIFICANT INCREASES IN ALCOHOL CIRRHOSIS RELATED… (5*) 490. . . . INFLAMMATION-INDUCED LOSS OF SPROUTY2 IN THE… (2*)|(6)|(NIH R01DK095004 (MRF) Crohn's & Colitis Foundation Career Development Award (MAS)) 509. . . . WOMEN GASTROENTEROLOGISTS ARE UNDERREPRESENTED IN RECOGNITION… (5*) 510. . . . STRATEGIES TO ACCOUNT FOR COLONOSCOPY VOLUME… (6*) 511. . . . ENDOSCOPIC HISTORY POTENTIALLY EXPLAINS SURVIVAL DIFFERENCES… (4*) 512. . . . DONOR HEALTH SCREENING FOR FECAL MICROBIOTA… (5*) 513. . . . MORTALITY IN MICROSCOPIC COLITIS - RESULTS… (5*) 514. . . . BEVERAGE INTAKE AND THE INCIDENCE OF… (2*) 515. . . . COLONOSCOPY AFTER HOLIDAYS IS AN INDEPENDENT… (5*) 516. . . . RACIAL DISPARITIES IN THE CARE OF… (4*) 517. . . . RACIAL AND ETHNIC TRENDS IN ESOPHAGEAL… (5*) 518. . . . RACIAL DISPARITIES IN RATES OF SURGERY… (5*) 519. . . . THE AGE TO STOP ENDOSCOPIC SURVEILLANCE… (2*) 520. . . . OVERUSE OF SURVEILLANCE ENDOSCOPY FOR BARRETT’S… (2*) 521. . . . NUMBER OF SESSIONS TO ACHIEVE COMPLETE… (7*)

522. . . . SEROTONIN MODULATES ARYL HYDROCARBON RECEPTOR (AHR)… (2*)|(6) 523. . . . KSR1 AND EXO70 INTERACT WITH ERK1/2… (2*) 524. . . . EPIDERMAL GROWTH FACTOR IMPROVES GLUCAGON-LIKE PEPTIDE-2-MEDIATED… (2*) 525. . . . ENDOCRINE PROGENITOR CELLS ORCHESTRATE THE INTESTINAL… (2*) 527. . . . LYSOPHOSPHATIDIC ACID TREATMENT AMELIORATES THE FUNCTION… (7*) 528. . . . IN BARRET’S EPITHELIAL CELLS, NUCLEOPHOSMIN 1… (2*) 529. . . . 3D ORGANOIDS REVEAL THE EXPANSION OF… (2*) 530. . . . ESOPHAGEAL SQUAMOUS CANCER CELLS CONDITION LYMPHATIC… (2*) 531. . . . TARGETING NERVE-CANCER METABOLISM IMPROVED OVERALL SURVIVAL… (2*)|(4) 532. . . . RSPO3 FUNCTIONS AS TUMOUR-SUPPRESSOR AND INHIBITS… (2*)|(( The project was supported by NSFC81472727,NSFC81272403,NSFC81773259; Science and Technology Commission of Shanghai Municipality (15JC1403100)).) 533. . . . GENERATION OF NOVEL PIK3CA-INDUCED GASTRIC CANCER… (2*) 534. . . . MRI IS HIGHLY PREDICTIVE OF THE… (5*) 535. . . . ILEAL BIOPSY EPITHELIAL CELL PYROPTOSIS PREDICTS… (3*)|(Takeda Pharma: grant support) 536. . . . PREDICTING VEDOLIZUMAB INDUCED ENDOSCOPIC REMISSION IN… (4*)|(2) 537. . . . FECAL CALPROTECTIN IS AN EARLY PREDICTOR… (3*)|(Truvion Healthcare (Preventis)) 538. . . . A BLOOD BASED PRE-SURGICAL TRANSCRIPTOMIC SIGNATURE… (6*)|(4) 539. . . . WEARABLE DEVICES CAN PREDICT DISEASE ACTIVITY… (3*)|(Takeda Pharmaceuticals) 567. . . . ADEQUATE INFLIXIMAB EXPOSURE DURING THE INDUCTION… (5*)


* = Primary Source



568. . . . HIGHER INFLIXIMAB AND ADALIMUMAB TROUGH LEVELS… (5*) 569. . . . ADALIMUMAB FOR PATIENTS WITH CROHN'S DISEASE… (3*)|(Abbvie) 570. . . . EARLY ENDOSCOPIC RETROGRADE CHOLANGIOGRAPHY WITH BILIARY… (2*)|(4) 571. . . . THE PREDICTIVE EFFECT OF A HIGH-QUALITY… (5*) 584. . . . EFFICACY AND SAFETY OF RIFAXIMIN TREATMENT… (3*)|(Funded by Salix Pharmaceuticals.) 585. . . . EFFECT OF THROMBOPOIETIN RECEPTOR AGONIST IS… (5*) 586. . . . BALLOON-OCCLUDED RETROGRADE TRANSVENOUS OBLITERATION (BRTO) VERSUS… (5*) 587. . . . PENTADECAPEPTIDE BPC 157 THERAPY IN BILE… (4*) 588. . . . COMPLICATIONS ASSOCIATED WITH ANESTHESIA SERVICES IN… (2*) 589. . . . QUALITATIVE DERIVATION AND QUANTITATIVE PREDICTION OF… (7*) 590. . . . HIGH DIAGNOSTIC YIELD USING ADVANCED ARTIFICIAL… (5*) 591. . . . DERIVATION AND VALIDATION OF QUANTITATIVE PARAMETERS… (7*) 592. . . . SEQUENTIAL DIAGNOSIS OF LIVER METASTASIS FROM… (5*) 593. . . . DEVELOPMENT, VALIDATION OF A POST-ERCP PANCREATITIS… (5*) 594. . . . ENDOSCOPIC ULTRASOUND-GUIDED TREATMENT OF GASTRIC VARICES… (5*) 595. . . . UTILITY OF SYMPTOM SEVERITY, FREQUENCY, AND… (3*)|(The origil study was funded by Alvine Pharmaceuticals. The data was then acquired by ImmunogenX. This is a post hoc alysis of the lead in data from that trial and shared with us from ImmunogenX. No funding for this current post hoc alysis was used from t) 596. . . . REAL LIFE PATTERNS OF GLUTEN-FREE DIET… (5*) 597. . . . A THEORY-BASED, BEHAVIORALLY FOCUSED COOKING INTERVENTION… (4*)

598. . . . IDENTIFICATION OF IMMUNOTOXIC PEPTIDES FROM DIETARY… (2*)|(4) 599. . . . EFFECT OF BIFIDOBACTERIUM INFANTIS NSL SUPER… (5*) 600. . . . CONCORDANCE OF BULB AND DISTAL DUODENAL… (5*) 601. . . . THE EFFECT OF ESOMEPRAZOLE ON THE… (2*)|(tural Science Fund of Chi (U1702281 and 81670551)) 602. . . . THROMBOEMBOLIC EVENTS IN ACUTE PANCREATITIS… (5*) 603. . . . NATURAL HISTORY OF LOW OUTPUT EXTERNAL… (5*) 604. . . . IMPACT OF STATIN USE ON CLINICAL… (5*) 605. . . . THE CLINICAL COURSE AND DIAGNOSTIC WORK-UP… (5*) 606. . . . CLINICAL FEATURES OF HYPERTRIGLYCERIDEMIA-INDUCED ACUTE PANCREATITIS… (5*) 607. . . . DYNAMIC ANALYSIS OF PATIENTS WITH ACUTE… (3*)|(This was not a funded study but it was performed in part by Ariel Precision Medicine, a commercial entity. We performed a cohort alysis that was agreed upon a priori by the investigators as a collaboration.) 608. . . . PAIN MODULATORY PHENOTYPES DIFFERENTIATE CHRONIC PANCREATITIS… (7*) 609. . . . RESULTS FROM A MULTICENTER, PHASE II,… (3*) 610. . . . CHRONIC PANCREATITIS IS ASSOCIATED WITH INCREASED… (5*) 611. . . . A NOVEL METHOD FOR ASSESSMENT AND… (7*) 612. . . . PANCREATIC ATROPHY DOES NOT CORRELATE WITH… (5*) 613. . . . PANCREATIC CANCER INCIDENCE IN A LARGE… (7*) 614. . . . PAIN “BURN-OUT” DURING THE NATURAL COURSE… (2*) 615. . . . ACCELERATED ONSET OF SPONTANEOUS PROXIMAL COLONIC… (2*) 616. . . . LOSS OF GLUTATHIONE PEROXIDASE 1 PROTECTS… (2*)

617. . . . SIMULTANEOUS LOSS OF BOTH ATYPICAL PROTEIN… (2*)|(7) 618. . . . ROLE OF LGR5 IN DCLK1+ CELL-DERIVED… (7*)|(4) 619. . . . MYELOID CALCINEURIN IN THE CONTROL OF… (4*) 620. . . . NEUTROPHILS RESTRICT TUMOR-ASSOCIATED MICROBIOTA TO DAMPEN… (2*) 621. . . . FECAL MICROBIOTA TRANSPLANTATION FOR THE TREATMENT… (3*)|(4)|(This study was an Investigator Initiated Study funded by Finch Therapeutics.) 622. . . . DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL OF WEEKLY… (3*)|(2)|(SERES THERAPEUTICS NIH Grant P30 DK40561 Massachusetts General Hospital Claflin Distinguished Scholar Award) 623. . . . SER-287, AN INVESTIGATIONAL MICROBIOME THERAPEUTIC, INDUCES… (3*)|(Seres Therapeutics) 624. . . . COMPARISON OF TWO OPEN-LABEL TRIALS DEMONSTRATES… (3*)|(This alysis was funded by Rebiotix Inc., Roseville, MN, USA.) 625. . . . DONOR FUNGI AND BACTERIA ENGRAFTMENT AFTER… (4*) 626. . . . GUT MICROBIOTA FROM COLORECTAL CANCER PATIENTS… (2*) 627. . . . DYSREGULATION OF EPITHELIAL TLR4 SELECTS FOR… (2*)|(6) 628. . . . IDENTIFICATION OF CROSSTALK BETWEEN GUT MICROBIOTA,… (2*) 629. . . . COLORECTAL CANCER-ASSOCIATED BACTERIA INDUCE TH1 AND… (6*) 630. . . . GUT MICROBIOTA MODULATES THE CHEMOPREVENTIVE EFFICACY… (2*) 631. . . . DIETARY INTAKE, H2S-PRODUCING MICROBES, AND RISK… (2*)|(6) 632. . . . DEVELOPMENT OF A NOVEL MIRNA-BASED SIGNATURE… (5*) 633. . . . GA-68 DOTATATE PET IN GASTRO-ENTERO-PANCREATIC NEUROENDOCRINE… (5*) 635. . . . THE UTILITY OF COMPUTED TOMOGRAPHY (CT)… (2*)


* = Primary Source



636. . . . DUODENAL NEUROENDOCRINE TUMORS EXHIBIT DISTINCT SOMATIC… (2*) 637. . . . DELINEATION OF THE PATHOGENESIS OF MESENTERIC… (4*) 649. . . . ECONOMIC BURDEN OF CELIAC DISEASE IN… (3*)|(Takeda Pharmaceuticals Intertiol Co.) 650. . . . PREVALENCE OF CELIAC DISEASE AUTOIMMUNITY AND… (5*) 651. . . . INTERNATIONAL STUDY GROUP OF PEDIATRIC PANCREATITIS:… (2*) 652. . . . CLINICAL OUTCOMES IN AUSTRALIAN CHILDREN WITH… (5*) 653. . . . EXTENSIVE GENE TESTING AND GENETIC INVOLVEMENT… (2*)|(Conflicts of Interests: Dr. C. Alexander Valencia worked at Cincinti Children’s when the study was conducted, he currently works at PerkinElmer genomics, Pittsburgh, PA, and this company has not provided any fincial support for the study. Dr. Abu-El-Hai) 654. . . . THE STOOL MICROBIOME MAY PREDICT OUTCOMES… (6*)|(4) 655. . . . STANDARDIZING THE CARE OF ACUTE SEVERE… (POSTER PRESENTATION)… (5*) 656. . . . MULTI-SYSTEM APPROACH TO DECREASING PROTON PUMP… (POSTER PRESENTATION)… (5*) 657. . . . FENTANYL WASTE WAS REDUCED BY CONSERVATION… (POSTER PRESENTATION)… (5*) 658. . . . IMPROVING FIRST-CASE START DELAYS IN A… (POSTER PRESENTATION)… (5*) 659. . . . NEW PATIENT ACCESS IN A GASTROENTEROLOGY… (POSTER PRESENTATION)… (5*) 660. . . . IMPROVING VACCINATION ADHERENCE IN INFLAMMATORY BOWEL… (POSTER PRESENTATION)… (2*)|(7) 661. . . . USE OF A SIMPLE 6-ITEM QUESTIONNAIRE… (POSTER PRESENTATION)… (5*) 662. . . . QUALITY GAPS IN PREVENTATIVE CARE PROVIDED… (POSTER PRESENTATION)… (5*) 663. . . . LET'S MAKE YOUR CLINIC VISIT A LITTLE SIMPLER - DEVELOPMENT OF A

QUESTION… (POSTER PRESENTATION)… (5*) 664. . . . HEPATOCELLULAR CARCINOMA SCREENING RATES IN A… (POSTER PRESENTATION)… (5*) 665. . . . EVALUATING THE IMPACT OF A NOVEL,… (POSTER PRESENTATION)… (5*) 666. . . . THE IMPACT OF DELAY BETWEEN BIOLOGIC… (POSTER PRESENTATION)… (5*) 667. . . . OPTIMIZING OUTPATIENT COLORECTAL CANCER SCREENING AND…(POSTER PRESENTATION)… (5*) 668. . . . RATE OF INAPPROPRIATE FIT TESTING AT… (POSTER PRESENTATION)… (5*) 669. . . . PROACTIVE MANAGEMENT OF IRON DEFICIENCY AND… (POSTER PRESENTATION)… (5*) 670. . . . UTILIZING A TIME SERIES STUDY TO… (POSTER PRESENTATION)…(5*) 671. . . . IMPLEMENTATION OF AN ACUTE CARE CLINICAL… (POSTER PRESENTATION)… (5*) 672. . . . HEMATOCHEZIA DECREASES USE OF VENOUS THROMBOEMBOLISM… (POSTER PRESENTATION)… (5*) 673. . . . STANDARDIZING INPATIENT BOWEL PREPARATION ORDERS IMPROVES… (POSTER PRESENTATION)… (5*) 674. . . . PATIENTS' SELF-IDENTIFIED STOOL COLOR IS COMPARABLE… (POSTER PRESENTATION)… (5*) 675. . . . REDUCING INAPPROPRIATE FECAL IMMUNOHISTOCHEMICAL TEST (FIT)… (POSTER PRESENTATION)… (5*) 676. . . . ENDOSCOPIC MANAGEMENT OF ACHALASIA: TIME FOR… (POSTER PRESENTATION)… (5*) 677. . . . ESOPHAGEAL MANOMETRY STANDARDIZATION - A COMMUNITY… (POSTER PRESENTATION)… (5*) 678. . . . IMPACT OF GUIDED RELAXATION AND MUSIC… (POSTER PRESENTATION)… (5*) 679. . . . DISCREPANCY BETWEEN SELF-REPORTED PREFERENCES ON POLYPECTOMY… (POSTER PRESENTATION)… (5*)

686. . . . RISK OF METACHRONOUS COLORECTAL CANCER AMONG… (4*) 687. . . . LONG-TERM RISK OF COLORECTAL CANCER AFTER… (2*) 688. . . . BASELINE FINDINGS ON SCREENING COLONOSCOPY IN… (2*) 689. . . . RISK OF COLORECTAL CANCER AND RELATED-MORTALITY… (2*)|(7) 690. . . . COMPLICATIONS OF SCREENING COLONOSCOPY IN A… (2*) 691. . . . INCREASING PHYSICIAN ADENOMA DETECTION RATE IS… (2*) 692. . . . ESCHERICHIA COLI HEAT-STABLE TOXIN IMPAIRS COLONIC… (2*) 693. . . . ATYPICAL PKCζ ACTIVITY AND RECRUITMENT TO… (2*) 694. . . . THE IBD CANDIDATE GENE, PTPN2, REGULATES… (2*)|(6) 695. . . . TTC7A-DEFICIENCT HUMAN COLONIC ENTEROIDS EXHIBIT ALTERED… (4*) 696. . . . TEDUGLUTIDE INCREASES ADAPTATION IN A MURINE… (3*)|(4)|(Shire, Lexington, USA - Investigator Initiated Research Grant) 697. . . . INTESTINAL PERMEABILITY IS AN IMPORTANT FACTOR… (2*) 698. . . . DISTINCTIVE SUBPOPULATION OF INNATE LYMPHOID CELLS… (5*) 699. . . . HUMAN MONOCYTES ENHANCE INTESTINAL STEM CELL… (2*) 700. . . . SEMAPHORIN-3E REGULATES APOPTOSIS DURING THE DEVELOPMENT… (7*) 701. . . . DIETARY INTAKE OF WALNUT TO MITIGATE… (4*) 702. . . . MOLECULAR CHARACTERIZATION OF MOUSE MODELS OF… (5*) 703. . . . TYPE 2 CYTOKINES PROMOTE HYPERPLASIA AND… (2*) 704. . . . PREOPERATIVE SERUM VEDOLIZUMAB LEVELS DO NOT… (5*) 705. . . . PRE-OPERATIVE BIOLOGICS SIGNIFICANTLY REDUCE POST-OPERATIVE LEAKS… (5*)


* = Primary Source



706. . . . A PROMINENT ROLE FOR CHEMOKINES, IN… (2*) 707. . . . RISK OF VENOUS THROMBOEMBOLISM ACCORDING TO… (5*) 708. . . . A SIGNIFICANT DECREASE IN THE RATE… (6*) 709. . . . COLECTOMY RATES ARE SIGNIFICANTLY HIGHER AMONG… (4*) 756. . . . FUNCTIONAL LUMINAL IMAGING PROBE (FLIP) ASSESSMENT… (2*) 757. . . . FUNCTIONAL GASTROINTESTINAL DISORDERS AND BEHAVIORAL PROBLEMS… (5*) 758. . . . LONG-TERM OUTCOMES OF GASTRIC ELECTRICAL STIMULATION… (5*) 759. . . . SIGNIFICANT VARIANTS IN MONOGENIC INFLAMMATORY BOWEL… (6*) 760. . . . MUTATIONS IN X-LINKED INHIBITOR OF APOPTOSIS… (2*)|(4) 773. . . . CYSTINE/GLUTAMATE ANTIPORTER (XCT) IS REQUIRED FOR… (2*) 774. . . . ROLE OF CELL CYCLE INHIBITOR P21WAF1/CIP1,… (2*) 775. . . . EXOGENOUS STIFFNESS RESULTS IN NUCLEAR TRANSLOCATION… (4*)|(7) 777. . . . LOSS OF TGF-β SIGNALING PROMOTES PROLIFERATION… (2*)|(4) 778. . . . NCX1/CA SIGNAL PATHWAY CONTRIBUTES TO THE… (2*) 779. . . . USE OF NON-ASPIRIN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS… (5*) 780. . . . INNOVATIVE SYSTEM FOR SELECTIVE ERADICATION OF… (5*) 781. . . . QUANTIFYING EVOLUTION OF EARLY DYSPLASTIC LESIONS… (2*)|(6) 782. . . . PATIENT-MATCHED STEM CELLS OF THE BARRETT'S-DYSPLASIA-ADENOCARCINOMA… (2*) 783. . . . LONG-TERM PROTON PUMP INHIBITOR USE AND… (3*)|(Investigator initiated research grant from Pfizer) 784. . . . VELUSETRAG IMPROVES GASTOPARESIS BOTH IN SYMPTOMS…

(3*)|(Theravance Biopharma R&D, Inc. Alfasigma S.p.A.) 785. . . . SEXUAL DIMORPHIC EPIGENETIC REGULATION OF CHRONIC… (2*) 786. . . . HOME BIOFEEDBACK THERAPY WITH NOVEL DEVICE… (7*)|(3)|(InControl Medical.) 787. . . . GUT DYSBIOSIS CONTRIBUTES TO VISCERAL HYPERSENSITIVITY… (2*) 788. . . . MICRORNA LET-7F IS OVEREXPRESSED IN COLONIC… (2*) 789. . . . FEAR OF PAIN AND SEROTONERGIC GENE… (4*) 790. . . . IMPACT OF PERSONALIZED COUNSELING ON DEPRESSION… (4*)|(5) 791. . . . A NOVEL HUMANIZED ANIMAL MODEL OF… (2*) 792. . . . EXOME SEQUENCING TO IDENTIFY RISK FACTORS… (2*) 793. . . . PATHWAYS OF PROGRESSION FROM INTRADUCTAL PAPILLARY… (2*) 794. . . . MUTATIONS IN REGULATORY ELEMENTS OF THE… (2*) 795. . . . VALIDATION OF PANCREATITIS ACTIVITY SCORING SYSTEM… (5*) 796. . . . REAL-WORLD EFFECTIVENESS OF TOFACITINIB IN ULCERATIVE… (5*) 797. . . . REAL-WORLD SAFETY OF TOFACITINIB IN INFLAMMATORY… (4*) 798. . . . EFFICACY AND SAFETY OF OPEN-LABEL TREATMENT… (3*)|(Pfizer Inc) 799. . . . EFFICACY OF UPADACITINIB AS AN INDUCTION… (3*)|(AbbVie-sponsored) 800. . . . IMPROVED ENDOSCOPIC OUTCOMES AND MUCOSAL HEALING… (3*)|(The authors and AbbVie scientists designed the study, and alysed and interpreted the data. AbbVie funded the research and provided writing support. All authors contributed to the development of the content. The authors and AbbVie reviewed and approved the) 801. . . . CLINICAL, ENDOSCOPIC, HISTOLOGIC AND BIOMARKER ACTIVITY… (3*)|(Theravance Biopharma US, Inc) 813. . . . CURCUMA LONGA LINN VERSUS OMEPRAZOLE IN… (7*)

814. . . . HELICOBACTER PYLORI INDUCES ABERRANT LRIG1 STEM… (2*) 815. . . . LONG-TERM CHANGES OF GUT MICROBIOTA, ANTIBIOTIC… (2*)|(4) 816. . . . EFFECTS OF ANTI-HELICOBACTER PYLORI THERAPY ON… (2*)|(4) 817. . . . EFFICACY OF 1-FOOD AND 4-FOOD ELIMINATION… (2*)|(4) 818. . . . CYTOKINE EXPRESSION ILLUSTRATES HETEROGENEITY OF ACTIVE… (2*)|(6) 819. . . . METABOLISM OF WHEAT AMYLASE TRYPSIN INHIBITORS… (2*) 820. . . . PROSPECTIVE LONGITUDINAL GUT METAGENOMIC ANALYSIS SUGGESTS… (2*) 821. . . . A RANDOMIZED, PLACEBO-CONTROLLED EVALUATION OF THE… (3*)|(ImmusanT, Inc.) 822. . . . FURTHER DEVELOPMENT OF A NOVEL IN… (4*) 823. . . . BENEFITS AND BARRIERS OF A HANDHELD… (2*)|(Nima Labs supplied 30 Nima devices (the capsules were purchased separately by the above-acknowledged grant support). Nima labs was not privy to the study design, results, or composition of the abstract.) 824. . . . ACUTE GLUTEN-INDUCED SYMPTOMS IN CELIAC DISEASE… (3*)|(ImmusanT, Inc.) 825. . . . AN ACUTE RISE IN SERUM IL-2… (6*)|(4)|(Nestle Research Center/Society for the Study of Celiac Disease) 826. . . . POLYGENIC RISK SCORE, FAMILY HISTORY, AND… (2*) 827. . . . OPTIMAL TIMING OF TOTAL GASTRECTOMY TO… (5*) 828. . . . WHAT`S MY RISK OF CANCER DOCTOR?… (5*) 829. . . . THE IDENTIFICATION OF DNA MISMATCH REPAIR… (2*)|(4) 830. . . . SCREENING UPPER ENDOSCOPY IS USEFUL FOR… (5*) 831. . . . AN EVALUATION OF THE RISKS AND… (5*) 832. . . . DASHBOARD DRIVEN DOSING OF INFLIXIMAB IS… (5*)


* = Primary Source



833. . . . EFFICACY AND SAFETY OF USTEKINUMAB AS… (3*)|(This study was funded by Janssen Research & Development, LLC) 834. . . . WITHDRAWAL OF THIOPURINES IN CROHN'S DISEASE… (2*)|(Grant from the Ministry of Health, Labour and Welfare of Japan (“Investigation and research for intractable inflammatory bowel disease”).) 835. . . . LONG-TERM SAFETY OF VEDOLIZUMAB IN ULCERATIVE… (3*)|(Takeda) 836. . . . IMMUNOLOGIC PREDICTORS OF RESPONSE TO VEDOLIZUMAB… (3*)|(The study was supported by Takeda (IISR-2014-100922)) 837. . . . PILOT STUDY OF EARLY SCREENING IN… (4*) 838. . . . IS 45 THE NEW 50? ADENOMA… (5*) 839. . . . DISPARITIES IN COLORECTAL CANCER SCREENING: THE… (5*) 840. . . . COLORECTAL CANCER SCREENING AMONG HISPANICS IN… (4*) 841. . . . PATIENT-DIRECTED MESSAGING TO INCREASE COLORECTAL CANCER… (5*) 842. . . . SEQUENTIAL OR ACTIVE CHOICE FOR COLORECTAL… (2*) 843. . . . IMPACT OF MAILED OUTREACH AND INREACH… (2*) 844. . . . IDENTIFICATION OF PUTATIVE CANCER STEM CELLS… (5*) 845. . . . GENOMEWIDE TRANSCRIPTOMIC PROFILING IDENTIFIES A NOVEL… (4*) 847. . . . MIR130B EXPRESSED BY SLFN4+-MDSCS STIMULATES EPITHELIAL… (2*) 848. . . . LOSS OF HUMAN EPIDIDYMIS PROTEIN (HE4)… (2*)|(3) 849. . . . LOSS OF SLC26A9 RESULTS IN THE… (2*) 850. . . . INDUCEMENT OF DOUBLE STRAND BREAKS (DSB)… (2*)|(4) 851. . . . ZINC FINGER PROTEIN 545 SUPPRESSES COLORECTAL… (2*) 852. . . . OVEREXPRESSION OF RAGE AND ITS LIGANDS… (2*)|(4)

853. . . . CHOLANGIOCARCINOMA (CCA) DERIVED EXTRACELLULAR VESICLES REPROGRAM… (7*)|(4) 855. . . . SLC25A22 DRIVES ONCOMETABOLITE SUCCINATE TO PROMOTE… (2*) 856. . . . ASSESSMENT OF THE IMPACT OF INTRODUCING… (5*) 857. . . . MEDICATION UTILIZATION AND SATISFACTION IN IRRITABLE… (5*) 858. . . . THERAPEUTIC RESPONSE TO SMALL INTESTINAL BACTERIAL… (5*) 859. . . . IDENTIFICATION OF BILE ACID DIARRHEA IN… (4*) 860. . . . LOW FODMAP DIET IN THE LONG… (5*) 861. . . . EFFECT OF KETOTIFEN ON ABDOMINAL SYMPTOMS,… (2*) 862. . . . INTESTINAL ACIDIFICATION SENSED BY PH-SENSING RECEPTOR… (4*) 863. . . . INDUCTION OF AUTOPHAGY IN CX3CR1+ MONONUCLEAR… (2*)|(4) 864. . . . PLATELETS AND THEIR INTERACTION WITH PRIMARY… (4*) 865. . . . CIRCULATING FIBROCYTES ARE INCREASED IN PATIENTS… (2*) 866. . . . ORALLY ACTIVE ELAFIN-EUDRAGIT INHIBITS COLITIS-ASSOCIATED INTESTINAL… (2*)|(6) 867. . . . THE BCL-2 INHIBITOR ABT-263 ATTENUATES INTESTINAL… (3*)|(Abbvie) 868. . . . THE ROLE OF NUCLEAR FACTOR NFIB-MEDIATED… (5*) 869. . . . SOX12 PROMOTES COLORECTAL CANCER PROLIFERATION AND… (2*)|(This study was supported by combined grants from the tiol tural Science Foundation of Chi (No.81522031, No. 81772623, No. 81627807, No.81430072 and No. 81421003), tiol Key Research and Development Program of Chi (2018YFC1312103) and tiol Center for Clinic) 870. . . . PLASMA BIOMARKERS OF INSULIN AND THE… (2*) 871. . . . TRANSCRIPTIONAL SIGNATURES OF WESTERN-STYLE AND PRUDENT… (4*)

872. . . . YOGURT CONSUMPTION AND RISK OF CONVENTIONAL… (2*) 873. . . . COGNITIVE BEHAVIORAL THERAPY-INDUCED CHANGES IN RESTING… (2*) 874. . . . GUT DYSBIOSIS CHARACTERIZED BY OVERABUNDANCE OF… (2*) 875. . . . FECAL MICROBIOTA FROM IBS PATIENT INDUCES… (4*) 876. . . . STRESS-INDUCED DISRUPTION OF INTESTINAL BARRIER AND… (7*)|(This study proposal received AGA Student Research Fellowship award.) 877. . . . MICROBIOTA PLAYS A KEY ROLE IN… (4*) 878. . . . GUT MICROBIOME BIOMARKERS BEFORE AND DURING… (2*) 879. . . . SWITCHING FROM INFLIXIMAB ORIGINATOR TO A… (5*) 880. . . . DELINEATING THE PHENOTYPE OF PEDIATRIC PSC-IBD… (5*) 881. . . . PILOT STUDY OF EOSINOPHILIC BIOMARKER MEASURED… (5*) 882. . . . NORMALIZATION OF FECAL CALPROTECTIN REQUIRES HIGHER… (5*) 883. . . . INTEGRATION OF CLINICAL, IMMUNOLOGIC AND GENOMIC… (2*) 884. . . . PROSPECTIVE COMPARISON OF SACRAL NERVE STIMULATION… (5*) 945. . . . GLUTEN AVOIDANCE AND SELF-REPORTED NON-CELIAC WHEAT… (3*)|(This study was supported by a grant from Prometheus laboratories.) 946. . . . A HIGH RATE OF IGE-NEGATIVE FOOD… (6*)|(2) 947. . . . PRIMING AND MATURATION OF THE HUMAN… (4*) 948. . . . NUCLEAR RECEPTOR LIVER RECEPTOR HOMOLOG-1 PROMOTES… (2*)|(6) 949. . . . DEVELOPMENT OF COORDINATED ELECTRICAL ACTIVITY IN… (6*) 950. . . . MATERNAL MILK ENHANCES INTESTINAL MUCOSAL BARRIER… (2*)|(6) 969. . . . PRIMARY CILIA TRANSDUCE INFLAMMATORY AND HEDGEHOG… (2*)


* = Primary Source



970. . . . REGULATION OF ONCOGENIC STRESS RESPONSE PATHWAY… (2*) 971. . . . THE INNATE IMMUNE MOLECULE NLRC5 PROTECTS… (2*)|(4) 972. . . . NLRP3 INFLAMMASOME-DERIVED INTERLEUKIN-1β ATTENUATES STRESS-INDUCED GASTRIC… (5*) 973. . . . FEASIBILITY OF ADIPOSE MESENCHYMAL STEM CELL… (4*)|(81770561 CXTDA2017033 BRA2014332 BE2015716) 974. . . . AURORA KINASE A ACTIVATES UNFOLDED PROTEIN… (2*) 975. . . . PROTON-PUMP INHIBITORS MAY ENHANCE INTESTINAL PERMEABILITY… (3*)|(DAIICHI SANKYO COMPANY, LIMITED EA Pharma Co., Ltd) 976. . . . A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, CROSSOVER, MULTIPLE-DOSE… (3*)|(Novartis was the Sponsor of this study) 977. . . . INTESTINE MICROBIOME ASPIRATION (IMBA) CAPSULE: A… (4*) 978. . . . IMPACT OF GASTROINTESTINAL PATHOGEN PANEL IMPLEMENTATION… (5*) 979. . . . A LARGE SCALE EVALUATION OF THE… (4*) 980. . . . CHARACTERISTICS OF GASTRIC MUCOSA AND FECAL… (2*) 982. . . . RISK FACTORS FOR EARLY-ONSET COLORECTAL CANCER… (2*) 983. . . . COMPREHENSIVE ASSESSMENT OF DIET QUALITY AND… (2*) 984. . . . U.S. SEER COLORECTAL CANCER INCIDENCE RATE… (5*) 985. . . . COST-EFFECTIVENESS AND NATIONAL IMPACT OF INITIATING… (4*) 986. . . . ALPHA-TOCOPHERYLQUINONE ENHANCES INTESTINAL EPITHELIAL TIGHT JUNCTION… (5*) 987. . . . VITAMIN D RECEPTOR REGULATES EPITHELIAL TIGHT… (2*) 988. . . . TCPTP REGULATES INTESTINAL EPITHELIAL AND MACROPHAGE… (2*) 989. . . . LOSS OF CLAUDIN-3 EXPRESSION INDUCES GUT… (2*)

990. . . . LONG NONCODING RNA H19 REGULATES AUTOPHAGY… (2*) 991. . . . MATRIX METALLOPROTEINASE 7 CONTRIBUTES TO INTESTINAL… (2*)|(4) 992. . . . HYPOXIA-INDUCIBLE FACTOR 1 ALPHA (HIF1A) COOPERATES… (2*)|(4) 993. . . . MYELOID TRANSLOCATION GENE ON CHROMOSOME 16… (2*) 994. . . . MIR-148A REGULATES CHIEF CELL PLASTICITY IN… (2*) 995. . . . TRANSGENIC EXPRESSION OF MIR-195 DISRUPTS INTESTINAL… (2*) 996. . . . THE EPIGENETIC PROTEIN SP140 DIRECTS INFLAMMATORY… (2*)|(3)|(Marie Skłodowska-Curie Actions and GlaxoSmithKline (Stevege, UK)) 997. . . . DIETARY AND PHENOTYPIC INSIGHTS INTO THE… (2*) 998. . . . VITAMIN, MINERAL, AND PROTEIN DEFICIENCES IN… (5*) 999. . . . IMPAIRED DUODENAL EPITHELIAL BARRIER AND SECRETORY… (2*) 1000. . . . SYMPTOMATIC CONTROL OF CYCLIC VOMITING SYNDROME… (4*) 1001. . . . IMPACT OF RECREATIONAL CANNABIS LEGALIZATION ON… (5*) 1002. . . . CYCLIC VOMITING SYNDROME PRACTICE GUIDELINES COMMITTEE… (6*)|(This article received exterl funding support from the Cyclic Vomiting Syndrome Association (CVSA).) 1004. . . . MAINTENENCE TREATMENT WITH MIRIKIZUMAB, A P19-DIRECTED… (3*)|(Eli Lilly and Company) 1005. . . . A CONTROLLED TRIAL OF AMISELIMOD, A… (3*)|(MITSUBISHI TABE PHARMA) 1006. . . . HISTOLOGIC REMISSION AND MUCOSAL HEALING IN… (3*)|(Are Pharmaceuticals, Inc.) 1007. . . . ABX464 IS SAFE AND EFFICACIOUS IN… (3*)|(ABIVAX) 1008. . . . ESTROGENS MODULATE THE EFFECT OF STRESS… (2*) 1009. . . . SENSORY NEUROPLASTICITY IN THE DORSAL ROOT… (2*)|(NIH/NIDDK)

1010. . . . CASPASE-11 IS CRITICAL FOR ENTERIC NITRERGIC… (2*) 1011. . . . THE VOLTAGE-GATED SODIUM CHANNEL NAV1.7 CONTRIBUTES… (2*) 1012. . . . GENOME-WIDE ASSOCIATION ANALYSIS OF DIVERTICULAR DISEASE… (2*)|(4) 1013. . . . EXPLORING THE ROLES OF VOLTAGE-GATED CALCIUM… (2*)|(7) 1014. . . . SEEKING DIETARY FIBERS TO AMELIORATE INFLAMMATORY… (2*) 1015. . . . PROBIOTICS DIFFERENTIALLY AFFECT THE GUT MICROBIAL… (2*) 1016. . . . PROBIOTICS FOR THE PREVENTION OF PEDIATRIC… (5*) 1017. . . . EFFECTS OF A FLATULOGENIC DIET COMBINED… (3*)|(Da Nutricia Research) 1018. . . . TRANSLATIONAL STUDIES OF LACTOBACILLUS GASSERI EFFECTS… (3*)|(4)|(Funded by Biogaia Probiotics, Stockholm, and ALF funding, Uppsala, Sweden.) 1019. . . . DISRUPTED CIRCADIAN OSCILLATION OF GUT-DERIVED SHORT… (2*)|(4) 1067. . . . A MACHINE LEARNING-BASED MODEL TO PREDICT… (6*)|(7) 1068. . . . INDEPENDENT VALIDATION OF A TISSUE SYSTEMS… (2*)|(3)|(This study was funded in part by Cernostics, Inc.) 1069. . . . A MULTICENTER STUDY OF THE ADEQUACY… (3*)|(Study was funded by Covidien/Medtronic.) 1070. . . . WHEN SHOULD WE LOOK FOR RECURRENCE… (7*) 1071. . . . MUCOSAL INTEGRITY TESTING CAN DETECT CHANGES… (4*) 1072. . . . DIAGNOSTIC UTILITY OF CONTRACTILE SEGMENT IMPEDANCE… (5*) 1073. . . . THE AVERAGE RECOVERY TIME OF THE… (5*) 1074. . . . PROLONGED WIRELESS PH MONITORING OFF PPI… (2*) 1075. . . . RUMINATION SYNDROME AND SUPRA-GASTRIC BELCHING CAN… (5*)


* = Primary Source



1076. . . . FORKHEAD BOX K2 (FOXK2) PROMOTES HUMAN… (2*)|(This study was supported by combined grants from the tiol tural Science Foundation of Chi (No.81522031, No. 81772623, No. 81627807, No.81430072 and No. 81421003), tiol Key Research and Development Program of Chi (2018YFC1312103) and tiol Center for Clinic) 1077. . . . A NOVEL GENE EXPRESSION SIGNATURE FOR… (4*) 1078. . . . METHYLATED DNA MARKERS DETECT ESOPHAGEAL SQUAMOUS… (3*)|(2)|(Exact Sciences, Madison, WI.) 1079. . . . A NOVEL GENE EXPRESSION SIGNATURE FOR… (5*) 1080. . . . CHARACTERIZATION OF SONIC HEDGEHOG IN ESOPHAGEAL… (2*) 1081. . . . GENOME-WIDE TRANSCRIPTOMIC PROFILING FOR THE IDENTIFICATION… (4*) 1082. . . . ‘TURNING-OFF’ STRESS-INDUCED VISCERAL PAIN VIA OPTOGENTIC… (2*)|(6) 1083. . . . GUT SENSING OF NUTRIENT CALORIC CONTENT… (2*)|(4) 1084. . . . ENTERIC ALPHA-SYNUCLEIN INCLUSIONS, COLONIC INFLAMMATION, INCREASED… (5*) 1085. . . . NEURONAL SEROTONIN AS A LINK BETWEEN… (2*)|(6) 1086. . . . BILATERAL BRAIN-GUT INTERACTIONS AND ANORECTAL SENSATION… (7*) 1087. . . . ENTERIC INFLAMMATION AND ALTERED COLONIC CHOLINERGIC… (4*) 1088. . . . META-ANALYSIS: THE RISK OF DEVELOPING NEW… (5*) 1090. . . . GASTROINESTINAL SYMPTOMS OBSERVED AFTER CHIMERIC ANTIGEN… (5*) 1091. . . . EARLY INTRODUCTION OF NON-STEROIDAL IMMUNOSUPPRESSIVE THERAPY… (5*) 1092. . . . IMPORTANCE OF ENDOSCOPIC AND HISTOLOGICAL EVALUATION… (5*) 1093. . . . A NOVEL ROLE OF S-ACYLATION IN… (2*)

1094. . . . ROLE OF HISTONE ACETYLATION IN UPREGULATION… (2*) 1095. . . . TRANSMEMBRANE PROTEIN 237 (TMEM237) INTERACTS WITH… (2*) 1096. . . . REGULATION OF NA-GLUTAMINE CO-TRANSPORT B0AT1 IN… (2*) 1097. . . . LINACLOTIDE STIMULATES DUODENAL BICARBONATE SECRETION VIA… (4*) 1098. . . . INCREASED DIVALENT METAL TRANSPORTER 1 (DMT1)… (2*) 1099. . . . THE MICROBIOME IN IRRITABLE BOWEL SYNDROME:… (2*) 1100. . . . REDUCED BACTERIA-DERIVED BILE SALT HYDROLASE ENZYMATIC… (3*)|(The study was sponsored by Nestle Institute of Health (NIHS).) 1101. . . . FMT WITH OR WITHOUT ANTIBIOTIC PRETREATMENT… (3*)|(FMT capsules provided by OpenBiome) 1102. . . . EFFICACY OF HUMAN MILK OLIGOSACCHARIDES ON… (3*) 1103. . . . DAILY INTAKE OF SULFORAPHANE-RICH BROCCOLI SPROUTS… (3*)|(Murakami Nohen Co. Ltd.) 1104. . . . INTEGRATED MULTI-OMICS ANALYSIS OF THE FAECAL… (2*) 1105. . . . IMPACT OF CONCURRENT PHARMACOTHERAPY WITH INTRAGASTRIC… (5*) 1106. . . . AN ANALYSIS OF LEPTIN AND INSULIN-GLUCOSE… (5*) 1107. . . . OBESITY IS AN INDEPENDENT RISK FACTOR… (5*) 1108. . . . TRANSPYLORIC SHUTTLE TREATMENT IMPROVES CARDIOMETABOLIC RISK… (3*)|(BaroNova) 1109. . . . ENDOSCOPIC MANAGEMENT OF LATE DUMPING SYNDROME:… (5*) 1110. . . . OUTCOMES OF A NOVEL BARIATRIC STENT… (5*) 1129. . . . LONG-TERM MULTIDONOR FECAL MICROBIOTA TRANSFER (FMT)… (5*) 1130. . . . TRANSFERABLE IGA-REACTIVE MICROBIOTA STRATIFY CLINICAL RESPONSE… (3*)|(2)|(Boehringer Ingelheim Pharmaceuticals provided the fincial support to conduct the study)

1131. . . . SPERMINE OXIDASE DELETION CONFERS PROTECTION FROM… (2*)|(4) 1132. . . . THE MACROPHAGE REVERSE TRANSSULFURATION PATHWAY MEDIATES… (2*)|(4) 1133. . . . ααINDUCTION OF GASTRIC DYSBIOSIS BY CARCINOGENIC… (2*) 1134. . . . POSTTRANSCRIPTIONAL CONTROL OF VDR EXPRESSION BY… (2*) 1135. . . . 5-HT3 RECEPTOR ACTIVATION INCREASES ANION SECRETION… (2*) 1136. . . . FUSOBACTERIUM NUCLEATUM INITIATES COLORECTAL CANCER BY… (2*) 1137. . . . FORWARD GENETICS IDENTIFIES HOST LOCUS RESPONSIBLE… (2*) 1138. . . . SHORT-CHAIN FATTY ACIDS POSTPONE THE PROGRESSION… (2*) 1139. . . . THE INTESTINAL VIROME IN CHILDREN WITH… (7*)|(2) 1140. . . . SYN-007, AN ORAL BETA-LACTAMASE PREVENTS GUT… (3*)|(Synthetic Biologics, Inc.) 1141. . . . TOWARDS HEALTH: RECURRENT CLOSTRIDIUM DIFFICILE INFECTION… (3*)|(This alysis was funded by Rebiotix Inc., Roseville, MN, USA.) 1142. . . . THE EFFECTS OF HUMAN MILK OLIGOSACCHARIDES… (4*)|(3)|(Supported by an unrestricted grant from Glycom A/S) 1143. . . . FUNCTIONAL LUMEN IMAGING PROBE DEMONSTRATES REDUCED… (5*) 1144. . . . ABNORMALITIES OF ESOPHAGEAL DISTENSION-CONTRACTION PROFILE DURING… (2*) 1145. . . . DISTENSION-INDUCED CONTRACTILITY IS FREQUENTLY PRESENT, BUT… (2*) 1146. . . . ESOPHAGEAL HYPERCONTRACTILITY IS ABOLISHED BY CHOLINERGIC… (4*) 1147. . . . PROSPECTIVE EVALUATION OF RISK FACTORS FOR… (5*) 1148. . . . CHARACTERIZATION AND MECHANISM OF THE ESOPHAGO-ESOPHAGEAL… (2*) 1149. . . . MICROBIAL SEQUENCING OF THE APPENDICEAL MICROBIOME… (4*)


* = Primary Source



1150. . . . INTRA-PERSONAL GUT MICROBIAL VARIATIONS IN PATIENTS… (6*) 1151. . . . CD8+ T CELL-SPECIFIC TUMOR NECROSIS FACTOR… (2*)|(6) 1152. . . . A HEALTHY HUMAN FECAL SPECIMEN INCLUDES… (3*)|(6)|(Janssen Research Development) 1153. . . . CRITICAL ROLE OF TOLL-LIKE RECEPTOR 2… (2*) 1154. . . . LACK OF VITAMIN D RECEPTOR IN… (2*) 1155. . . . COMPARATIVE IN-VIVO DIAGNOSTIC PERFORMANCE OF CURRENT… (5*) 1156. . . . INTELLIGENT REAL-TIME IMAGE SEGMENTATION (IRIS) IMPROVES… (3*)|(NinePoint Medical, Inc.) 1157. . . . GOBLET CELL METAPLASIA VARIATIONS IN TARGETED… (3*) 1158. . . . RISK STRATIFICATION OF BARRETT'S ESOPHAGUS WITH… (5*) 1159. . . . RELIABILITY OF VIDEOCONFERENCING PATHOLOGY IN THE… (5*) 0. . . . INTERLEUKIN-33 PROMOTES REG3G EXPRESSION IN INTESTINAL… (2*) 0. . . . CATHARTOCYTOSIS, A NOVEL CELLULAR PROCESS ESSENTIAL… (4*)|(2) 0. . . . THE ROLE OF TUFT CELL SPECIFICATION… (2*) 0. . . . GENOME ANALYSIS OF DUODENAL GASTRINOMAS AND… (2*) 0. . . . EFFICACY IN BIOLOGIC-FAILURE AND NONBIOLOGIC-FAILURE POPULATIONS… (3*)|(This study was funded by Janssen Research & Development, LLC) 0. . . . INTERLEUKIN-27-PRODUCING IMMUNE CELLS IN THE GASTRIC… (2*) 0. . . . RNA BINDING PROTEIN IMP1 PROMOTES EXOSOME… (2*)|(7) 0. . . . A NOVEL ROLE FOR γδ INTRAEPITHELIAL… (2*)|(4) 0. . . . TRENDS IN YOUNG-ONSET COLORECTAL CANCER INCIDENCE… (2*)

0. . . . DELETION OF CLAUDIN-7 LEADS TO THE… (2*)

AGA Poster Presentations


* = Primary Source



BSQS12|Sa1117. . . . TNKS2 PROMOTES WNT/β-CATENIN SIGNALING THROUGH DEGREDATION… (2*) BSQS17|Su1879. . . . NOVEL ROLE FOR DEATH RECEPTOR 3… (2*) BSQS9|Su1033. . . . CONTRASTING EFFECTS OF GLOBAL VERSUS TISSUE-SPECIFIC… (2*) Sa1000. . . . A NATIONAL SURVEY OF INTERNISTS' PERCEPTIONS… (4*) Sa1001. . . . STRONG RECOMMENDATIONS BASED ON LOWER QUALITY… (5*) Sa1002. . . . UNDERUTILIZATION OF ASPIRIN IN PATIENTS WITH… (1*)|(5) Sa1003. . . . POOR KNOWLEDGE OF PERSONAL AND FAMILIAL… (5*) Sa1004. . . . UNDISCLOSED PAYMENTS BY PHARMACEUTICAL AND MEDICAL… (5*) Sa1005. . . . UTILITY OF AND COMPLIANCE WITH RECOMMENDED… (5*) Sa1006. . . . ADHERENCE TO GUIDELINES AND BEST PRACTICES… (4*) Sa1007. . . . INTERNATIONAL GUIDELINES ON THE MANAGEMENT OF… (5*) Sa1008. . . . INTERNATIONAL GUIDELINES ON THE MANAGEMENT OF… (5*) Sa1009. . . . IS COLONOSCOPY NECESSARY AFTER AN ACUTE… (5*) Sa1010. . . . LACK OF RECOMMENDED PNEUMOCOCCAL CONJUGATE VACCINE… (3*)|(This study was sponsored by Pfizer Inc. All authors are employees of Pfizer Inc.) Sa1011. . . . A COMPARISON OF CHARACTERISTICS IN LEFT… (5*) Sa1012. . . . TARGETED SCREENING FOR HEPATITIS C AND… (5*) Sa1013. . . . A MULTICENTER STUDY ON GUIDELINE ADHERENCE… (4*) Sa1014. . . . PREVALENCE AND RELEVANCE OF FINANCIAL CONFLICTS… (5*) Sa1015. . . . HIGH SMOKING CESSATION RATES IN A… (5*) Sa1016. . . . CHARACTERIZING INAPPROPRIATE PROPHYLACTIC TRANSFUSION OF BLOOD… (5*) Sa1017. . . . COLONIC BIOPSY PRACTICE IN PATIENTS WITH… (5*)

Sa1018. . . . WOMEN WITH HEPATITIS C VIRUS (HCV)… (3*)|(Abbvie - investigator initiated research grant support) Sa1019. . . . IS ETHNICITY ASSOCIATED WITH RATES OF… (5*) Sa1020. . . . RACIAL DISPARITIES IN TIME FROM ADMISSION… (5*) Sa1021. . . . HISPANICS UNDER-UTILIZE BARIATRIC SURGERY… (5*) Sa1022. . . . RACIAL DISPARITIES IN COLORECTAL CANCER MORTALITY:… (2*) Sa1023. . . . PATIENT AND PROVIDER REPORTED BARRIERS TO… (4*) Sa1024. . . . RACIAL DISPARITIES IN THE EVALUATION AND… (5*) Sa1025. . . . A QUESTIONNAIRE STUDY TO ASSESS THE… (3*)|(Takeda (Chi) Intertiol Trade Co., Ltd.) Sa1026. . . . DEVELOPING A STUDY OF COLORECTAL CANCER… (2*) Sa1027. . . . BEYOND AVAILABILITY: EVALUATING ACCEPTABILITY OF HIGH… (2*)| Sa1028. . . . COST SAVINGS FROM GENERIC PROTON PUMP… (5*) Sa1029. . . . COST-EFFECTIVENESS OF FIRST-LINE BIOLOGICS FOR THE… (4*) Sa1030. . . . PATIENT OUTCOMES BASED ON REFERRAL PATTERNS… (5*) Sa1031. . . . WHAT IS THE NATURAL HISTORY OF… (3*)|(Janssen Cada) Sa1032. . . . SUBSTANTIAL INCREASE IN ANESTHESIA ASSISTANCE FOR… (5*) Sa1033. . . . HEALTHCARE RESOURCE USE AND DIRECT MEDICAL… (3*)|(The funding for this study was provided by Allergan plc. Writing assistance by Complete HealthVizion, funded by Allergan plc.) Sa1034. . . . CAN ALBUMIN-BILIRUBIN GRADE (ALBI) PREDICT PRESENCE… (5*)|(Non) Sa1035. . . . IN-HOSPITAL MORTALITY OF TOXIC MEGACOLON HAS… (5*) Sa1036. . . . VEDOLIZUMAB CLINICAL DECISION SUPPORT TOOL PREDICTS… (3*)|(Takeda Pharmaceuticals U.S.A., Inc.)

Sa1037. . . . TRENDS AND HEALTHCARE DISPARITIES IN CIRRHOTICS… (5*) Sa1082. . . . DEVELOPMENT AND VALIDATION OF A MACHINE-LEARNING… (2*) Sa1083. . . . AUTOMATED TIME-RELEASED REMINDERS IMPROVES PATIENT ACCESS… (4*) Sa1084. . . . MOBILE APPLICATION USE IMPROVES NO-SHOW RATES… (5*)|(Mobile app (MageMySurgery) is a product of Higgs Boson Health and use of app was doted. No direct study funding was provided.) Sa1085. . . . COLONOSCOPY VOLUME OF COLONIC IRRIGATION (VOCI)… (5*) Sa1086. . . . DIGITAL RECTAL EXAMS ARE RARELY PERFORMED… (5*) Sa1087. . . . A NOVEL ELECTRONIC MEDICAL RECORD-BASED WORKFLOW… (5*) Sa1088. . . . CORRELATION BETWEEN SURROGATE QUALITY INDICATORS FOR… (5*) Sa1089. . . . A RETROSPECTIVE REVIEW OF INTRAVENOUS IRON… (5*) Sa1090. . . . ANEMIA IN PEDIATRIC INFLAMMATORY BOWEL DISEASE:… (5*) Sa1091. . . . APPLICATION OF BAYESIAN MODELING WITH INFLIXIMAB… (5*)|(1) Sa1092. . . . LUMINAL NITRIC OXIDE AND PLASMA NITRITE/NITRATE… (1*) Sa1093. . . . HEALTH CARE COSTS OF ENDOSCOPY AND… (5*) Sa1094. . . . FACTORS INFLUENCING TIMING OF PARACENTESIS AFTER… (5*) Sa1095. . . . UNDERSTANDING THE ROLE OF PHYSICIAN ATTIRE… (5*) Sa1096. . . . A PERSONALIZED MODEL TO ASSESS INTESTINAL… (4*) Sa1097. . . . HUMAN COLON ORGANOID MODEL OF SESSILE… (4*) Sa1098. . . . MOLECULAR RESPONSE OF CANINE INTESTINAL ORGANOIDS… (4*) Sa1099. . . . ESTABLISHMENT OF LONG-TERM NORMAL HUMAN INTESTINAL… (2*)


* = Primary Source



Sa1100. . . . KRÜPPEL-LIKE FACTOR 4 REGULATES BMI1+ INTESTINAL… (2*) Sa1101. . . . KRÜPPEL-LIKE FACTOR 5 IS CRITICAL FOR… (2*) Sa1102. . . . PROTEIN KINASE D PROMOTES INTESTINAL STEM… (2*) Sa1103. . . . STEM CELL EXPANSION AND INCREASED MESENCHYMAL… (2*) Sa1104. . . . DEFICIENCY OF NT-NTR1 SIGNALING PREVENTS THE… (2*) Sa1105. . . . CONDITIONAL KNOCKOUT OF CDC42/RAC NUCLEOTIDE EXCHANGE… (2*) Sa1106. . . . INTERACTION BETWEEN PANCREATIC CANCER CELLS AND… (2*)|(5) Sa1107. . . . ADENYLATE CYCLASE 6 AND CYSTIC FIBROSIS… (2*) Sa1108. . . . ANALYSING INTESTINAL ORGANOIDS IN A MULTI-OMICS,… (2*) Sa1109. . . . ROTAVIRUS-MEDIATED DEGRADATION OF DGAT1: A PREVIOUSLY… (2*) Sa1110. . . . CROSS PRESENTATION OF MICROBIAL TRANSGLUTAMINASE BY… (1*) Sa1111. . . . REGULATION OF THE BMP SIGNALING INHIBITOR… (2*) Sa1112. . . . THE ROLE OF NADPH OXIDASE 2… (2*)|(Brain Korea 21 PLUS Project for medical science) Sa1113. . . . GUT DYSBIOSIS WITH DECREASED AKKERMANSIA MUCINIPHILA.AND… (2*) Sa1114. . . . RUBICON INHIBITS AUTOPHAGY AND ACCELERATES THE… (5*) Sa1115. . . . THE POTENTIAL FUNCTION OF CIRCULAR RNA… (2*) Sa1116. . . . MYPT1 LEVEL MAY BE REGULATED THROUGH… (2*) Sa1118. . . . DEVELOPMENT OF A NOVEL GALLBLADDER CANCER… (2*) Sa1119. . . . DEOXYCHOLIC ACID ENHANCES LYMPHOCYTE MIGRATION TO… (4*) Sa1120. . . . SUPPRESSION OF PLASMACYTOID DENDRITIC CELL MIGRATING… (5*)

Sa1121. . . . A BUTYRATE-TARGETING SYNBIOTIC ATTENUATES CHRONIC-BINGE ETHANOL… (2*) Sa1122. . . . THE ELECTROGENIC NA+/HCO3- CO-TRANSPORTER (NBCE1/SLC4A4) IS… (2*) Sa1123. . . . ACTIVATION OF KV7 CHANNELS IN ENTERIC… (2*) Sa1124. . . . CHRONIC RETARDATION OF GASTROINTESTINAL TRANSIT TIME… (3*)|(YUYANG Dnu Co., Ltd) Sa1125. . . . INDUCIBLE GENETIC LINEAGE TRACING REVEALS UNEXPECTED… (2*) Sa1126. . . . PROBENICID IS EFFICIENT IN THE RECOVERY… (4*) Sa1127. . . . INTESTINAL GUANYLATE CYCLASE C MRNA EXPRESSION… (3*)|(This study was sponsored by Allergan plc and Ironwood Pharmaceuticals.) Sa1128. . . . ALTERED GASTROINTESTINAL IMMUNOGLOBULINS, MICROBIAL COMMUNITIES AND… (2*)| Sa1129. . . . EFFECTS OF BUTYRATE SUPPLEMENTATION ON NHE8KO… (2*) Sa1130. . . . LOSS OF NHE8 IMPAIRS GOBLET CELL… (2*) Sa1131. . . . LACTOBACILLUS RHAMNOSUS GG COLONIZATION IN EARLY… (2*) Sa1132. . . . EARLY LIFE LACTOBACILLUS RHAMNOSUS GG COLONIZATION… (2*)|(tiol tural Science Foundation of Chi (NO.81741075)) Sa1133. . . . LACTOBACILLUS REUTERI DSM 17938 FEEDING OF… (2*) Sa1135. . . . GENOMIC BIOMARKERS FOR CANCER RISK IN… (7*) Sa1136. . . . DETECTION OF BARRETT’S ESOPHAGUS THROUGH EXHALED… (3*)|(The AeonoseTM was provided by the eNose company for free.) Sa1137. . . . LIQUID NITROGEN SPRAY CRYOTHERAPY ERADICATES DYSPLASIA… (3*)|(CSA Medical) Sa1138. . . . ASSESSING THE AMERICAN COLLEGE OF GASTROENTEROLOGY… (2*) Sa1139. . . . RISK OF DYSPLASTIC PROGRESSION IN PATIENTS… (5*)

Sa1140. . . . HISTOPATHOLOGIST FEATURES PREDICTIVE OF DIAGNOSTIC CONCORDANCE… (6*) Sa1141. . . . VALIDATION AND COMPARISON OF TOOLS FOR… (2*) Sa1142. . . . HISTOLOGIC CHANGES IN THE NEOSQUAMOUS EPITHELIUM… (6*) Sa1143. . . . SURFACE KI-67 EXPRESSION ON HISTOPATHOLOGY PREDICTS… (5*) Sa1144. . . . WIDE AREA TRANSEPITHELIAL SAMPLING IMPROVES DETECTION… (3*)|(CDx Diagnostics) Sa1145. . . . NEOSQUAMOUS EPITHELIUM FOLLOWING ENDOSCOPIC ABLATION OF… (2*) Sa1146. . . . ESOPHAGEAL EXTRACELLULAR MATRIX HYDROGEL MITIGATES METAPLASTIC… (4*)|(C.R. BARD (B.D.)) Sa1147. . . . ANALYSIS OF SOCIO-ECONOMIC FACTORS AFFECTING THE… (4*) Sa1148. . . . THE MAJORITY OF PATIENTS WITH CONFIRMED… (5*) Sa1149. . . . INCIDENCE OF HIGH GRADE DYSPLASIA (HGD)… (5*) Sa1150. . . . BACK TO THE FUTURE - MULTIMODAL… (5*) Sa1151. . . . MUTATIONAL LOAD PREDICTS RISK OF PROGRESSION… (5*) Sa1152. . . . AGE OF DIAGNOSIS IN FAMILIAL ESOPHAGEAL… (2*) Sa1153. . . . NON-INVASIVE SCREENING FOR BARRETT’S ESOPHAGUS USING… (5*)|(The eNose Company, Zutphen, NL, provided Aeonose device for study but no funding.) Sa1154. . . . CLINICAL CONSEQUENCES OF NON-ADHERENCE IN SURVEILLANCE… (5*) Sa1155. . . . INCIDENCE OF DYSPLASIA IN OBESE VERSUS… (5*) Sa1156. . . . PARTICIPATION IN NON-ENDOSCOPIC SCREENING TECHNIQUES FOR… (2*) Sa1157. . . . ULTRA-SHORT SEGMENT BARRETT`S OESOPHAGUS: IS IT… (5*) Sa1158. . . . LINKED COLOR IMAGING (LCI), A NOVEL… (5*)


* = Primary Source



Sa1159. . . . THE IMPACTS OF ON-DEMAND VERSUS CONTINUOUS… (4*) Sa1160. . . . THE NATURAL HISTORY OF LOW GRADE… (5*) Sa1161. . . . LATE RECURRENCE OF DYSPLASTIC BARRETT’S ESOPHAGUS… (5*) Sa1162. . . . UTILITY AND YIELD OF POSITRON EMISSION… (5*) Sa1163. . . . THE RISK OF PREVALENT AND INCIDENT… (5*) Sa1164. . . . MEN WITH ESOPHAGEAL ADENOCARCINOMA RISK FACTORS… (5*) Sa1165. . . . GASTROESOPHAGEAL REFLUX INDUCES ISOLG-P53 ADDUCTS IN… (2*) Sa1166. . . . ESOPHAGEAL INFUSION OF MENTHOL DOES NOT… (2*)|(.) Sa1167. . . . HUMAN ESOPHAGEAL MYOFIBROBLASTS EXPOSED TO GASTRO-ESOPHAGEAL… (2*) Sa1168. . . . REDUCED ESOPHAGEAL CONTRACTILITY IS A RISK… (5*) Sa1169. . . . GERD SYMPTOMS EXACERBATION AFTER PPI DISCONTINUATION… (4*) Sa1170. . . . ASSESSMENT OF GASTROESOPHAGEAL REFLUX DISEASE BY… (5*) Sa1171. . . . ASSOCIATION BETWEEN SKELETAL MUSCLE ATTENUATION AND… (5*) Sa1172. . . . WEIGHT REGAIN FOLLOWING ROUX-EN-Y GASTRIC BYPASS:… (5*) Sa1173. . . . SALIVA SECRETION IN PATIENTS WITH PPI-RESISTANT… (4*) Sa1174. . . . ESOPHAGEAL MUCOSAL INNERVATION IN FUNCTIONAL HEARTBURN… (4*) Sa1175. . . . EARLY ADULTHOOD CHRONIC ANTIBIOTIC USE AND… (2*)|(UM1 CA186107, K24 DK098311, R01DK088782) Sa1176. . . . IMPACT OF PRE-TRANSPLANT REFLUX TESTING ON… (5*) Sa1177. . . . GASTROESOPHAGEAL REFLUX IS ASSOCIATED WITH CHRONIC… (5*) Sa1178. . . . ABNORMAL REFLUX ON COMBINED HYPOPHARYNGEAL-ESOPHAGEAL IMPEDANCE-PH… (5*)

Sa1179. . . . PROTON PUMP INHIBITOR THERAPY REDUCES RISK… (5*) Sa1180. . . . COMPARISON OF ESOPHAGEAL FUNCTION TESTING PROFILES… (5*) Sa1181. . . . IDENTIFYING GASTROESOPHAGEAL REFLUX DISEASE POST-LUNG TRANSPLANT… (5*) Sa1182. . . . AN EXPLORATORY LATENT CLASS ANALYSIS OF… (7*) Sa1183. . . . STRAIN DIFFERENCES IN ACID MEDIATED ESOPHAGO-CARDIOVASCULAR… (2*) Sa1184. . . . INCREASED SENSITIVITY OF COUGH REFLEX IS… (2*)|(.) Sa1185. . . . BARIUM SWALLOW FINDINGS DO NOT CORRELATE… (5*) Sa1186. . . . EFFICACY OF PNEUMATIC DILATATION FOR SEVERE… (5*) Sa1187. . . . ON ORDINARY DOSE OF PPI, RESIDUAL… (5*) Sa1188. . . . ABNORMAL BOLUS REFLUX ON IMPEDANCE-PH MONITORING… (5*) Sa1189. . . . GASTROESOPHAGEAL REFLUX DISEASE IS AN INDEPENDENT… (5*) Sa1190. . . . PREVALENCE OF DYSBIOSIS IN PATIENTS ON… (5*) Sa1191. . . . MEASURING HEARTBURN SEVERITY AND REGURGITATION FREQUENCY… (3*)|(Ironwood Pharmaceuticals, Inc.) Sa1192. . . . AMELIORATING EFFECTS AND AUTONOMIC MECHANISMS OF… (5*) Sa1193. . . . PATIENT AND PHYSICIAN PERSPECTIVES AND PRACTICE… (5*) Sa1194. . . . 1-YEAR INTERIM ANALYSIS RESULTS OF VISION… (3*)|(Takeda Pharmaceutical Company Limited) Sa1195. . . . TREATMENT OUTCOMES IN PATIENTS WITH GLOBUS:… (4*) Sa1196. . . . A SLEEP POSITIONING DEVICE REDUCES ESOPHAGEAL… (5*) Sa1197. . . . PROTON PUMP INHIBITORS THERAPY AND THE… (5*) Sa1198. . . . MANAGEMENT PATTERNS FOR NONACID REFLUX PATIENTS… (5*)

Sa1199. . . . PREVALENCE AND PROFILE OF PATIENTS WITH… (3*) Sa1200. . . . HYPERGASTRINEMIA SECONDARY TO LONG-TERM PROTON PUMP… (2*) Sa1201. . . . SIGNIFICANT DIFFERENCE IN THE PROPORTION OF… (1*) Sa1202. . . . CONCOMITANT AZITHROMYCIN AND HIGH DOSE PROTON… (5*) Sa1203. . . . ACUTE EFFECT OF CURCUMINOID ON REFLUX… (2*) Sa1204. . . . A COMPARISON OF DIFFERENT TREATMENTS FOR… (1*) Sa1205. . . . PREDICTING FACTORS OF RECURRENCE IN PATIENTS… (4*) Sa1206. . . . LONG TERM PROTON PUMP INHIBITOR USE… (5*) Sa1207. . . . THE EFFECT OF A MEDICAL DEVICE… (3*)|(SOFAR S.p.A) Sa1208. . . . SERUM CONCENTRATION AND PHARMACOKINETICS OF SINGLE… (4*) Sa1293. . . . TRANSPYLORIC FEED IN GASTROESOPHAGEAL REFLUX ASSOCCIATED… (5*) Sa1294. . . . PHARYNGEAL AND UPPER ESOPHAGEAL SPHINCTER MOTOR… (5*) Sa1295. . . . SERPINB12 AS A POSSIBLE MARKER OF… (5*) Sa1296. . . . MIR-597-5P IS ASSOCIATED WITH TUMOR INVASION… (2*) Sa1297. . . . THERAPEUTIC EFFECT OF NIVOLUMAB THERAPY ON… (5*) Sa1298. . . . GASTRIC XANTHOMA IS A USEFUL PREDICTOR… (5*) Sa1299. . . . WOMEN WITH GASTRIC CANCER ARE SIGNIFICANTLY… (5*) Sa1300. . . . HER2 REGULATES THE CANCER STEM CELL… (5*) Sa1301. . . . SEVERE ATROPHIC GASTRITIS IS A RISK… (5*) Sa1302. . . . THE ANTITUMOR EFFECT OF TALAPORFIN PHOTO… (5*) Sa1303. . . . THE EFFECT OF TALAPORFIN-MEDIATED PHOTODYNAMIC THERAPY… (4*)


* = Primary Source



Sa1304. . . . CLINICOPATHOLOGIC FEATURES OF SUBMUCOSAL PAPILLARY GASTRIC… (5*) Sa1305. . . . GENETIC POLYMORPHISMS AS RISK FACTORS FOR… (2*) Sa1306. . . . BIOMARKERS IN MULTIVISCERAL AND INTESTINAL TRANSPLANTATION… (5*) Sa1307. . . . CHRONIC MORPHINE TREATMENT IMPAIRS THE ANTINOCICEPTIVE… (6*) Sa1308. . . . ABDOMINAL PAIN IN QUIESCENT INFLAMMATORY BOWEL… (4*) Sa1309. . . . ANTIBIOTICS TREATMENT AFFECTS BODY METABOLISM AND… (5*) Sa1310. . . . ALTERATION OF COLONIC MUCOSAL PERMEABILITY UNDER… (5*) Sa1311. . . . ANTI-INFLAMMATORY AND VISCERAL PAIN RELIEVING EFFECTS… (4*) Sa1312. . . . AMELIORATING EFFECTS OF SACRAL NERVE STIMULATION… (5*) Sa1313. . . . DEVELOPMENT AND VALIDATION OF A TEST-SPECIFIC… (5*) Sa1314. . . . DELETION OF SCAVENGER RECEPTOR PROTECTS AGAINST… (4*) Sa1315. . . . REDUCED ABDOMINAL PAIN PERCEPTION IN INFLAMMATORY… (4*) Sa1316. . . . ETHNIC DISPARITIES IN MORTALITY RATES FOLLOWING… (5*) Sa1317. . . . GLOBAL INCIDENCE OF ACUTE PANCREATITIS THROUGH… (5*)|(Nil) Sa1318. . . . DIFFERENCES IN OUTCOMES AND ETIOLOGIES OF… (5*) Sa1319. . . . OUTCOMES OF ACUTE PANCREATITIS IN JULY:… (5*) Sa1320. . . . THE CURRENT STATE OF ACUTE PANCREATITIS… (5*) Sa1321. . . . SEVERE ACUTE PANCREATITIS INCIDENCE AND OUTCOMES… (5*) Sa1322. . . . EFFECT OF THE AMERICAN GASTROENTEROLOGICAL ASSOCIATION… (5*) Sa1323. . . . THE QUALITY OF EARLY ACUTE PANCREATITIS… (5*)

Sa1324. . . . PATIENT-REPORTED SYMPTOM BURDEN IN PANCREATIC CANCER… (5*) Sa1325. . . . GEOGRAPHICAL COST VARIATION OF ACUTE PANCREATITIS… (5*) Sa1337. . . . EXERCISE-INDUCED MYOKINES AS A MECHANISM FOR… (5*) Sa1338. . . . DEVELOPMENT OF A NOVEL CIRCULATING TUMOR… (2*) Sa1339. . . . ANALYSIS OF 1200 CANCER-RELATED GENES FOR… (2*) Sa1340. . . . TUMOR SUPPRESSOR ROLE OF MIR-107 AND… (2*) Sa1341. . . . PANCREATIC ACINAR CARCINOMA HAS DISTINCT MUTATION… (4*) Sa1342. . . . BROWN ADIPOSE TISSUE ACTIVATION DETECTED BY… (5*) Sa1343. . . . RATES OF PANCREATIC NEOPLASIA IN A… (4*) Sa1344. . . . DEVELOPMENT OF A PREOPERATIVE PREDICTIVE RISK… (5*) Sa1345. . . . PROGNOSTIC FACTORS FOR PATIENTS WITH BORDERLINE… (5*) Sa1346. . . . ASSOCIATION BETWEEN HELICOBACTER PYLORI INFECTION AND… (5*) Sa1347. . . . COMPARISON OF EFFICACY BETWEEN ADJUVANT CHEMOTHERAPY… (5*) Sa1348. . . . EUS DETECTION OF TRACE ASCITES IN… (5*) Sa1349. . . . HIGH FAT, HIGH CALORIE DIET EFFECTS… (2*)| Sa1350. . . . UPDATED INTERNATIONAL CANCER OF THE PANCREAS… (4*) Sa1351. . . . ELEVATED HEMOGLOBIN A1C IS ASSOCIATED WITH… (4*) Sa1352. . . . RISING INCIDENCE OF PANCREATIC CANCER IN… (5*) Sa1353. . . . FACTORS AFFECTING EUS-FNA DIAGNOSTIC YIELD FOR… (5*) Sa1354. . . . SEX AND AGE DISPARITIES IN PANCREATIC… (2*) Sa1355. . . . OUTCOMES OF NEOADJUVANT CHEMORADIATION WITH AND… (4*)

Sa1356. . . . DEPRESSION AS A SYMPTOM OF PANCREATIC… (5*) Sa1357. . . . PANCREATIC CANCER IN LIVER TRANSPLANT RECIPIENTS… (5*) Sa1358. . . . EPIDEMIOLOGY, ENVIRONMENTAL AND METABOLIC RISK FACTORS… (5*) Sa1359. . . . CHOLECYSTITIS IN PANCREATIC CARCINOMA: A POORLY… (5*) Sa1360. . . . HEAT SHOCK PROTEIN 27 (HSP27) EXPRESSION… (5*) Sa1361. . . . UTILITY OF LIQUID BIOPSY USING URINE… (4*) Sa1362. . . . PROTON PUMP INHIBITOR (PPI) AND HISTAMINE-2… (5*) Sa1363. . . . PREDICTIVE FACTORS FOR THE DEVELOPMENT OF… (5*) Sa1364. . . . A NEW INVESTIGATION OF DRUG REPURPOSING… (5*) Sa1365. . . . PATIENT-REPORTED BURDEN OF INTENSIFIED SURVEILLANCE AND… (4*) Sa1366. . . . INCREASED MEDIUM-TERM RISK OF PANCREATIC CANCER… (5*) Sa1367. . . . HALF OF SPORADIC PANCREATIC DUCTAL ADENOCARCINOMA… (5*) Sa1368. . . . GENOMIC PROFILING OF PANCREATIC DUCTAL ADENOCARCINOMA… (5*) Sa1369. . . . DEPRESSION PRECEDING PANCREATIC CANCER: A LONGITUDINAL… (5*) Sa1370. . . . EARLY DETECTION OF PANCREATIC CANCER LEADS… (5*) Sa1371. . . . EUS AND CT SCAN DIAGNOSTIC YIELD… (5*) Sa1372. . . . PANCREATIC DUCTAL ADENOCARCINOMA DETECTED AFTER ACUTE… (5*) Sa1374. . . . IMPACT OF ABO BLOOD TYPE IN… (5*) Sa1375. . . . THE UTILITY OF CA 19-9 IN… (5*) Sa1376. . . . EXPRESSION OF NOTCH RECEPTORS AND THEIR… (2*)


* = Primary Source



Sa1377. . . . REDUCTION IN AMYLASE/LIPASE SUPERFLUOUS TESTING: A… (5*) Sa1378. . . . RIFAXIMIN IN SELECTIVE DIGESTIVE DECONTAMINATION IN… (5*) Sa1379. . . . ACUTE PANCREATITIS IN SARCOIDOSIS: IS THERE… (5*) Sa1380. . . . ACUTE PANCREATITIS NATIONAL OUTCOMES IN THE… (5*) Sa1381. . . . SYSTEMIC ANTICOAGULATION IS ASSOCIATED WITH DECREASED… (5*) Sa1382. . . . THE EPIDEMIOLOGY OF ACUTE PANCREATITIS IN… (5*) Sa1383. . . . THE IMPACT OF OPIOID AND NON-OPIOID… (5*) Sa1384. . . . EARLY FEEDING IN ACUTE PANCREATITIS IN… (5*) Sa1385. . . . PANCREATITIS IN TYPE 2 DIABETES: A… (5*) Sa1386. . . . CONTINUOUS REGIONAL ARTERIAL INFUSION OF PROTEASE… (5*) Sa1387. . . . HOMA-ESTIMATED INSULIN RESISTANCE AS AN INDEPENDENT… (5*) Sa1388. . . . IS AGGRESSIVE FLUID RESUSCITATION THE BEST… (5*) Sa1389. . . . INTENSIVE-FLUSHING TREATMENT IN ABDOMINAL CAVITY DURING… (5*) Sa1391. . . . SEVERITY IN ACUTE PANCREATITIS: EFFECT OF… (4*) Sa1392. . . . DOES ANTI-INTERLEUKIN MEDICATIONS IMPACT ACUTE PANCREATITIS… (5*) Sa1393. . . . RELATION BETWEEN PREGNANCY AND ACUTE PANCREATITIS:… (4*) Sa1394. . . . INCIDENCE OF ACUTE PANCREATITIS IS NOT… (5*) Sa1395. . . . ACUTE PANCREATITIS IN ADVANCED CHRONIC KIDNEY… (5*) Sa1396. . . . EVALUATION OF REAL-TIME PANCREATIC PARENCHYMAL AND… (5*) Sa1397. . . . CHRONIC ASYMPTOMATIC PANCREATIC HYPERENZYMEMIA (CAPH): META-ANALYSIS… (5*)

Sa1398. . . . NOVEL BIO-DEGRADABLE STENT IN PATIENTS WITH… (5*) Sa1399. . . . PANCREATIC FUNCTIONAL AND STRUCTURAL EVALUATION WITH… (5*) Sa1523. . . . UTILITY OF SHEAR WAVE ELASTOGRAPHY TO… (4*) Sa1524. . . . VALIDATION AND OPTIMIZATION OF AN EARLY… (4*) Sa1532. . . . NON-CALCULOUS BENIGN CHOLANGITIS IS MORE LIKELY… (5*) Sa1533. . . . ASSOCIATION BETWEEN BACTEREMIA AND 30-DAY MORTALITY… (4*) Sa1534. . . . PRIMARY BILIARY CHOLANGITIS PATIENTS WHO ARE… (5*) Sa1535. . . . PREDICTORS OF 30-DAY READMISSION AFTER INPATIENT… (5*) Sa1536. . . . ENDOSCOPIC SPHINCTEROTOMY ON THIENOPYRIDINE THERAPY HAS… (5*) Sa1537. . . . ROLE OF PROPHYLACTIC CHOLECYSTECTOMY AFTER ENDOSCOPIC… (5*) Sa1538. . . . THE EPIDEMIOLOGY OF ULCERATIVE COLITIS-PRIMARY BILIARY… (5*) Sa1539. . . . POTENTIAL REPURPOSING OF ANGIOTENSIN INHIBITORS OR… (6*) Sa1540. . . . INCREASED ODDS OF ACUTE CHOLANGITIS IN… (5*) Sa1541. . . . METABOLOMIC ANALYSIS OF PRIMARY SCLEROSING CHOLANGITIS… (6*)|(Pfizer Inc.) Sa1542. . . . DETECTION OF LOW PHOSPHOLIPID ASSOCIATED CHOLELITHIASIS… (5*) Sa1543. . . . DECREASED ODDS OF MORTALITY IN PATIENTS… (5*) Sa1544. . . . EVALUATION OF HYPERBILIRUBINEMIA IN PATIENTS WHO… (5*) Sa1545. . . . LONG TERM TREATMENT OF PRIMARY BILIARY… (5*) Sa1546. . . . PREDICTING LATE CBD STONE AFTER LAPAROSCOPIC… (5*)

Sa1547. . . . RAPID CHOLESTEROL (CH) CRYSTALLIZATION VIA THE… (2*) Sa1548. . . . INVESTIGATIONS INTO VIRAL ETIOLOGY OF PRIMARY… (6*) Sa1549. . . . CAUSATIVE PATHOGENS PATTERN IN ENDOSCOPIC ULTRASOUND-GUIDED… (5*) Sa1550. . . . THE EFFECT OF STATIN WITH EZETIMIBE… (5*) Sa1551. . . . SULFASALAZINE COMPARED TO MESALAMINE IN PRIMARY… (5*) Sa1552. . . . FIBROSCAN ASSESSMENT OF PATIENTS UNDERGOING ENDOSCOPY… (3*)|(1)|(Echosens) Sa1553. . . . RELIABILITY AND VALIDITY ASSESSMENT IF THE… (3*)|(1)|(Intercept Pharmaceuticals) Sa1554. . . . FIBROSCAN RISK ASSESSMENT OF NON-ALCOHOLIC FATTY… (3*)|(Echosens) Sa1555. . . . LIVER DISEASE AMONG OLDER MEXICAN AMERICANS… (2*) Sa1556. . . . PERCEPTIONS AND KNOWLEDGE ABOUT ADVANCE CARE… (5*) Sa1645. . . . A NEW PEDIATRIC INTESTINAL PSEUDO-OBSTRUCTION SYNDROM… (5*) Sa1646. . . . GASTROINTESTINAL (GI) FEATURES OF 22Q11.2 DELETION… (5*) Sa1647. . . . FEASABILITY OF A SPIRULINA BREATH TEST… (4*)|(tionwide Children's Hospital 4 provided a total of $1250 for patient incentives. (Each healthy volunteer who underwent the breath test received an incentive of $50.) Cairn Diagnostics provided the GEBT kits (with the meal components and test tubes for) Sa1648. . . . SACRAL NERVE STIMULATION FOR CHILDREN WITH… (5*) Sa1649. . . . OXYTOCIN PLASMA CONCENTRATIONS IN ADOLESCENTS WITH… (2*) Sa1650. . . . ENDORECTAL BALLOON (ERB) DURING IMAGE GUIDED… (2*) Sa1651. . . . DOES COACHING IMPROVE A TRAINEES' ABILITY… (5*) Sa1652. . . . TOWARDS AN OPTIMAL TOOL FOR ASSESSMENT… (2*)|(Intone MV.)


* = Primary Source



Sa1653. . . . CLINICAL UTILITY OF TRANSLUMBOSACRAL ANORECTAL MAGNETIC… (2*) Sa1654. . . . VALIDATION OF A PROSPECTIVE STOOL DIARY… (5*) Sa1655. . . . CAN THE RESULTS OF ANORECTAL INVESTIGATIONS… (6*) Sa1656. . . . REPETITIVE TRANSPELVIC MAGNETIC STIMULATION (TPMS) ATTENUATES… (4*) Sa1657. . . . ANAL TAPE A GENUINE EXTERNAL DEVICE FOR… (5*) Sa1658. . . . INFLUENCE OF A DEFECATION POSTURE MODIFICATION… (5*) Sa1659. . . . COMPARISON OF CHANGES IN RECTAL AREA… (2*) Sa1660. . . . COEXISTENCE OF FECAL INCONTINENCE AND CONSTIPATION… (5*) Sa1661. . . . IDENTIFYING SUBTYPES IN PATIENTS WITH FUNCTIONAL… (2*) Sa1662. . . . CHARACTERISTICS OF PATIENTS WHO ‘FAIL’ BIOFEEDBACK… (5*) Sa1663. . . . FECOBIONICS DEFECATORY FUNCTION TESTING IN HEALTHY… (2*) Sa1664. . . . ARE DYSSYNERGIC DEFECATION AND ALTERED RECTAL… (5*) Sa1665. . . . SPONTANEOUS INTERNAL ANAL SPHINCTER RELAXATION ON… (5*) Sa1666. . . . INTEGRATION OF SMOOTH MUSCLE AND NEURAL… (2*) Sa1667. . . . USE OF [LYS5,MELEU9,NLE10]-NKA(4–10) (LMN-NKA) AS A… (2*)|(Dignify Therapeutics, LLC) Sa1668. . . . ON-DEMAND, DRUG-INDUCED DEFECATION FOLLOWING INTRAVENOUS (IV),… (2*)|(Dignify Therapeutics, LLC) Sa1669. . . . FLATUS INCONTINENCE IN WOMEN: COMPARISON WITH… (5*) Sa1670. . . . LONG TERM CLINICAL AND PHYSIOLOGICAL CONSEQUENCES… (5*)|(no funding) Sa1671. . . . ANATOMICAL DEFECTS OF THE ANAL SPHINCTER… (2*) Sa1672. . . . EVALUATION OF DIFFERENCES IN SYMPTOM AND… (4*)

Sa1673. . . . EVALUATION OF COMPLIANCE AND RECTAL SENSITIVITY… (5*) Sa1674. . . . OBESITY IS INDEPENDENTLY ASSOCIATED WITH INCREASED… (5*) Sa1675. . . . THE IMMEDIATE AND DELAYED EFFECTS OF… (5*) Sa1676. . . . IDENTIFICATION AND CHARACTERIZATION OF RVM NEURONS… (2*) Sa1677. . . . CHRONIC COLONIC ADMINISTRATION OF THE GUANYLATE… (3*)|(Ironwood Pharmaceuticals) Sa1678. . . . FOLIC ACID ATTENUATES CHRONIC VISCERAL HYPERSENSITIVITY… (2*)|(The present work was supported in part by grants from the tiol tural Science Foundation of Chi (81471137 and 31730040).) Sa1679. . . . MULTIPLE RATHER THAN SPECIFIC ANTIBODIES WERE… (2*) Sa1680. . . . SECOND GENERATION ANTI-CDTB AND ANTI-VINCULIN TESTING… (5*) Sa1681. . . . GC-C AGONISM WITH LINACLOTIDE ATTENUATES CHRONIC… (3*)|(Ironwood Pharmaceuticals, Inc.) Sa1682. . . . METABOLIC ALTERATIONS TO FECAL GUT MICROBIOTA… (2*)|(This study was supported by Grant-in-Aids for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan and by Research Grant from Miyarisan Pharmaceutical Co., Ltd., Tokyo, Japan.) Sa1683. . . . POTENTIAL CLINICAL VALUE OF LACTOBACILLUS RHAMNOSUS… (2*) Sa1684. . . . ALTERATION OF MICROBIOTA BY MATERNAL SEPARATION… (2*) Sa1685. . . . PROTEOMIC CHARACTERIZATION OF IBS VS CONTROL… (3*)|(Nestlé Institute of Health Sciences) Sa1686. . . . ASSESSMENT OF THE FECAL MICROBIOME AND… (4*) Sa1687. . . . EXPOSURE TO PETS IS ASSOCIATED WITH… (5*) Sa1688. . . . INDUCTION OF BRAIN-DERIVED NEUROTROPHIC FACTOR IN… (4*) Sa1689. . . . PILOT STUDY OF TERMINAL ILEUM MUCOSA… (5*)

Sa1690. . . . EFFECT OF CONSUMPTION OF NOPAL FIBER… (2*) Sa1691. . . . PROSPECTIVE EVALUATION OF THE CLINICAL IMPACT… (4*) Sa1692. . . . CLINICAL POTENTIAL OF CIRCULATING TUMOR CELLS… (2*) Sa1693. . . . COHESIN SA1 REGULATES FATTY ACID METABOLISM,… (2*) Sa1694. . . . CONVENIENT METHOD TO CAPTURE CIRCULATING TUMOR… (5*) Sa1695. . . . EVALUATING THE THERAPEUTIC ROLE OF METFORMIN… (4*) Sa1696. . . . STAT3-MEDIATED GENE AND MIRNA EXPRESSION PROFILING… (4*) Sa1697. . . . IS COMPUTED TOMOGRAPHY AN ACCURATE DIAGNOSTIC… (4*) Sa1698. . . . INITIAL EXPERIENCE WITH PEPTIDE RECEPTOR RADIONUCLIDE… (5*) Sa1699. . . . ENDOSCOPIC SUBMUCOSAL RESECTION WITH AN ENDOSCOPIC… (5*) Sa1700. . . . CHANGE IN INCIDENCE, CHARACTERISTICS AND MANAGEMENT… (4*) Sa1701. . . . RECURRENCE RATES AFTER ENDOSCOPIC RESECTION OF… (5*) Sa1702. . . . OPERATIVE RESECTION OF DUODENAL CARCINOID TUMORS:… (5*)|(Shria Kumar is supported by a tiol Institutes of Health T32 grant (5 T32 DK 7740-22). dim Mahmud is supported by a tiol Institutes of Health T32 grant (2-T32-DK007740-21A1).) Sa1703. . . . IS SURVEILLANCE WITH GASTRIC ACID MEASUREMENT… (2*) Sa1704. . . . ENDOSCOPIC MANAGEMENT OF DUODENAL NEUROENDOCRINE TUMORS… (5*) Sa1705. . . . CHARACTERISTICS AND ENDOSCOPIC MANAGEMENT OF GASTRIC… (5*) Sa1706. . . . MAP9 DEFICIENCY SPONTANEOUSLY DRIVES COLON TUMORIGENESIS… (2*) Sa1707. . . . USING ENDOSCOPIC FINE NEEDLE BIOPSIES OF… (2*) Sa1708. . . . SELENOPROTEIN P MODIFIES WNT-DRIVEN SPORADIC COLORECTAL… (2*)


* = Primary Source



Sa1709. . . . TARGETING DR5 IN BOTH MDSCS AND… (2*)|(( The project was supported by NSFC81472727,NSFC81272403,NSFC81773259; Science and Technology Commission of Shanghai Municipality (15JC1403100)).) Sa1710. . . . TRPV1 INHIBITS GASTRIC CANCER DEVELOPMENT VIA… (2*)|(tiol Key Research and Development Program of Chi (No. 2016YFC1302200) and tiol tural Science Foundation of Chi (No. 81570477)) Sa1711. . . . BONE MARROW-DERIVED MYOFIBROBLASTS PROMOTES GASTRIC CANCER… (2*)|(( The project was supported by NSFC81472727,NSFC81272403,NSFC81773259; Science and Technology Commission of Shanghai Municipality (15JC1403100)).) Sa1712. . . . THE EXPRESSION OF CIRCULAR RNA, CDR1-AS,… (2*) Sa1713. . . . MIR-143 SUPPRESSES TUMORIGENESIS AND PROGRESSION OF… (2*) Sa1714. . . . OXALIPLATIN INHIBITS DIFFERENTIATION OF M-MDSCS INTO… (2*) Sa1715. . . . DECREASED P62 PROTEIN EXPRESSION IS ASSOCIATED… (5*) Sa1716. . . . STAT6 SIGNALING IN COLON CANCER CELLS… (4*) Sa1717. . . . DEVELOPMENT OF A SWALLOWABLE DIGANOSTIC CAPSULE… (3*)|(Progenity Inc.) Sa1718. . . . A NEAR-INFRARED PROBE FOR IN VIVO… (6*) Sa1719. . . . COMPARISON OF TWO CUT-OFF VALUES OF… (2*) Sa1720. . . . EFFECT OF COLONOSCOPY ASSISTED DEVICES ON… (5*) Sa1721. . . . MORE LESIONS PER PATIENT DETECTED WITH… (3*)|(Norgine) Sa1722. . . . ASSESSMENT OF COLONOSCOPY QUALITY IN NON-ACADEMIC… (5*) Sa1723. . . . MUCOSAL HEALING DEFINED BY ADVANCED ELECTRONIC… (5*) Sa1724. . . . MOXIFLOXACIN PROMOTES MULTIPHOTON MICROSCOPIC IMAGING FOR… (5*)

Sa1725. . . . LEOPARD STUDY - ITALIAN MULTICENTER PROSPECTIVE… (1*) Sa1726. . . . IN VIVO AND EX VIVO MICROSTRUCTURE… (5*) Sa1727. . . . OUTCOMES OF GI POLYPS RESECTED USING… (5*) Sa1728. . . . THE PROGNOSTIC VALUE OF A NEW… (1*) Sa1729. . . . RISK FACTORS FOR COLONIC DIVERTICULOSIS: A… (1*) Sa1730. . . . THE HISTOLOGICAL HEALING IN ULCERATIVE COLITIS… (5*) Sa1731. . . . A TRANS-NASAL, IMAGE-GUIDED APPROACH FOR BRUSH… (6*) Sa1732. . . . PREDICTORS OF 30 DAYS READMISSIONS AFTER… (5*) Sa1733. . . . ETIOLOGIES AND TRENDS OF 30 DAYS… (5*) Sa1734. . . . EVALUATING THE EFFICACY OF HEMOSTATIC NANOPOWDER… (5*) Sa1735. . . . BASELINE BOWEL STIFFNESS ON REAL-TIME SHEAR… (5*) Sa1736. . . . THE ROLE OF “ROSE” FOR ERCP-GUIDED… (5*) Sa1737. . . . FXR AGONIST M480, EXHIBITS EFFICACY IN… (3*)|(Metacrine) Sa1738. . . . OLORINAB (FORMERLY APD371), A PERIPHERALLY RESTRICTED,… (3*)|(Are Pharmaceuticals Inc. and NHMRC Australia.) Sa1739. . . . USING THE ZONULIN TRANSGENIC MOUSE MODEL… (2*) Sa1740. . . . SPONTANEOUS MOUSE COLITIS PRODUCED BY DELETION… (2*)| Sa1741. . . . IDENTIFICATION AND CHARACTERIZATION OF THE FIRST… (2*)| Sa1742. . . . INTERLEUKIN-10 KNOCKOUT MICE DO NOT EXHIBIT… (6*) Sa1743. . . . INVESTIGATION OF THE RELATIONSHIP BETWEEN ASPIRIN-INDUCED… (1*) Sa1744. . . . A NOVEL PORCINE MODEL OF CROHN’S… (2*) Sa1745. . . . GLACIAL ACETIC ACID-INDUCED ULCERATIVE COLITIS LESIONS… (4*)

Sa1746. . . . ORAL CALCIUM NANOPARTICLE THERAPY AIDS IN… (4*) Sa1747. . . . FXR AGONISTS WITH SUSTAINED ACTIVITY EXHIBIT… (3*)|(Metacrine) Sa1748. . . . THE BOWEL CLEANSING NATIONAL INITIATIVE (BCLEAN):… (3*)|(received arm-length funding from Pendopharm Inc.) Sa1749. . . . GASTROENTEROLOGY-RELATED HASHTAG UTILIZATION ON INSTAGRAM AND… (5*) Sa1750. . . . PREVALENCE AND OUTCOMES OF PORTOMESENTERIC VEIN… (5*) Sa1751. . . . OUTCOME, COMPLICATION AND LONG-TERM FOLLOW UP… (5*) Sa1752. . . . VALIDATION OF A FECAL INCONTINENCE BOWEL… (2*)|(Medspira Scientific provided software and physiological recorders at discounted prices.) Sa1753. . . . IBD NURSE INTERVENTION FOR PATIENTS ASSIGNED… (3*)|(This work was supported by the Pfizer independent grants for learning & change) Sa1754. . . . SLEEP DISTURBANCE AND TRAVEL INTERRUPTION WITH… (3*)|(Pendopharm) Sa1755. . . . PRESENTING SYMPTOM SEVERITY AND HEALTH-RELATED QUALITY… (5*) Sa1756. . . . EFFECTS OF PHARMACEUTICAL DIRECT-TO-CONSUMER ADVERTISING (DTCA)… (5*) Sa1757. . . . IMPROVEMENT IN DISEASE ACTIVITY IS ASSOCIATED… (5*) Sa1758. . . . THE RELATIONSHIP BETWEEN SERUM BILIRUBIN AND… (2*) Sa1759. . . . TRENDS IN TNF-ALPHA INHIBITOR UTILIZATION IN… (5*) Sa1760. . . . RISK FACTORS FOR POST-OPERATIVE CROHN'S DISEASE… (5*) Sa1761. . . . CHITINASE 3-LIKE-1 PROTEIN: A NOVEL BIOMARKER… (6*) Sa1762. . . . LARGE-SCALE PROTEOMICS IDENTIFIES ANTI-TNF RESPONSE SIGNATURE… (2*)


* = Primary Source



Sa1763. . . . A MULTI-PROTEIN SERUM TEST PREDICTS MUCOSAL… (3*)|(Prometheus Laboratories performed a blood assay and covered the cost for that assay.) Sa1764. . . . PERIPHERAL BLOOD EOSINOPHILIA IS A BIOMARKER… (2*) Sa1766. . . . INVESTIGATIONS OF THE CHARACTERISTICS AND ANTI-TNFα… (5*) Sa1767. . . . SOMASCAN AS A DISCOVERY PLATFORM TO… (6*) Sa1768. . . . THE INTESTINAL MICROBIOME IN INFLAMMATORY BOWEL… (2*)|(This Tobacco Formula grant is under the Pennsylvania Commonwealth Universal Research Enhancement (C.U.R.E) program with the grant number SAP # 4100068710.) Sa1769. . . . WORLDWIDE INCIDENCE OF OLDER-ONSET INFLAMMATORY BOWEL… (2*) Sa1770. . . . DE-NOVO INFLAMMATORY BOWEL DISEASE AFTER BARIATRIC… (5*) Sa1771. . . . THE GLOBAL BURDEN OF INFLAMMATORY BOWEL… (5*) Sa1772. . . . PREVALENCE OF CERVICAL DYSPLASIA IN WOMEN… (5*) Sa1773. . . . NONALCOHOLIC LIVER DISEASE SIGNIFICANTLY MORE PREVALENT… (5*) Sa1774. . . . INCREASED PREVALENCE OF NONALCOHOLIC LIVER DISEASE… (5*) Sa1775. . . . CROHN'S DISEASE AND ULCERATIVE COLITIS WAS… (5*) Sa1776. . . . THE 30-YEAR TREND ANALYSIS IN THE… (2*)|(This work was supported by a Korean Health Technology R&D Project grant from the Korea Health Industry Development Institute (A120176) and by a research grant from Janssen Korea Ltd.) Sa1777. . . . OVARIAN CANCER AND UTERINE CANCER ARE… (5*) Sa1778. . . . INCREASED RISK OF MENINGITIS IN PATIENTS… (6*)|(Crohn's and Colitis Foundation (Grant Number 568735 to BK)) Sa1779. . . . HOSPITALIZATIONS FOR IBD THROUGHOUT THE WORLD:… (2*) Sa1780. . . . REVISITING THE ASSOCIATION BETWEEN INFLAMMATORY BOWEL… (5*) Sa1781. . . . THE RISK OF INFLAMMATORY BOWEL DISEASE… (5*)

Sa1782. . . . EFFECT OF VACCINATION AND IMMUNOSUPPRESSIVE MEDICATIONS… (5*) Sa1783. . . . INCIDENCE OF INDETERMINATE COLITIS IN THE… (5*) Sa1784. . . . INFLAMMATORY BOWEL DISEASE IN UK PRIMARY… (6*) Sa1785. . . . THE PREVALENCE AND EPIDEMIOLOGY OF POUCHITIS… (5*) Sa1786. . . . ASSESSMENT OF METAL EXPOSURES IN DECIDUOUS… (4*) Sa1787. . . . THE PROGRESSION OF INFLAMMATORY BOWEL DISEASE… (5*) Sa1788. . . . NATURAL HISTORY OF DIABETES MELLITUS AND… (2*) Sa1789. . . . DOSE–RESPONSE RELATIONSHIP BETWEEN CIGARETTE SMOKING AND… (5*) Sa1790. . . . MULTI-PARAMETER DATA-SETS ARE REQUIRED TO IDENTIFY… (1*) Sa1791. . . . ASSOCIATION BETWEEN ALBUMIN GLOBULIN RATIO AND… (5*) Sa1792. . . . THE INCIDENCE OF INFLAMMATORY BOWEL DISEASE:… (4*) Sa1793. . . . EVALUATION OF THE 10-YEAR CARDIOVASCULAR DISEASE… (4*) Sa1794. . . . EXTRA INTESTINAL MANIFESTATIONS AND OTHER COMORBIDITIES… (3*)|(Janssen Immunology sponsored) Sa1795. . . . SEXUAL FUNCTION IN PATIENTS WITH INFLAMMATORY… (5*) Sa1796. . . . ASSOCIATION BETWEEN USE OF ANTIHYPERTENSIVE AGENTS… (5*) Sa1797. . . . FERTILITY, CONCEPTION AND DELIVERY IN PATIENTS… (5*) Sa1798. . . . THE PREVALENCE OF INFLAMMATORY BOWEL DISEASE… (2*)|(Funding for Oria M. Damas: This work was supported by NIH N3U54MD010722-03S1. Funding for Maria T. Abreu: This work was supported by The Micky & Madeleine Arison Family Foundation Crohn's & Colitis Discovery Laboratory and Martin Kalser Chair.) Sa1799. . . . CHARACTERIZATION OF WOMEN WITH INFLAMMATORY BOWEL… (2*)

Sa1800. . . . EPIDEMIOLOGY, NATIONAL TRENDS AND OUTCOMES OF… (5*) Sa1801. . . . EMERGING IBD DEMOGRAPHICS IN SOUTH ASIA… (5*) Sa1802. . . . DOES CLOSTRIDIUM DIFFICILE INCREASE THE RISK… (5*) Sa1803. . . . TOTAL ABDOMINAL COLECTOMY AMONGST HOSPITALIZED PATIENTS… (5*) Sa1804. . . . INCIDENCE OF OBSTRUCTIVE COMPLICATIONS AFTER INTRA-ABDOMINAL… (5*) Sa1805. . . . MEDICATION PRESCRIPTION PATTERNS IN ULCERATIVE COLITIS… (2*)|(Funds for statistical support provided by Pfizer) Sa1806. . . . INFLAMMATORY BOWEL DISEASE AND MEDICATION USE… (5*) Sa1807. . . . RATES OF COLECTOMY IN PATIENTS WITH… (5*) Sa1808. . . . TRENDS OF 5-ASA MEDICATION USE IN… (5*) Sa1809. . . . ADMISSION TRENDS AND ECONOMIC BURDEN OF… (5*) Sa1810. . . . SURGERY AND HOSPITALIZATIONS RATES IN INFLAMMATORY… (1*)|(5)(The study was supported by the McGill CAS Research Support Program.) Sa1811. . . . GENOTYPE AND POST-OPERATIVE IMMUNOSUPPRESSION IMPACT SURGICAL… (2*) Sa1812. . . . ENDOSCOPIC AND DEEP REMISSION AT 1… (5*) Sa1813. . . . CUFFITIS IS ASSOCIATED WITH A SIGNIFICANT… (5*) Sa1814. . . . EARLY COMBINED IMMUNOSUPPRESSION IS MORE EFFECTIVE… (3*)|(Robarts clinical trials) Sa1815. . . . THE IMPACT OF OPIOID ABUSE/DEPENDENCE DISORDER… (5*) Sa1816. . . . ELEVATED FECAL CALPROTECTIN IN HEALTHY FIRST… (6*) Sa1817. . . . FIBROSIS CONSTITUTES LESS THAN 0.5 OF… (4*) Sa1818. . . . INNATE IMMUNE DYSREGULATION, DETECTABLE UP TO…


* = Primary Source



(3*)|(Support for this study was provided by Janssen Pharmaceuticals and Prometheus Laboratories under a Cooperative Research and Development Agreement entitled ‘Antimicrobial antibodies as predictors of inflammatory bowel diseases’ NCRADA number NMR-11-3920.) Sa1819. . . . RETROSPECTIVE STUDY ON INCIDENCE RATES OF… (5*) Sa1820. . . . NON-ADHERENCE TO SELF-INJECTABLE BIOLOGIC MEDICATION IN… (5*) Sa1821. . . . DOES INFLAMMATION IN IBD BURNOUT OVER… (2*) Sa1822. . . . ELDERLY-ONSET VS ADULT-ONSET ULCERATIVE COLITIS: A… (5*) Sa1823. . . . FEMALE ADOLESCENTS WITH ULCERATIVE COLITIS MAY… (2*) Sa1824. . . . OBESITY IS FREQUENT IN INFLAMMATORY DISEASE… (2*) Sa1825. . . . SOUTH ASIAN IMMIGRANTS IN THE UNITED… (5*) Sa1826. . . . CLINICAL CHARACTERISTICS OF NASH/NAFLD PATIENTS IN… (5*) Sa1827. . . . THE NATURAL COURSE OF INFLAMMATORY BOWEL… (5*) Sa1828. . . . CONSUMPTION OF DIETARY TRIGGER FOODS AMONG… (2*) Sa1829. . . . DIET STABILITY IN PERSONS WITH IBD:… (2*) Sa1830. . . . INSTABILITY IN SATURATED FAT AND SUGAR… (2*) Sa1831. . . . ELEVATED SERUM IMMUNOGLOBULIN G4 FAILS TO… (5*) Sa1832. . . . CROHN’S LIKE DISEASE OF THE ILEAL… (5*) Sa1833. . . . MUCOSAL EOSINOPHILIA IS AN INDEPENDENT PREDICTOR… (2*) Sa1834. . . . OUTCOME AFTER DISCONTINUATION OF IMMUNOSUPPRESSANT OR… (5*) Sa1835. . . . CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH… (5*) Sa1836. . . . NUTRITIONAL STATUS EFFECT ON HEALTH CARE… (5*)

Sa1837. . . . EVALUATION AND MANAGEMENT OF POUCHITIS IN… (5*) Sa1838. . . . NONALCOHOLIC FATTY LIVER DISEASE WITH ADVANCED… (5*) Sa1839. . . . THE DILEMMA IN COMPLICATED ILEAL POUCH… (5*) Sa1841. . . . PREDICTIVE FACTORS OF A SUBSEQUENT ANO-PERINEAL… (5*) Sa1842. . . . DELAYED DIAGNOSIS OF CROHN’S DISEASE IS… (7*) Sa1843. . . . PREGNANCY COUNSELING BENEFICIAL IN PATIENTS WITH… (3*)|(UCB sponsored) Sa1844. . . . CLINICAL SIGNIFICANCE OF GRANULOMAS IN CROHN’S… (5*) Sa1845. . . . FOLLOW-UP OF ULCERATIVE COLITIS PATIENTS WITH… (5*) Sa1846. . . . FAMILIAL VERSUS SPORADIC INFLAMMATORY BOWEL DISEASE… (2*)|(This work was supported by NIH N3U54MD010722-03S1, The Micky & Madeleine Arison Family Foundation Crohn's & Colitis Discovery Laboratory, and Martin Kalser Chair.) Sa1847. . . . ADVERSE ANTEPARTUM OUTCOMES IN PREGNANT WOMEN… (5*) Sa1848. . . . TEMPORAL TREND IN DISEASE CHARACTERISTIC, TREATMENT… (5*) Sa1849. . . . ASSOCIATION OF SEROLOGIC MARKERS AND SURGERY… (5*) Sa1850. . . . FAMILIAL MEDITERRANEAN FEVER IN THE UNITED… (5*) Sa1851. . . . WESTERN VERSUS MEDITERRANEAN DIETARY MARKERS DIFFER… (4*) Sa1852. . . . HOW DO DIETARY PATTERNS FOR INFLAMMATORY… (4*) Sa1853. . . . PSEUDOPOLYPS IN INFLAMMATORY BOWEL DISEASE: HISTOLOGIC… (2*) Sa1854. . . . IMPACT OF BARIATRIC SURGERY ON THE… (5*) Sa1855. . . . ANALYSIS OF THE CLINICAL, GASTROSCOPIC, AND… (5*) Sa1856. . . . RISK FACTORS ASSOCIATED WITH PROXIMAL DISEASE… (5*)

Sa1857. . . . UPPER GASTROINTESTINAL TRACT PHENOTYPE OF CROHN’S… (5*) Sa1858. . . . RATE AND RISK FACTORS ASSOCIATED WITH… (2*) Sa1859. . . . THE IMPACT OF TOBACCO SMOKING ON… (5*) Sa1860. . . . RISK FACTORS FOR REPEATED VISITS TO… (5*) Sa1861. . . . IMPACT OF BIOLOGIC THERAPY ON RESOLUTION… (2*) Sa1862. . . . REAL WORLD USE OF THE IBD… (5*) Sa1863. . . . PATIENT EMPOWERMENT THROUGH AN EDUCATIONAL INTERVENTION… (3*)|(Funding provided through an unrestricted educatiol grant from Abbvie.) Sa1864. . . . GUT-BRAIN-AXIS REVISITED: SHEDDING LIGHT ON THE… (2*) Sa1865. . . . THERE IS MORE THAN PHARMACOLOGY: COMPREHENSIVE… (6*) Sa1866. . . . ASSOCIATION OF PSYCHIATRIC COMORBIDITIES WITH OPIOID… (5*) Sa1867. . . . SEXUAL QUALITY OF LIFE IN INFLAMMATORY… (4*) Sa1868. . . . FERTILITY IMPACT OF INITIAL SURGICAL MODALITY… (5*) Sa1869. . . . PSYCHOLOGICAL FACTORS ASSOCIATED WITH ADHERENCE TO… (4*) Sa1870. . . . THE USE OF AN EMR PATIENT… (5*) Sa1871. . . . HIGH INFLIXIMAB TROUGH LEVELS HAVE NO… (3*)| Sa1872. . . . MEASURING THE MEDIATING EFFECTS OF TOFACITINIB… (3*)|(Pfizer Inc) Sa1873. . . . MEASURING THE MEDIATING EFFECTS OF MAYO… (3*)|(Pfizer Inc) Sa1874. . . . THE VISCERAL SENSITIVITY INDEX: A NOVEL… (4*) Sa1875. . . . DISEASE-RELATED WORRIES AND CONCERNS IN PATIENTS… (3*)|(AbbVie funded the study, contributed to its design, and was involved in the collection, alysis, and interpretation of the data, and in the writing, review, and approval of the publication. Medical writing support was provided by Catherine DeBrosse, PhD, a)


* = Primary Source



Sa1876. . . . BODY IMAGE DISSATISFACTION IS INCREASED IN… (5*) Sa1877. . . . INDIVIDUALISED, UNSUPERVISED EXERCISE PROGRAM ACHIEVES HIGH… (4*) Sa1878. . . . EFFECTS OF SUBCUTANEOUS VEDOLIZUMAB ON HEALTH-RELATED… (3*)|(Takeda) Sa1879. . . . DISABILITY IN PATIENTS WITH ILEAL POUCH… (5*) Sa1880. . . . LONGITUDINAL PSYCHOLOGICAL HEALTH IN VETERANS WITH… (5*) Sa1881. . . . EFFECTS OF INTRAVENOUS VEDOLIZUMAB ON HEALTH-RELATED… (3*)|(Takeda) Sa1882. . . . PSYCHIATRIC OUTCOMES ARE SIGNIFICANTLY IMPACTED WITH… (4*) Sa1883. . . . ALTERATIONS IN FUNCTIONAL AND MICROSTRUCTURAL DEFAULT… (2*) Sa1884. . . . UNMET NEED OF INFLAMMATORY BOWEL DISEASE… (3*)|(Janssen Inc. provided an educatiol grant to the Gastrointestil Society. The doctors were not paid for their participation.) Sa1885. . . . PERCEIVED DISEASE SEVERITY AND TREATMENT SATISFACTION… (3*)|(Pfizer Inc) Sa1886. . . . SEXUAL DYSFUNCTION IN PATIENTS WITH INFLAMMATORY… (5*) Sa1887. . . . GENERAL HEALTH STATUS IN PATIENTS WITH… (3*)|(This study was funded by Janssen Research & Development, LLC) Sa1888. . . . USTEKINUMAB THERAPY INDUCED CLINICALLY MEANINGFUL IMPROVEMENT… (3*)|(This study was funded by Janssen Research & Development, LLC) Sa1889. . . . DOES PREGNANCY ADVERSELY IMPACT THE HEALTH… (4*) Sa1890. . . . THE ASSESSMENT OF INDIVIDUAL PATIENT PREFERENCES… (6*) Sa1891. . . . A SURVEY OF DISCLOSURE PREFERENCES IN… (5*) Sa1892. . . . NUTRITIONAL STATUS CORRELATES WITH QUALITY OF… (5*)

Sa1893. . . . A SINGLE CELL SURVEY OF LARGE… (3*) Sa1894. . . . ENTERIC GLIAL MHC II CONTRIBUTES TO… (2*) Sa1895. . . . CHARACTERIZATION AND MODELING OF THE CREEPING… (3*) Sa1896. . . . SERUM BIOMARKERS OF DEGRADATION AND FORMATION… (5*) Sa1897. . . . HDAC INHIBITORS DRIVE TGF-β1-MEDIATED STRENGTHENING AND… (2*) Sa1898. . . . LIPIDOMIC PROFILING REVEALS ALTERED LIPID COMPOSITION… (5*) Sa1899. . . . FIBROSIS IN PEDIATRIC PATIENTS WITH ULCERATIVE… (2*) Sa1900. . . . INTEROBSERVER AGREEMENT AMONG ENDOSCOPISTS IN EVALUATING… (6*)|(Kenneth-Rainin Foundation) Sa1901. . . . EXPRESSION OF INTEGRIN A4B7 AND MADCAM1… (3*)|(Takeda Pharmaceuticals) Sa1902. . . . A COMPARISON OF DIVERTICULITIS IN CROHN’S… (5*) Sa1903. . . . THE ROLE OF SUB-MUCOSAL COLLAGEN DEPOSITION… (5*) Sa1904. . . . LONG-TERM SAFETY AND OUTCOMES OF COLONOSCOPIC… (5*) Sa1905. . . . A PHASE I RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED… (3*)|(Study funded by 4D Pharma. RH and RKR supported by Career Researcher Fellowships from NHS Research Scotland.) Sa1906. . . . DOSE ESCALATION WITH ORIGINATOR INFLIXIMAB IS… (3*)|(Janssen Scientific Affairs, LLC supported this study) Sa1907. . . . ANTIBIOTICS WORSEN VISCERAL BUT NOT SOMATIC… (6*) Sa1908. . . . ABERRANT ENTERIC NEUROMUSCULAR SYSTEM AND DYSBIOSIS… (2*)| Sa1909. . . . DEEP SEQUENCING OF THE ENTIRE HUMAN… (4*) Sa1910. . . . LIFE COURSE ANTIBIOTIC USE AND ALTERATIONS… (2*) Sa1911. . . . ANALYSIS OF THE SMALL INTESTINAL MICROBIOME… (4*) Sa1912. . . . REVEALING THE ENTIRE INTESTINAL MICROBIOTA AND… (4*)

Sa1913. . . . IDENTIFYING REGULATORS OF MICROBIOME-ENCODED BILE ACID… (2*) Sa1914. . . . THE PREDICTION MODEL FOR GASTRIC MICROBIOME… (2*) Sa1915. . . . ALTERED CIRCADIAN RHYTHM CYCLING OF MICROBES… (2*) Sa1916. . . . DIFFERENT EFFECTS OF HISTAMINE 2 RECEPTOR… (4*)|(Chung Shan Medical University Hospital, Taichung, Taiwan (CSH-2014-D-004-Y2)) Sa1917. . . . A MICROBIAL SIGNATURE PREDICTS ADVANCED FIBROSIS… (4*) Sa1918. . . . JEJUNAL BUT NOT COLONIC HYDROGEN SULFIDE… (2*) Sa1919. . . . INTESTINAL MICROBIOME CHANGES AFTER AN ANTIBIOTIC… (4*)|(Monica Lester Charitable Trust) Sa1920. . . . ORAL HEALTH AND THE COLONIC MUCOSA-ASSOCIATED… (2*)| Sa1921. . . . ALTERING NITROGEN-SENSING IN E. COLI CAUSES… (7*)| Sa1922. . . . DISTINCT SHIFTS IN GUT MICROBIOTA COMPOSITION… (2*) Sa1923. . . . THE IMPACT OF INTESTINAL DYSBIOSIS IN… (4*) Sa1924. . . . EFFECT OF SHORT CHAIN FATTY ACIDS… (4*) Sa1925. . . . ALTERATION IN GUT MICROBIOTA IS ASSOCIATED… (2*) Sa1926. . . . SELECTIVE MICROBIOTA TRANSPLANTATION IS EFFECTIVE FOR… (1*)| Sa1927. . . . ASSOCIATIONS OF EARLY LIFE ADVERSITY AND… (2*) Sa1928. . . . HUMAN BREAST MILK PROMOTES THE SECRETION… (3*)|(BioGaia AB) Sa1929. . . . DISTINGUISHING DISEASE AND ANTIBIOTIC EFFECTS IN… (2*)|(This work was supported by a Tobacco Formula grant, under the Commonwealth Universal Research Enhancement (C.U.R.E) program with the grant number SAP # 4100068710.) Sa1930. . . . FECAL MICROBIOTA TRANSPLANTATION: PERCEPTIONS AND EXPERIENCES… (4*)


* = Primary Source



Sa1931. . . . PHYSICO-CHEMISTRY, PROTEOMICS AND IN VIVO COMPARATIVE… (5*) Sa1932. . . . EFFECT OF SACCHAROMYCES BOULARDII CNCM I-745… (3*)|(The current project was partially funded by a Biocodex grant, however they were not involved neither in the study design, patients recruitment nor data alysis. USFQ, UTE and UDLA (Private Universities in Ecuador) also funded partially the current research) Sa1933. . . . GUT MICROBIOME CROSS-TALK: PLAUSIBLE OR JUST… (5*) Sa1934. . . . THE FECAL-ANTI CANDIDA ACTIVITY CAN BE… (5*) Sa1935. . . . COMPARING FAECAL VOLATILE ORGANIC COMPOUNDS FOLLOWING… (5*) Sa1936. . . . EFFICACY AND SAFETY OF SACCHAROMYCES BOULARDII… (4*) Sa1937. . . . FIVE CASES OF BACILLUS LICHENIFORMIS BACTEREMIA… (1*) Sa1938. . . . ENTEROBACTERIACEAE ARE ESSENTIAL FOR THE MODULATION… (3*) Sa1939. . . . THE GUT MICROBIOME AS A NOVEL… (7*) Sa1940. . . . FECAL AND MUCOSAL MICROBIOTA PROFILING IN… (2*) Sa1941. . . . STRUCTURED PATIENT GROUP EDUCATION VERSUS STRUCTURED… (2*)| Sa1942. . . . REAL-WORLD IMPLEMENTATION OF THE LOW FODMAP… (2*) Sa1943. . . . IMPACT OF IRRITABLE BOWEL SYNDROME ON… (5*) Sa1944. . . . DIFFERENCES OF GASTROINTESTINAL (GI) SYMPTOMS BETWEEN… (5*) Sa1945. . . . FECAL MICROBIOTA TRANSPLANTATION IN IRRITABLE BOWEL… (5*) Sa1946. . . . THE MOST BOTHERSOME SYMPTOM IN FUNCTIONAL… (4*) Sa1947. . . . RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF COLESEVELAM… (5*) Sa1948. . . . NEEDLELESS TRANSCUTANEOUS ELECTRICAL ACUSTIMULATION IMPROVES IRRITABLE… (5*)

Sa1949. . . . POSTMENOPAUSAL WOMEN WITH IRRITABLE BOWEL SYNDROME… (5*) Sa1950. . . . EFFECT OF SYMPTOM SEVERITY AND GENDER… (5*) Sa1951. . . . VALIDITY AND SAFETY OF SYMPTOM IMPROVEMENT… (2*) Sa1952. . . . ROLE OF LOW-GRADE INFLAMMATION IN THE… (5*) Sa1953. . . . PICTOGRAMS ARE HIGHLY EFFECTIVE FOR DIAGNOSING… (4*) Sa1954. . . . POST INFECTION IBS (PI-IBS) IS VERY… (4*) Sa1955. . . . IS ROME IV CRITERIA FOR IBS… (5*) Sa1956. . . . ANXIETY, DEPRESSION AND STRUCTURAL FACTORS IMPACT… (2*) Sa1957. . . . INCIDENCE, PREVALENCE AND RISK FACTORS ASSOCIATED… (3*)|(This project was supported by a grant from Prometheus laboratories.) Sa1958. . . . MEASURING DIET INTAKE AND GASTROINTESTINAL SYMPTOMS… (2*) Sa1959. . . . EVALUATION OF THE PSYCHOSOCIAL FEATURES OF… (2*) Sa1960. . . . A SURVEY-BASED STUDY OF IRRITABLE BOWEL… (5*) Sa2004. . . . HIGH METHYL DIET IMPAIRS E.COLI OVERGROWTH,… (4*) Sa2005. . . . EXPERT CONSENSUS ON MANAGING IRON DEFICIENCY… (3*)|(Vifor Pharma) Sa2006. . . . MODERATE ETHANOL CONSUMPTION INHIBITS VILLUS CELL… (2*) Sa2007. . . . ASPIRIN/NSAID USE GREATER THAN 4 YEARS… (2*)| Sa2008. . . . RISK OF METACHRONOUS SESSILE SERRATED ADENOMAS… (5*) Sa2009. . . . COMBINATORIAL BLOCKADE OF DE NOVO CHOLESTEROL… (2*) Sa2010. . . . LIPOPHILIC STATINS INHIBIT YAP NUCLEAR LOCALIZATION,… (2*) Sa2011. . . . USEFULNESS OF TRACE ACETALDEHYDE/ETHANOL MEASUREMENTS IN… (5*)

Sa2012. . . . REGULATION OF COLON CARCINOGENESIS BY THE… (5*) Sa2013. . . . ASPIRIN IS PROTECTIVE AGAINST GASTRIC CANCER… (2*) Sa2014. . . . ASPIRIN USE AND THE INCIDENCE OF… (2*) Sa2015. . . . 5-AMINOSALICYLIC ACID INHIBITS XENOBIOTIC METABOLISM IN… (4*) Sa2016. . . . TRANSCRIPTIONAL AND POST-TRANSLATIONAL IMPLICATIONS OF COHESIN… (2*) Sa2017. . . . PREEMPTIVE ADALIMUMAB AMELIORATED CACHEXIA THROUGH CONCERTED… (4*) Sa2018. . . . COLORECTAL NEOPLASMS IN NEW USERS OF… (4*) Sa2019. . . . CHEMOPREVENTION OF COLORECTAL CANCER IN THE… (5*) Sa2020. . . . TARGETING CYCLOOXYGENASE 2 (COX-2) WITH EXERCISE-INDUCED… (2*) Sa2021. . . . A MULTICENTER STUDY OF THE SAFETY… (3*)|(Covidien/Medtronic) Sa2022. . . . EXPLORING RELATIONSHIPS BETWEEN HANDGRIP STRENGTH, MID-UPPER… (3*)|(Baxter Cada) Sa2023. . . . 13C-CAFFEINE BREATH TEST FOR THE IDENTIFICATION… (4*) Sa2024. . . . ASSOCIATION BETWEEN MALNUTRITION, NUTRITIONAL ASSESSMENT TOOLS,… (4*) Sa2025. . . . DYSREGULATION OF LIVER MITOCHONDRIAL FUNCTION AND… (3*)|(Tsumura & Co.) Sa2026. . . . IMPROVEMENT IN NUTRITION STATUS IS ASSOCIATED… (4*) Sa2027. . . . VALIDATION OF THE MODIFIED NUTRIC SCORE… (5*) Sa2028. . . . DIETARY FIBER IS ESSENTIAL TO MAINTAIN… (6*) Sa2029. . . . HABITUAL DIETARY INTAKE OF DUTCH IBD… (5*) Sa2030. . . . RANDOMIZED CLINICAL TRIAL TO COMPARE TWO… (5*) Sa2031. . . . HIGH PREVALENCE OF FOOD AVOIDANCE DIETS… (4*)


* = Primary Source



Sa2032. . . . ALCOHOL CONSUMPTION AND THE COLONIC MUCOSA-ASSOCIATED… (2*) Sa2033. . . . SHORT- AND LONG-TERM ALCOHOL INTAKE AND… (2*) Sa2034. . . . INTRAPERITONEAL TREATMENT WITH KISSPEPTIN MODIFIES FEEDING… (4*) Sa2035. . . . DIETARY INTERVENTIONS RAPIDLY ALTER METABOLOMICS PROFILE… (6*) Sa2036. . . . AN EVALUATION OF DIETARY INTAKE, MACRO… (4*)|(5) Sa2037. . . . EFFECT OF CALCIUM AND VITAMIN D… (2*) Sa2038. . . . LACK OF EXPERIMENTAL REPRODUCIBILITY IN PRECLINICAL… (2*) Sa2039. . . . UNDERSTANDING HOW DIFFERENCES IN SOCIOECONOMIC STATUS,… (5*) Sa2040. . . . VITAMIN B12 MALABSORPTION AND DEFICIENCY FOLLOWING… (5*) Sa2041. . . . DIETARY ADHERENCE IN FUNCTIONAL GASTROINTESTINAL DISORDERS:… (5*) Su1006. . . . INTERACTION BETWEEN LONG NONCODING RNA UC.173… (2*) Su1007. . . . NLRP3 INFLAMMASOME-MEDIATED IL-1β ACTIVATION ENHANCES 5-FU… (4*) Su1008. . . . MIR874-3P IS INVERSELY CORRELATED WITH ITS… (7*)|(We like to acknowledge the Intertiol Organization for the study of Inflammatory Bowel Disease (IOIBD), and the tiol Institute of Diabetes and Digestive and Kidney Diseases IBD Genetics Consortium [NIDDK IBDGC] for their fincial support.) Su1009. . . . LOSS OF RAB25 AGGRAVATES A HYPERTROPHIC… (2*) Su1010. . . . ABNORMAL ACTIVATION OF HNRNPA0 INHIBITS CANCER… (2*) Su1011. . . . HUMAN LAMINA PROPRIA LYMPHATIC CELLS AS… (5*) Su1012. . . . MECHANICAL STIMULI AFFECT ENTEROTOXIGENIC E. COLI… (2*)|(Emulate Inc.) Su1013. . . . INCREASED BASOPHIL RECRUITMENT TO THE COLON… (4*)

Su1014. . . . IMMUNE PROFILING OF THE HUMAN GASTRIC… (4*) Su1015. . . . WNT SIGNALING REGULATES SIRT2 EXPRESSION IN… (2*) Su1016. . . . PROTEIN KINASE D REGULATES THE NUCLEAR… (2*) Su1017. . . . ESTABLISHMENT AND CHARACTERIZATION OF A LEAKY… (3*)|(Innovate Biopharmaceuticals Inc, Raleigh NC) Su1018. . . . INTESTINAL BARRIER DYSFUNCTION ORCHESTRATES THE ONSET… (6*)|(Primary Source: Intertiol Foundation for Ethical Research Additiol Source 1: Bio & Medical Technology Development Program of the tiol Research Foundation funded by the Ministry of Science and ICT Additiol Source 2: Cancer Research Institute Additiol So) Su1019. . . . LARAZOTIDE PROTECTS THE INTESTINAL TIGHT JUNCTION… (3*)|(Innovate Biopharmaceuticals Inc., Raleigh, NC, USA) Su1020. . . . NAFAMOSTAT MESYLATE, A BROAD SPECTRUM SERINE… (4*) Su1021. . . . PROTEINASE 3 ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES IN… (5*) Su1022. . . . INTERLEUKIN 4 RECEPTOR α DEFICIENCY ALLEVIATES… (5*) Su1028. . . . WHOLE-GENOME SEQUENCING OF AFRICAN AMERICANS IDENTIFIES… (6*) Su1029. . . . TIO2 NANOPARTICLES ABROGATE THE PROTECTIVE EFFECT… (2*) Su1030. . . . UTILITY OF TARGETED NEXT-GENERATION SEQUENCING PANEL… (2*) Su1031. . . . PREVALENCE OF GERMLINE MUTATIONS AND VARIABLE… (2*) Su1032. . . . MIST+ ISTHMUS STEM CELLS CONTRIBUTE TO… (2*) Su1034. . . . REBAMIPIDE REDUCES GASTRIC EPITHELIAL CELL APOPTOSIS… (4*) Su1035. . . . SCREENING ANTI-FIBROTIC AGENTS: EXPLORATION OF PROMISING… (4*)

Su1036. . . . SULFORAPHANE ALLEVIATES DEXTRAN SODIUM SULFATE (DSS)-INDUCED… (2*) Su1037. . . . HEPATOCARCINOGENESIS WITHOUT CIRRHOSIS IN THE ELDERLY… (4*) Su1038. . . . NOD1 DEFICIENT GASTRIC STEM CELLS FAIL… (4*) Su1039. . . . HUMAN DIFFERENTIATED ENTEROID MONOLAYERS EXHIBIT EGFR/MEK-… (2*) Su1040. . . . EARLY ACTIVATION OF SOX9-POSITIVE CELLS IN… (2*) Su1041. . . . NEW DIAGNOSTIC APPROACH FOR BILIARY TRACT… (2*)|(Grant-in-Aid for Scientific Research (B), Japan Society for the Promotion of Science) Su1042. . . . HUMAN CYTOKINE PRODUCTION BY THE INTACT… (2*) Su1043. . . . EXPLORING GLP2 ACTIVITY AND CELLULAR TARGETS… (4*) Su1044. . . . OPTIMIZATION OF CULTURE CONDITIONS FOR IMPROVED… (3*)|(AbbVie) Su1045. . . . MINIMUM ESSENTIAL ORGANDOIDS CULTURE MEDIA (MEOM)… (2*) Su1046. . . . CRISPR/CAS9-MEDIATED GENOME EDITING OF MULTI-DRUG RESISTANCE… (4*) Su1047. . . . THE CHARACTERIZATION OF THE FUNCTION OF… (2*)|(JSPS KAKENHI Grandts Numbers 15K10124 (KY and YIK) and grants from the tiol Center for Global Health and Medicine (26-117 and 29-1019).) Su1048. . . . INTESTINAL EPITHELIAL BARRIER ABNORMALITIES AND CHANGES… (2*) Su1049. . . . MULTIPLEX NANOSCALE HIGH RESOLUTION FLOW CYTOMETRY… (4*) Su1050. . . . COMPARISON OF FISH VERSUS DDPCR-BASED GENE… (4*) Su1051. . . . CONSTRUCTION OF COLORECTAL CANCER SUBTYPES BASED… (5*) Su1052. . . . A NOVEL MICRORNA PANEL FOR NON-INVASIVE… (5*)


* = Primary Source



Su1053. . . . HIGH RISK POPULATION SCREENING FOR COLORECTAL… (5*) Su1054. . . . PYRROLINE-5-CARBOXYLATE REDUCTASE 1(PYCR1) UPREGULATION CONTRIBUTES TO… (2*) Su1055. . . . REPRIMO-LIKE: A POTENTIAL TUMOR SUPPRESSOR AND… (2*) Su1056. . . . A CHEMORADIOTHERAPY TREATMENT RESPONSE MRNA SIGNATURE… (7*) Su1057. . . . INCREASED EXPRESSION OF THE LONG NONCODING… (2*) Su1058. . . . POTENTIAL OF URINARY CYSTEINE-RICH PROTEIN 61… (3*)|(the Kobayashi Foundation for Cancer Research) Su1059. . . . IMMUNE CELL INFILTRATION AND TUMOUR LOCATION… (5*) Su1060. . . . CLINICAL UTILITY OF THE QUANTITATIVE MONITORING… (2*) Su1061. . . . IDENTIFICATION OF A ROBUST MICRORNA SIGNATURE… (2*) Su1062. . . . MOLECULAR DEPENDENCIES IN ESOPHAGEAL ADENOCARCINOMA: A… (2*) Su1063. . . . MIR-4715-3P MODULATES AURKA AND INDUCES FERROPTOSIS… (2*) Su1065. . . . CANCER-DERIVED EXOSOMES ACTIVATE FIBROBLASTS THROUGH SUPPRESSION… (5*) Su1066. . . . NOVEL METABOLOMIC PREDICTORS OF INCIDENT COLORECTAL… (2*) Su1067. . . . GENETIC COLORECTAL CANCER RISK VARIANTS ASSOCIATED… (2*) Su1068. . . . MUTATIONAL LANDSCAPE OF EARLY-ONSET COLORECTAL CANCER… (2*) Su1069. . . . THE ROLE OF RARE VARIANTS IN… (2*) Su1070. . . . MORPHOLOGICAL AND MOLECULAR RISK MARKERS FOR… (5*) Su1071. . . . NOVEL LONG NON-CODING RNA MOLECULAR SUBTYPES… (4*) Su1072. . . . HELICOBACTER PYLORI-RELATED DNA METHYLATION IN PRIMARY… (2*) Su1073. . . . GENE NETWORK DIFFERENCES OF COLON CANCER… (5*)

Su1074. . . . ASSOCIATION BETWEEN SINGLE NUCLEOTIDE POLYMORPHISMS IN… (2*) Su1096. . . . CALCIUM SIGNALING IN THE REGULATION OF… (2*) Su1097. . . . NCX1/CA/NF-KB SIGNAL PATHWAY COULD BE A… (2*) Su1098. . . . TUMOR-DERIVED EXOSOMES PROMOTE TUMOR GROWTH AND… (4*) Su1099. . . . MYOARCHITECTURE OF THE SLING FIBERS OF… (2*) Su1100. . . . MUCOSAL BARRIER DYSFUNCTION OF ATROPHIC MUCOSA… (5*) Su1101. . . . CAN NSAID-INDUCED INJURY OF GASTRIC EPITHELIAL… (2*) Su1102. . . . CARBON MONOXIDE RELEASED FROM ITS PHARMACOLOGICAL… (4*)|(Grant from tiol Science Centre, Poland (UMO-2016/23/N/NZ4/01890).) Su1103. . . . DOES PPI PLAY A PROTECTIVE ROLE… (5*) Su1104. . . . A RANDOMIZED CONTROLLED STUDY ON THE… (5*) Su1105. . . . ESOPHAGEAL MUCOSAL IMMUNE RESPONSE TO CANDIDA… (5*) Su1106. . . . TACROLIMUS-INDUCED PAN-ESOPHAGEAL AND DUODENAL ULCERATION: A… (5*) Su1107. . . . CLINICAL SIGNIFICANCE OF SERUM MARKERS IN… (5*) Su1108. . . . COLLAGENOUS GASTRITIS: A RARE CAUSE OF… (5*) Su1109. . . . DEVELOPMENT OF NEOSQUAMOUS EPITHELIUM IN THE… (5*) Su1110. . . . EVALUATION OF SMALL BOWEL INJURY IN… (5*) Su1111. . . . GRADING OF ACUTE ESOPHAGEAL GRAFT VERSUS… (5*) Su1112. . . . ESOPHAGEAL PEMPHIGUS: THE EXPERIENCE FROM A… (5*) Su1113. . . . RISK FACTORS, ENDOSCOPIC FEATURES, AND CLINICAL… (5*) Su1114. . . . SWOLLEN STIMULANTS OF ORAL CAVITY MAY… (5*)

Su1115. . . . ACTIVATION OF EGFR-DNA-PK PATHWAY BY IGFBP2… (4*) Su1116. . . . EOSINOPHILS ARE PRESENT IN HUMAN AND… (5*) Su1117. . . . APURINIC/APYRIMIDINIC ENDONUCLEASE-1 IS ASSOCIATED WITH ANGIOGENESIS… (1*) Su1118. . . . MEDICATION EFFECTS ON METHYLATION-RELATED BIOLOGICAL AGING… (2*)| Su1119. . . . IS THE AGE OF DIAGNOSIS OF… (5*) Su1120. . . . HAS ACCURACY OF CLINICAL STAGING OF… (5*) Su1121. . . . M1A DISEASE SHOULD BE RECONSIDERED IN… (5*) Su1122. . . . COMPREHENSIVE MUTATIONAL ANALYSIS OF BACKGROUND MUCOSA… (5*) Su1123. . . . ADDED VALUE OF MRI TO ENDOSCOPIC… (5*) Su1124. . . . LONG TERM RESULTS OF ENDOSCOPIC TREATMENT… (4*) Su1125. . . . ESOPHAGEAL STENT PLACEMENT FOR POST-OPERATIVE COMPLICATIONS… (5*) Su1126. . . . CLINICAL PREDICTORS OF LOCALLYADVANCED ESOPHAGEAL ADENOCARCINOMA… (5*) Su1127. . . . INCREASED SOX2 EXPRESSION IN THE EARLY… (2*) Su1128. . . . CLINICAL EPIDEMIOLOGY OF ESOPHAGEAL CANCER: NATIONWIDE… (7*)|(Korean College of Helicobacter and Upper Gastrointestil Research) Su1129. . . . PREDICTIVE SIGNIFICANCE OF ENDOSONOGRAPHIC (EUS) STAGING… (1*) Su1130. . . . OUTCOMES AFTER ESOPHAGECTOMY FOR ESOPHAGEAL CANCER… (5*) Su1131. . . . HIGH CHOLESTEROL AND HEMOGLOBIN A1C LEVELS… (4*) Su1132. . . . NOVEL APPLICATION OF IMPEDANCE-PH TECHNOLOGY SHOWS… (5*) Su1133. . . . ACID SUPPRESSION DOES NOT IMPROVE LARYNGOMALACIA… (2*)


* = Primary Source



Su1146. . . . USE OF FECAL OCCULT BLOOD TESTING… (2*) Su1147. . . . BLEEDING AND THROMBOSIS RISK IN CRTICALLY… (5*) Su1148. . . . RISK OF ADVANCED METACHRONOUS NEOPLASIA IS… (5*) Su1149. . . . ARE PPIS ASSOCIATED WITH DEMENTIA? -… (5*) Su1150. . . . RISK OF TUBERCULOSIS IN PATIENTS WITH… (5*) Su1151. . . . EARLY VS DELAYED ERCP IN ACUTE… (5*) Su1152. . . . IMPACT OF NURSE OR TRAINEE PARTICIPATION… (5*) Su1247. . . . SCREENING FOR GASTRIC INTESTINAL METAPLASIA: WHAT… (4*) Su1248. . . . COMBINATION OF HELICOBACTER PYLORI STATUS AND… (5*) Su1249. . . . DEMOGRAPHIC, LIFESTYLE AND DIETARY RISK FACTORS… (5*) Su1250. . . . FEASIBILITY OF GASTRIC INTESTINAL METAPLASIA SURVEILLANCE… (5*) Su1251. . . . CLINICOPATHOLOGICAL FEATURES OF SPORADIC NON-AMPULLARY DUODENAL… (5*) Su1252. . . . INCIDENT DIAGNOSES OF GASTRIC INTESTINAL METAPLASIA… (5*) Su1253. . . . EVALUATION OF DNA AND RNA EXTRACTION… (4*) Su1254. . . . OLGA AND OLGIM STAGE DISTRIBUTION ACCORDING… (5*) Su1255. . . . AUTOIMMUNE METAPLASTIC ATROPHIC GASTRITIS (AMAG) –… (5*) Su1257. . . . CHARACTERISTICS OF GASTROINTESTINAL STROMAL TUMORS USING… (5*) Su1258. . . . MISSED OPPORTUNITIES FOR SCREENING OR SURVEILLANCE… (5*) Su1259. . . . THE INCIDENCE OF GASTRIC CANCER IN… (5*) Su1260. . . . LOW PREVALENCE OF HELICOBACTER PYLORI-POSITIVE PEPTIC… (5*) Su1261. . . . SMOKING, HELICOBACTER PYLORI SEROLOGY, AND GASTRIC… (2*)

Su1262. . . . PREVALENCE OF HELICOBACTER PYLORI INFECTION IN… (5*) Su1263. . . . ASSESSMENT OF GASTRIC PREMALIGNANT LESIONS BY… (2*) Su1264. . . . HELICOBACTER PYLORI ANTIBODY PREVALENCE BY YEAR… (2*) Su1265. . . . PROSPECTIVE COMPARISON VALIDATION STUDY OF 13C-UREA… (5*) Su1266. . . . HELICOBACTER PYLORI TESTING AND TREATMENT IN… (3*)|(Otsuka Pharmaceutical Development and Commercialization, Inc. (Rockville, MD)) Su1267. . . . MANAGEMENT OF HELICOBACTER PYLORI INFECTION AT… (5*) Su1268. . . . HELICOBACTER PYLORI INFECTION: PRACTICE PATTERNS IN… (5*) Su1269. . . . HELICOBACTER PYLORI INFECTION AND IRON DEFICIENCY… (5*) Su1270. . . . CLINICAL PERFORMANCE OF THE H. PYLORI… (3*) Su1271. . . . CHANGES IN GUT MICROBIOTA AFTER HELICOBACTER… (5*) Su1272. . . . THE RATIO OF PEPSINOGEN I TO… (4*) Su1273. . . . HELICOBACTER PYLORI ERADICATION CANNOT RESTORE THE… (2*)|(This work was supported by the tiol Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (2017R1C1B5075233)) Su1274. . . . HELICOBACTER PYLORI INFECTION AMONG YOUNG PEOPLE… (5*) Su1275. . . . HELICOBACTER PYLORI IN SOUTH TEXAS: ERADICATION… (5*) Su1276. . . . LONG-TERM FOLLOW UP OF ENDOSCOPIC/HISTOLOGICAL ATROPHY,… (5*) Su1277. . . . THE MANAGEMENT OF H. PYLORI IS… (5*) Su1278. . . . ASSOCIATION OF HELICOBACTER PYLORI INFECTION AND… (4*) Su1279. . . . IMPACT OF PRIOR EXPOSURE TO MACROLIDE… (5*)

Su1280. . . . EFFICACIES OF TAILORED THERAPY VERSUS GUIDELINE-RECOMMENDED… (4*) Su1281. . . . TETRACYCLINE-LEVOFLOXACIN QUADRUPLE THERAPY ACHIEVES A HIGHER… (4*) Su1282. . . . ERADICATION RATES OF TRIPLE, TRIPLE WITH… (5*) Su1283. . . . TEN-DAY CONCOMITANT, 10-DAY SEQUENTIAL, AND 7-DAY… (2*)|(Ministry of Health and Welfare, Republic of Korea) Su1284. . . . EFFICACY AND SAFETY OF VONOPRAZAN, SITAFLOXACIN… (5*) Su1285. . . . SYNERGISTIC INHIBITORY EFFECTS OF NANOPARTICLE HEATING… (2*) Su1286. . . . A POTASSIUM-COMPETITIVE ACID BLOCKER-BASED REGIMEN AS… (5*) Su1287. . . . A PHASE 1, RANDOMIZED, DOUBLE-BLIND STUDY… (3*)|(Takeda Pharmaceutical Company Limited) Su1288. . . . FIRST LINE HELICOBACTER PYLORIERADICATION IN PATIENTS… (5*) Su1289. . . . INFLUENCE OF CLOSTRIDIUM BUTYRICUM AS PROBIOTICS… (5*) Su1290. . . . EFFICACY AND SAFETY OF LACTOBACILLUS REUTERI… (5*) Su1291. . . . EFFECTIVENESS OF HIGH DOSE DUAL THERAPY… (1*) Su1292. . . . TRIPLE-DRUG BLISTER-PACKAGED DRUG WITH VONOPRAZAN IMPROVES… (5*) Su1293. . . . LONG-TERM EFFET FOR LIPID METABOLISM BY… (5*) Su1294. . . . ERADICATION RATIO AND ADVERSE EVENTS INCIDENCE… (1*) Su1295. . . . SUSCEPTIBILITY-BASED THIRD LINE RESCUE THERAPY FOR… (4*) Su1296. . . . SUPERBUG OR SOMETHING ELSE: FACTORS CONTRIBUTING… (5*) Su1297. . . . GENETIC AND BACTERIAL FACTORS FOR OUTCOME… (5*) Su1298. . . . CLARITHROMYCIN VERSUS METRONIDAZOLE CONTAINING FIRST-LINE VONOPRAZAN… (5*)


* = Primary Source



Su1299. . . . A RANDOMIZED CONTROLLED STUDY FOR LEVOFLOXACIN-BASED… (4*) Su1300. . . . NATION-WIDE ANTIBIOTIC RESISTANCE MAPPING OF HELICOBACTER… (2*) Su1301. . . . CHANGES OF GASTRIC CORPUS MICROBIOTA AFTER… (5*) Su1302. . . . PRESENTATION, CLINICAL COURSE AND OUTCOME IN… (5*) Su1303. . . . PEDIATRIC CAPSULE ENDOSCOPY: ACHIEVING 0 CAPSULE… (5*) Su1304. . . . A NOVEL HISTOLOGY INDEX FOR EVALUATION… (6*) Su1305. . . . SEROTONIN ACTING VIA 5-HT3 RECEPTORS MEDIATES… (2*) Su1306. . . . A NOVEL POTENT POST-SYNAPTIC SIGNALING PATHWAY… (2*) Su1307. . . . EZH2 REGULATES GASTRIC PACEMAKER STEM CELL… (2*) Su1308. . . . FIRST IN MAN PATCH CLAMP RECORDINGS IN FRESHLY… (2*) Su1309. . . . IMPACT OF GUT SURGICAL MANIPULATION ON… (2*) Su1310. . . . BETA 2 ADRENERGIC RECEPTOR MEDIATES THE… (2*) Su1311. . . . OPTOGENETIC ANALYSIS OF CHOLINERGIC NERVE PATHWAYS… (2*) Su1312. . . . ABNORMAL BIOELECTRICAL SLOW-WAVE IN PATIENTS WITH… (2*) Su1313. . . . ROLE OF ETV1 IN REGULATING GASTROINTESTINAL… (2*) Su1314. . . . INTERSTITIAL CELLS OF CAJAL PLAY A… (5*) Su1315. . . . EPIGENETIC CHANGES IN GASTRIC ANTRAL SMOOTH… (5*) Su1316. . . . DAIKENCHUTO, A TRADITIONAL JAPANESE (KAMPO) MEDICINE,… (2*) Su1317. . . . INHIBITING FATTY ACID AMIDE HYDROLASE AMELIORATES… (4*) Su1318. . . . P2X2 RECEPTOR SIGNALING INDUCES ENTERIC GLIA… (2*) Su1319. . . . KAMPO FORMULA DAIKENCHUTO FACILITATES MUCOSAL HYPEREMIC… (2*)

Su1320. . . . IDENTIFICATION OF NOVEL NEURONAL MARKERS IN… (2*) Su1418. . . . ROLE OF THERAPEUTIC ANTICOAGULATION IN SPLANCHNIC… (5*) Su1419. . . . ONE YEAR RISK OF OPIOID ADDICTION… (5*) Su1420. . . . MULTI-ORGAN FAILURE IS THE STRONGEST DETERMINANT… (5*) Su1421. . . . TRENDS AND TIMING OF CHOLECYSTECTOMY IN… (5*) Su1422. . . . THE IMPACT OF OPIOID ABUSE/DEPENDENCE DISORDER… (5*) Su1423. . . . GASTROINTESTINAL FAILURE IS A PREDICTOR OF… (5*) Su1424. . . . IS EARLY CT OVERUTILIZED IN MANAGEMENT… (5*) Su1425. . . . ANNULAR PANCREAS AND ITS ASSOCIATION WITH… (5*) Su1426. . . . PATIENTS TAKING ANTI-TUMOR NECROSIS FACTOR α… (5*) Su1427. . . . A MULTIVARIATE MODEL FOR PREDICTION OF… (5*) Su1428. . . . DOES INTRACELLULAR FLUID SHIFT CONTRIBUTE TO… (4*) Su1429. . . . NEUTROPHIL CD64 EXPRESSION IS A NOVEL… (4*) Su1430. . . . ISOLATED EXTRA-PANCREATIC NECROSIS IS ASSOCIATED WITH… (5*) Su1431. . . . NECROTIZING ACUTE PANCREATITIS: CAN MRI DIFFUSION-WEIGHTED… (5*) Su1432. . . . THE CLINICAL SPECTRUM OF GROOVE PANCREATITIS… (5*) Su1433. . . . ACUTE PANCREATITIS IN PATIENTS WITH HEMOPHILIA:… (5*) Su1434. . . . ACUTE PANCREATITIS IN PATIENTS WITH HEART… (5*) Su1435. . . . AGGRESSIVE FLUID REPLACEMENT IN ACUTE PANCREATITIS;… (5*) Su1436. . . . ORGAN FAILURE PERSISTING FOR MORE THAN… (5*) Su1437. . . . IDENTIFYING REDUCED PANCREATIC FUNCTION AND FAT… (3*)|(Abbvie, Inc)

Su1438. . . . METABOLOMIC PROFILING IDENTIFIES PHOSPHOLIPID SIGNATURE IN… (4*)|(nil) Su1439. . . . RISK FACTORS FOR DIABETES MELLITUS IN… (5*) Su1440. . . . COEXISTENCE OF ALCOHOLIC LIVER DISEASE (ALD)… (4*) Su1441. . . . ASSOCIATION OF AUTOIMMUNE DISEASES IN CHILDREN… (2*) Su1442. . . . METABOLIC SYNDROME RELATED DISORDERS ARE LESS… (5*) Su1443. . . . PREVALENCE, TREND AND DETERMINANTS OF LEAVING… (5*) Su1444. . . . RISK FACTORS AND NOMOGRAM FOR STEATORRHEA… (5*) Su1445. . . . IS CHRONIC PANCREATITIS WITH HIGH BMI… (5*) Su1446. . . . CLINICAL CHARACTERISTICS OF PATIENTS WITH SYMPTOMS… (2*) Su1447. . . . CLINICAL FEATURES OF IGG4 NEGATIVE AUTOIMMUNE… (5*) Su1448. . . . PREDICTIVE VALUE OF ISLET PROCESSING PARAMETERS… (5*) Su1449. . . . DO PATIENTS WITH CHRONIC PANCREATITIS RECEIVE… (5*) Su1450. . . . CHRONIC PANCREATITIS ASSOCIATED WITH CYSTIC FIBROSIS… (5*) Su1451. . . . AMMANN PAIN TYPE AND THE NATURAL… (4*) Su1452. . . . CHARACTERIZATION OF NUTRITIONAL STATUS THROUGH PHASE… (5*) Su1453. . . . DIAGNOSIS AND TREATMENT OF AUTOIMMUNE PANCREATITIS:… (4*) Su1454. . . . PANCREATIC CYSTIC LESIONS: ACTIVE VERSUS PASSIVE… (7*) Su1455. . . . NATURAL HISTORY OF PANCREATIC CYSTIC LESIONS… (7*) Su1456. . . . ASSESSMENT OF ENDOSCOPIC ULTRASOUND (EUS) AND… (5*) Su1457. . . . COMPARISON OF DOTATATE PET-CT SCAN AND… (5*) Su1458. . . . PANCREATIC ISLET CELL TUMORS: NATIONWIDE ANALYSIS… (5*)


* = Primary Source



Su1459. . . . IMAGING RESOURCE UTILIZATION IN ACTIVE PANCREATIC… (5*) Su1460. . . . PANCREATIC MIXED ACINAR CELL/NEUROENDOCRINE CARCINOMA: GENOMIC… (4*) Su1519. . . . RIFAXIMIN AND LACTULOSE COMBINATION THERAPY VERSUS… (3*)|(Salix Pharmaceuticals) Su1520. . . . A NATIONAL ESTIMATE OF COMPENSATED AND… (5*) Su1521. . . . COMBINATION THERAPY VS MONOTHERAPY FOR EUS-GUIDED… (5*) Su1522. . . . PREVALENCE OF UPPER GASTROINTESTINAL NEOPLASIA IN… (5*) Su1523. . . . IMPACT OF TRANSFER STATUS ON OUTCOMES… (5*) Su1524. . . . FLASH GLUCOSE-SENSING TECHNOLOGY AS A REPLACEMENT… (5*) Su1525. . . . SUPRAHEPATIC INFERIOR CAVAL VEIN OCCLUSION AND… (4*) Su1526. . . . COMPLICATIONS OF PORTAL TRIAD OBSTRUCTION AND… (4*) Su1527. . . . POTENTIALLY PREVENTABLE READMISSIONS AND COMPLICATIONS IN… (2*)|(Partly from Investigator Initiated Grants from Grifols and Valeant and from NCATS NIH) Su1528. . . . ENDOSCOPIC FINDINGS IN PATIENTS WITH CIRRHOSIS… (5*) Su1529. . . . PORTAL TRIAD OBSTRUCTION AND REPERFUSION IN… (4*) Su1530. . . . PRE-EXISTING LIVER DISEASE INCREASES RISK OF… (5*) Su1531. . . . SPLENECTOMY IN RATS INDUCED PORTAL AND… (4*) Su1532. . . . COMPLICATIONS OF SUPRAHEPATIC INFERIOR CAVAL VEIN… (4*) Su1533. . . . ADMISSION SERUM UREA IS A BETTER… (5*) Su1534. . . . BPC 157 GIVEN DURING REPERFUSION COUNTERACTS… (4*) Su1535. . . . SAFETY AND EFFICACY OF COMBINED ENDOSCOPIC… (5*) Su1536. . . . PROGNOSTIC VALUE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO IN… (5*)

Su1537. . . . NON-VARICEAL UPPER GASTROINTESTINAL BLEEDING IN PATIENTS… (5*) Su1538. . . . ASSOCIATION BETWEEN VARICEAL BLEED AND HELICOBACTER… (5*) Su1539. . . . PENTADECAPEPTIDE BPC 157 COUNTERACTS PORTAL HYPERTENSION,… (4*) Su1571. . . . GABA IN THE GUT: DISTRIBUITION OF… (4*) Su1572. . . . ENTERIC NERVOUS SYSTEM: A NOVEL NEURO-EPITHELIAL… (4*) Su1573. . . . CHOLINERGIC-INDUCED ANION SECRETION IN MOUSE JEJUNAL… (2*) Su1574. . . . CLOSTRIDIOIDES DIFFICILE INFECTION INDUCES INCREASED S100B… (2*)|(CAPES/PROCAD CAPES/FUNCAP/PRONEX CAPES/PDSE University of Virginia/Department of Infectious Diseases) Su1575. . . . ESTROGEN INCREASES THE EXPRESSION OF BKCA… (5*) Su1576. . . . METABOLOMIC PROFILING OF SUBJECTS WITH FUNCTIONAL… (2*) Su1577. . . . UNDERSTANDING THE ROLE OF BILE ACIDS… (2*) Su1578. . . . CHRONIC INTRACOLONIC ADMINISTRATION OF LINACLOTIDE INHIBITS… (2*)|(Supported by Ironwood Pharmaceuticals Inc, Allergan) Su1579. . . . ENTERIC NEURONAL SILENT AND MEMORY PROPERTIES… (2*) Su1580. . . . A LONGITUDINAL STUDY EXAMINING THE EFFECT… (2*) Su1581. . . . GPCR-CONTAINING B7-2+ EXTRACELLULAR VESICLES FROM IMMUNE… (2*) Su1582. . . . ANTI-INFLAMMATORY AND EPITHELIAL PROTECTIVE EFFECTS OF… (3*) Su1583. . . . MORTALITY RISK IN IRRITABLE BOWEL SYNDROME:… (7*) Su1584. . . . PSYCHOLOGICAL, PHYSICAL COMORBIDITIES AND FUNCTIONAL IMPAIRMENT… (2*)|(Study was funded by NIDDK K23 103911 and Intramural Research Program of the NIMH (ZIAMH002806).)

Su1585. . . . RACIAL DISPARITY IN HEALTH CARE UTILIZATION… (5*) Su1586. . . . RACIAL DISPARITIES IN PATIENTS WITH IRRITABLE… (5*) Su1587. . . . NEW PATIENT REPORTED OUTCOME MEASURE: DIARY… (3*)|(This study was funded by Allergan plc and Ironwood Pharmaceuticals.) Su1588. . . . HOW COST AFFECTS TREATMENT CHOICE FOR… (5*) Su1589. . . . PREDICTIVE FACTORS OF RESPONSE TO RIFAXIMIN… (5*) Su1590. . . . STUDY ON THE EFFECTIVENESS OF HERBAL… (5*) Su1591. . . . COMMUNICATION BETWEEN CLINICIANS AND PATIENTS WITH… (3*)|(Synergy Pharmaceuticals) Su1592. . . . THE INTESTINAL GAS QUESTIONNAIRE (IGQ): PSYCHOMETRIC… (3*)|(Da funded the study) Su1593. . . . LOW FODMAPS DIET IMPROVES FUNCTIONAL GASTROINTESTINAL… (5*) Su1594. . . . REDUCTION IN OVERALL HOSPITALIZATIONS FOR FUNCTIONAL… (5*) Su1595. . . . DIETARY EDUCATION IN FUNCTIONAL GASTROINTESTINAL DISORDERS:… (5*) Su1596. . . . RELATIONSHIP BETWEEN IDEAL (BRISTOL TYPE IV)… (5*) Su1597. . . . INCREASING INPATIENT BURDEN OF CONSTIPATION AND… (5*) Su1598. . . . ESTIMATION OF OPIOID USE FOR THE… (3*)|(The funding for this study was provided by Ironwood Pharmaceuticals, Inc. Writing assistance by Complete HealthVizion, funded by Ironwood Pharmaceuticals, Inc.) Su1599. . . . PANCREATITIS FOLLOWING ELUXADOLINE USE: 1-YEAR REASSESSMENT… (5*) Su1600. . . . MANAGEMENT OF FUNCTIONAL ABDOMINAL PAIN IN… (5*) Su1601. . . . DIAGNOSTIC ACCURACY OF TWO HOUR AND… (5*) Su1602. . . . NOVEL USE OF TIMED BARIUM ESOPHAGRAM… (5*)


* = Primary Source



Su1603. . . . WHEN ANTEGRADE ENEMAS GO RETROGRADE: SIGNIFICANCE… (5*) Su1604. . . . A PRELIMINARY STUDY OF THE IMPACT… (5*) Su1605. . . . ALTERATIONS IN BRAIN FUNCTIONAL CONNECTIVITY IN… (2*) Su1606. . . . AUTONOMIC NERVOUS SYSTEM RESPONSE IN IRRITABLE… (2*) Su1607. . . . SOCIAL STRAIN AND LOW SOCIAL SUPPORT… (4*) Su1608. . . . VAGUS NERVES PROVIDE A ROBUST AFFERENT… (2*) Su1609. . . . NEUROMODULATION AND COLON MOTILITY MAPPING IN… (2*) Su1610. . . . DYSREGULATION OF PARKINSON’S DISEASE RELATED GENES… (2*) Su1611. . . . COLORECTAL DISTENSION MODULATES THE PAG FUNCTIONAL… (2*) Su1612. . . . EFFECT OF VISCERO-VISCERAL INTERACTION ON FMRI… (2*) Su1613. . . . THE ASSOCIATION OF VISCERAL ADIPOSITY WITH… (2*) Su1614. . . . HYPOGLYCEMIC EFFECTS OF CHRONIC VAGAL NERVE… (5*) Su1615. . . . PROMOTING EFFECTS AND AUTONOMIC MECHANISMS OF… (5*) Su1616. . . . ANTI-INFLAMMATORY EFFECTS AND MECHANISMS OF SACRAL… (2*) Su1617. . . . NEUROANATOMICAL AND CONNECTIVITY ABNORMALITIES IDENTIFIED IN… (4*) Su1618. . . . SEXUALLY DIMORPHIC BRAIN SIGNATURES IN STIMULUS… (2*) Su1619. . . . RIKKUNSHITO IMPROVES CCK AND STRESS-INDUCED ANOREXIA… (4*) Su1620. . . . NERVE FIBER SPROUTING AND NEURO-IMMUNE INTERACTIONS… (4*) Su1621. . . . AMELIORATING EFFECTS OF SACRAL NERVE STIMULATION… (2*) Su1622. . . . DETERMINE GINGER CONSTITUENT 6-SHOGAOL-INDUCED EFFECT ON… (5*) Su1623. . . . ABNORMAL PERIPHERAL AUTONOMIC AND CENTRAL AUTONOMIC… (2*)

Su1624. . . . GENETIC ETHNICITY AFFECTS RESPONSE VARIABILITY IN… (4*) Su1625. . . . IN VIVO AND IN VITRO EFFECTS… (2*)|(NIH/NIDDK) Su1626. . . . POST-STROKE CONSTIPATION IS ASSOCIATED WITH IMPAIRED… (5*) Su1627. . . . OPIOID USAGE IS SIGNIFICANTLY ASSOCIATED WITH… (5*) Su1628. . . . INVASIVE AND NONINVASIVE VAGAL NERVE STIMULATION… (5*) Su1629. . . . THE AGEING GUT: SYMPTOMS COMPATIBLE WITH… (4*)| Su1630. . . . SENSORY DOMAINS, NOT STOOL FREQUENCY, PREDICT… (5*) Su1631. . . . MACHINE LEARNING WITH PAIN MEASURES ALONE… (5*) Su1632. . . . PARKINSON’S DISEASE PATIENTS WITH CONSTIPATION: RESULTS… (5*) Su1633. . . . LACTOBACILLUS RHAMNOSUS GG SUPERNATANT IMPROVES DEFECATION… (5*) Su1634. . . . IRRITABLE BOWEL SYNDROME AND STRUCTURAL ABNORMALITIES… (5*) Su1635. . . . ORAL IRON SUPPLEMENTATION, MICROBIOME RELATED METHANOGENESIS… (5*) Su1636. . . . THE PLACEBO RESPONSE IN CHRONIC IDIOPATHIC… (5*) Su1637. . . . THE RELATIONSHIPS AMONG FECAL MICROBIOTA AND… (2*)|(This study was supported by Dalian municipal science and technology plan project (NO. 2015F11GH098).) Su1638. . . . CSP01, A NOVEL SUPERABSORBENT HYDROGEL, REDUCES… (3*)|(Gelesis Inc.) Su1639. . . . DAIKENCHUTO (TU-100), A TRADITIONAL JAPANESE HERBAL… (3*)|(Tsumura & Co.) Su1640. . . . PERSISTENT IMPROVEMENT IN CHRONIC CONSTIPATION WITH… (5*) Su1641. . . . RANDOMIZED DOUBLE BLIND CONTROLLED TRIAL TO… (3*)|(Study sponsored by Bustar Alimentos S.A.P.I de C.V)

Su1642. . . . SUPERIOR PERFORMANCE OF GASTROINTESTINAL ULTRASOUND OVER… (5*) Su1643. . . . DEVELOPMENT OF VALIDATED QUESTIONNAIRE EVALUATING PARENT-PERCEIVED… (4*) Su1644. . . . INTEROBSERVER ANALYSIS TRIAL ON COLONIC MOTOR… (4*) Su1645. . . . NALOXEGOL RESTORES CODEINE-INDUCED INHIBITION OF HIGH-AMPLITUDE… (4*)|(No industry or commercial source funding was received for this study.) Su1646. . . . THE INFLUENCE OF BRAIN METASTASES ON… (3*)|(This work was supported by Salix Pharmaceuticals, Bridgewater, NJ, USA, which has licensed the rights to develop and commercialize Relistor® from Progenics Pharmaceuticals, Inc., New York, NY, USA.) Su1647. . . . THE INFLUENCE OF AGE ON CENTRAL… (3*)|(This work was supported by Salix Pharmaceuticals, Bridgewater, NJ, USA, which has licensed the rights to develop and commercialize Relistor® from Progenics Pharmaceuticals, Inc., New York, NY, USA.) Su1648. . . . EFFICACY VARIABLES IN CANCER VERSUS NONCANCER… (3*)|(This work was supported by Salix Pharmaceuticals, Bridgewater, NJ, USA, which has licensed the rights to develop and commercialize Relistor® from Progenics Pharmaceuticals, Inc., New York, NY, USA.) Su1649. . . . WHY PATIENTS WITH CHRONIC CONSTIPATION OR… (5*) Su1650. . . . SACRAL NERVE STIMULATION FOR SLOW TRANSIT… (2*) Su1651. . . . A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL ON… (5*) Su1652. . . . CONSTIPATION MANAGEMENT STRATEGIES: CONSUMER PREFERENCES AND… (3*)|(Sanofi) Su1653. . . . THE STUDY ON HEALTH-RELATED QUALITY OF… (5*) Su1654. . . . THE PREVALENCE OF HLA-DQ GENES, CELIAC… (5*) Su1655. . . . ADMINISTRATION OF NEOSTIGMINE AND GLYCOPYRROLATE BY… (4*)


* = Primary Source



Su1657. . . . FECAL MICROBIAL MARKERS IN COLORECTAL CANCER… (5*) Su1658. . . . MACHINE LEARNING ENABLES DETECTION OF EARLY-STAGE… (5*) Su1659. . . . POSITIVE FAECAL OCCULT BLOOD TEST AFTER… (5*) Su1660. . . . COLORECTAL CANCER SCREENING: COMPLIANCE WITH MULTI-TARGET… (3*)|(Exact Sciences) Su1661. . . . A FAVORABLE SURVIVAL OF THE SCREENING-DETECTED… (5*) Su1662. . . . TIME TO DIAGNOSIS OF EARLY-ONSET VS.… (2*) Su1663. . . . WATER EXCHANGE (WE) ENHANCED DETECTION OF… (2*)| Su1664. . . . HIGH YIELD OF TOTAL AND RIGHT-SIDED… (4*) Su1665. . . . USE OF SCREENING COLONOSCOPY IN AFRICAN… (5*) Su1666. . . . PREDICTORS OF MODIFIABLE FAILURES TO SCREEN… (2*) Su1667. . . . INCREASING UPTAKE OF COLON CANCER SCREENING… (5*) Su1668. . . . THE CORRELATION OF FIT LEVELS WITH… (5*)|(The first author completed this research as part of an Newman Fellowship, which was funded by Boston Scientific.) Su1754. . . . OVERESTIMATION OF THE PREVALENCE OF EOSINOPHILIC… (2*) Su1771. . . . SYSTEMS GENOMICS OF ULCERATIVE COLITIS: COMBINING… (6*) Su1772. . . . INFLAMMATION-DEPENDENT TRANSCRIPTIONAL RE-PROGRAMMING OF THE HIF… (2*) Su1773. . . . INTESTINAL ORGANOIDS DERIVED FROM HUMAN INDUCED… (5*) Su1774. . . . AN INTERPLAY OF PAK1 AND NRF2… (2*) Su1775. . . . ARTIFICIAL SWEETENER ACESULFAMEPOTASSIUMENHANCED LYMPHOCYTE MIGRATION TO… (4*) Su1776. . . . ASSOCIATION OF BIOLOGIC PRESCRIBING FOR INFLAMMATORY… (5*) Su1777. . . . RECEIPT OF PREVENTIVE CARE SERVICES AMONG… (5*)

Su1778. . . . THE TORONTO IBD GLOBAL ENDOSCOPIC REPORTING… (5*) Su1779. . . . TEXT MESSAGE-BASED TELEMEDICINE DOES NOT IMPROVE… (2*) Su1780. . . . INSURANCE GENEROSITY AND INFLAMMATORY BOWEL DISEASE:… (2*) Su1781. . . . THE ECONOMIC BURDEN OF ULCERATIVE COLITIS… (3*)|(Funded by Janssen Scientific Affairs, LLC) Su1782. . . . REDUCTION OF OPIOID USE AND DEPRESSION… (5*)|(There are no industry or commercial sources.) Su1783. . . . RATES OF TREATMENT INEFFECTIVENESS AFTER INITIATING… (6*)| Su1784. . . . REINVENTING INFLAMMATORY BOWEL DISEASE (IBD) CLINICAL… (5*) Su1785. . . . RECENT TRENDS IN DIAGNOSTIC PREVALENCE AND… (3*) Su1786. . . . REDUCTION IN COSTS OF CARE IN… (3*)|(Project Sor is a joint venture between Blue Cross Illinois, SorMD Inc.) Su1787. . . . DEVELOPMENT OF A DEEP LEARNING ALGORITHM… (5*) Su1788. . . . MONITORING RESPONSE TO ANTI-TNF THERAPY IN… (3*)|(AbbVie Deutschland GmbH & Co. KG) Su1789. . . . PATIENTS WHO UNDERGO COLECTOMY FOR PEDIATRIC… (2*) Su1790. . . . INFLIXIMAB RESCUE LESS EFFECTIVE IN PREVENTING… (2*) Su1791. . . . LONGTERM OUTCOME OF PEDIATRIC PATIENTS WITH… (5*) Su1792. . . . ELEVATION OF PLASMA ONCOSTATIN M IS… (2*)| Su1793. . . . TRENDS OF UTILIZATION OF TUMOR NECROSIS… (7*) Su1794. . . . PROPOSED MODIFICATION OF PARIS CLASSIFICATION TO… (2*) Su1795. . . . UTILIZATION OF ANTI-TNF THERAPY (BIOLOGICS) IN… (6*) Su1796. . . . ROOM FOR IMPROVEMENT IN TRANSITION OF… (5*) Su1797. . . . CHILDREN WITH CROHN’S DISEASE WHO RESPOND… (5*)

Su1798. . . . THE INFLUENZA VACCINATION AND PEDIATRIC INFLAMMATORY… (5*) Su1799. . . . INCREASING TRENDS IN DIAGNOSTIC PREVALENCE AND… (3*) Su1800. . . . EFFECT OF ADDITION OF AN IMMUNOMODULATOR… (5*) Su1801. . . . A NOVEL SALT OF RESOLVIN E1… (2*)|(This work was funded in part by Thetis Pharmaceuticals.) Su1802. . . . SLCO2A1 DEFICIENCY EXACERBATES EXPERIMENTAL COLITIS VIA… (5*) Su1803. . . . TWEAK/FN14 AMELIORATES EXPERIMENTAL ILEITIS BY REGULATING… (2*) Su1804. . . . THE COMMON IBD COMPLICATIONS IRON DEFICIENCY… (2*) Su1805. . . . WHEAT AMYLASE/TRYPSIN INHIBITORS AGGRAVATE EOSINOPHILIC ESOPHAGITIS… (2*) Su1806. . . . BERBERINE REGULATES LYSOPHOSPHATIDYLCHOLINE TO PROTECT DSS-INDUCED… (2*)|(This work was kindly funded by grants from tiol tural Science Foundation of Chi (Project No. 81560676), Logan Charitable Foundation, Hong Kong Baptist University Research Grant (No. LIUYE/15-16/01-CLNC) and Shenzhen Science and Technology Innovation Commi) Su1807. . . . POST-OPERATIVE RECURRENCE AFTER ILEO-CAECAL RESECTION FOR… (5*)|(Lesaffre Intertiol, Lesaffre Group, Marcq-en-Barœul, France) Su1808. . . . DOWNREGULATION OF RALGTPASE-ACTIVATING PROTEIN LEADS TO… (2*)|(Japan Society for the Promotion of Science (JSPS) Grants-in-Aid for Scientific Research (KAKENHI)) Su1809. . . . A COMPARISION STUDY OF SYSTEMIC VERSUS… (3*)|(Progenity Inc.) Su1810. . . . COMBINATORIAL TREATMENT WITH A HIF-HYDROXYLASE INHIBITOR… (2*)|(Sigmoid Pharma) Su1811. . . . NOVEL INSIGHT INTO MECHANISM OF PROTECTIVE… (4*)|(tiol Science Centre, Poland (grant number UMO-2015/19/B/NZ4/03130).) Su1812. . . . TREATMENT WITH HYDROLYZED DIET SUPPLEMENTED WITH… (3*)|(Bioiberica SAU)


* = Primary Source



Su1813. . . . THERAPEUTIC EFFICACY OF BILE ACID SEQUESTRATION… (2*) Su1814. . . . DETERMINATION OF MINIMAL EFFICACIOUS DOSES OF… (3*)|(Karyopharm Therapeutics) Su1815. . . . GRAPE SEED EXTRACT AND EMU OIL… (4*) Su1816. . . . PROTECTION BY CCR6 BLOCKADE IN A… (4*) Su1817. . . . BIOTIN SUPPLEMENTATION AMELIORATES MURINE COLITIS BY… (2*) Su1818. . . . PRECLINICAL EFFICACY AND SAFETY OF NX-13:… (5*) Su1819. . . . NEW CLASS OF ANTI-INFLAMMATORY THERAPEUTICS BASED… (2*)|(Inwex Ltd. is an employer of Remigiusz Szczepaniak) Su1820. . . . THE EFFECT OF PROBIOTIC LACTOBACILLUS CASEI… (1*)|(PROGRES Q40-15 from Charles University.) Su1821. . . . TARAXACUM OFFICINALE EXTRACTS AMELIORATES MURINE EXPERIMENTAL… (2*) Su1822. . . . NP-120 AND NP-178: REPURPOSED NEUROLOGICAL DRUGS… (3*)|(SH Pharmaceuticals (a subsidiary of Breathtec Biomedical Inc.)) Su1823. . . . TRADITIONAL CHINESE MEDICINE-DERIVED MIR5368 ALLEVIATES ULCERATIVE… (2*) Su1824. . . . EFFECT OF ZOFENOPRIL ON ACETIC ACID-INDUCED… (2*) Su1825. . . . FIBROBLAST GROWTH FACTOR 21 DEPLETION ATTENUATES… (2*) Su1826. . . . SMALL INTESTINAL EPITHELIAL MICROVILLI-ASSOCIATED DEFECTS PRESENT… (2*)| Su1827. . . . ORGANOIDS DERIVED FROM INFLAMED AND NON… (4*) Su1828. . . . MIR-124 MEDIATES THE IMPAIRMENT OF INTESTINAL… (2*) Su1829. . . . LACTOBACILLUS ACIDOPHILUS CAUSES AN ENHANCEMENT OF… (2*) Su1830. . . . INDUCIBLE NITRIC OXIDE MEDIATED PHOSPHORYLATION REGULATES… (2*) Su1831. . . . ACTIVATION OF ADENOSINE A3 RECEPTOR INHIBITS… (2*)|(tural

Science Foundation of Guangdong Province, Chi grant 2016A030313009; Science and Technology Innovation Commission of Shenzhen Municipality, Chi grant JCYJ20150331142757394.) Su1832. . . . INHIBITION OF INTESTINAL EPITHELIAL CELL PYROPTOSIS… (3*)|(Takeda Pharmaceutical Company Ltd) Su1833. . . . ELEVATED CAP-D3 LEVELS IN INTESTINAL EPITHELIAL… (2*) Su1834. . . . REDUCED AQUAPORIN 5 EXPRESSION IN COLORECTAL… (4*) Su1835. . . . VEDOLIZUMAB USE IS NOT ASSOCIATED WITH… (3*)|(Medical writing assistance was provided by Fraser Harris of Oxford PharmaGenesis, Oxford, UK, and was supported by Takeda Pharmaceutical Company Ltd.) Su1836. . . . HIGH EXPOSURE TO INFLIXIMAB IS ASSOCIATED… (5*) Su1837. . . . HIGHER DISCONTINUATION RATES OF ANTI-TNF THERAPY… (2*)|(The IBDREAM registry is facilitated by Janssen, Pfizer, MSD, Takeda, Celgene, AbbVie, DrFalk, MundiPharma.) Su1838. . . . COMPARATIVE RISK OF SERIOUS INFECTIONS WITH… (2*) Su1839. . . . RISKS OF CANCERS IN THIOPURINES USERS… (5*) Su1840. . . . HIGHER ADALIMUMAB SERUM LEVELS DO NOT… (4*) Su1841. . . . FACTORS ASSOCIATED WITH WEIGHT GAIN IN… (5*) Su1842. . . . CHARACTERISTICS OF HEPATOSPLENIC T-CELL LYMPHOMA IN… (3*)|(Janssen Scientific Affairs, LLC supported this study) Su1843. . . . SAFETY AND EFFICACY OF GLUCAGON-LIKE-PEPTIDE-2 ANALOGUE… (5*) Su1844. . . . HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN INFLAMMATORY BOWEL DISEASE… (5*) Su1845. . . . HOME INFUSION OF BIOLOGIC MEDICATIONS IN… (5*) Su1846. . . . OUTCOMES OF PREGNANCY IN IBD PATIETNS… (5*) Su1847. . . . RAPID 30-MINUTE INFLIXIMAB INFUSION PROTOCOLS ARE… (1*)|(This research was supported by a Pfizer Grant.)

Su1848. . . . CLINICAL CHARACTERISTICS AND RISK FACTORS FOR… (5*) Su1849. . . . RISK OF NEW OR RECURRENT CANCER… (5*) Su1850. . . . RATE OF SERIOUS INFECTION IN ELDERLY… (4*) Su1851. . . . ANTI-TNF INDUCED LYMPHOCYTOSIS IN PATIENTS WITH… (5*) Su1852. . . . POST-OPERATIVE COMPLICATIONS FOLLOWING ELECTIVE SURGERY IN… (5*) Su1853. . . . TUBERCULOSIS INFECTION UNDER ANTI-TNF THERAPY –… (5*) Su1854. . . . PROFILE OF PATIENTS WITH INFLAMMATORY BOWEL… (5*) Su1855. . . . VEDOLIZUMAB IS NOT ASSOCIATED WITH INCREASED… (5*) Su1856. . . . A PILOT STUDY COMPARING POSTOPERATIVE OUTCOMES… (5*) Su1857. . . . COMPARATIVE SAFETY AND EFFECTIVENESS OF TUMOR… (5*) Su1858. . . . REAL-WORLD EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB… (3*)|(The study was sponsored by Takeda Pharmaceuticals Company Ltd. Evidera was funded by Takeda Pharmaceuticals Company Ltd to conduct this study and provide medical writing assistance. The abstract was prepared by Evidera; no additiol medical writing assista) Su1859. . . . REAL-WORLD EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB… (3*)|(This study was sponsored by Takeda Pharmaceuticals Company Ltd. Evidera was funded by Takeda Pharmaceuticals Company Ltd to conduct this study and provide medical writing assistance. The abstract was prepared by Evidera; no additiol medical writing assist) Su1860. . . . COMPARISON OF REAL-WORLD TREATMENT OUTCOMES WITH… (3*)|(This study was sponsored by Takeda Pharmaceutical Company, Ltd.) Su1861. . . . COMPARATIVE EFFICACY AND SPEED OF ONSET… (1*) Su1862. . . . LOW-DOSE METHOTREXATE IS EQUALLY EFFECTIVE AS… (5*) Su1863. . . . COMPARATIVE EFFICACY OF VEDOLIZUMAB AND ADALIMUMAB… (5*)


* = Primary Source



Su1864. . . . THE FRAGILITY OF LANDMARK RANDOMIZED TRIALS… (5*) Su1865. . . . REAL-WORLD SHORT-TERM EFFECTIVENES OF USTEKINUMAB IN… (5*) Su1866. . . . INTEGRATING EFFICACY AND SAFETY OF VEDOLIZUMAB… (3*)|(Takeda) Su1867. . . . SUSTAINANILITY OF BIOLOGIC THERAPIES IS LESS… (5*) Su1868. . . . COMPARATIVE EFFICACY AND SAFETY OF PROBIOTICS… (5*) Su1869. . . . EFFECT OF THALIDOMIDE ON CLINICAL REMISSION… (5*) Su1870. . . . IDENTIFYING THE OPTIMAL TREATMENT SEQUENCE WITH… (3*)|(This research was funded by an investigator-initiated grant from Janssen Pharmaceuticals) Su1871. . . . CURCUMIN USE IN ULCERATIVE COLITIS -… (5*) Su1872. . . . EVALUATION OF REAL-WORLD MAINTENANCE DOSING FOR… (3*)|(Funded by Janssen Scientific Affairs LLC, USA.) Su1873. . . . REMISSION TO VEDOLIZUMAB IS NOT HIGHER… (5*) Su1874. . . . SUBCUTANEOUSLY ADMINISTERED ANTI-TNFS FOR THE TREATMENT… (3*)|(Janssen Inc.) Su1875. . . . DEVELOPMENT OF TARGETED THERAPEUTIC ANTIBODIES FOR… (3*)|(Progenity Inc.) Su1876. . . . INFLIXIMAB INDUCTION REGIMES IN STEROID REFRACTORY… (5*) Su1877. . . . IMPACT OF IMMUNOSUPPRESSIVE THERAPY ON THE… (5*) Su1878. . . . INTERLEUKIN-33 DELAYS RECOVERY OF MUCOSAL INFLAMMATION… (4*) Su1880. . . . SECONDARY BILE ACIDS PROTECT AGAINST INTESTINAL… (6*) Su1881. . . . THE NUCLEAR RECEPTOR LRH-1 IS A… (2*) Su1882. . . . CYCLIC GMP-AMP SYNTHASE (CGAS) PLAYS A… (2*) Su1883. . . . COLON IL-33 IS PRIMARILY PRODUCED BY… (2*)

Su1884. . . . COMBINED RNASEQ AND CYTOF ANALYSIS OF… (4*)|(CCFA CDA) Su1885. . . . ANALYSIS OF HUMAN COLONIC TISSUE AND… (2*)| Su1886. . . . SACRAL NERVE STIMULATION INHIBITS THE MAPK/NF-KB… (5*) Su1887. . . . ENDOGENOUS OPIOIDS IN CHRONIC COLITIS INDUCE… (6*) Su1888. . . . ESTROGEN RECEPTOR β ACTIVATION INHIBITS INFLAMMATION… (2*) Su1889. . . . T HELPER 2 (TH2)-MEDIATED REGULATION OF… (2*) Su1890. . . . PREDICTED FECAL MICROBIOTA SIGNATURES ARE ASSOCIATED… (2*) Su1891. . . . MONOCYTE/MACROPHAGE PHENOTYPIC ALTERATION WITH ENHANCED PRO-INFLAMMATORY… (2*) Su1892. . . . PERIOSTIN PROMOTES ENDOPLASMIC RETICULUM STRESS-MEDIATED FIBROSIS… (6*) Su1893. . . . LYSOPHOSPHATIDYLSERINE DETERIORATES MURINE TNBS-INDUCED COLITIS… (5*) Su1894. . . . THE JAK INHIBITOR-TOFACITINIB INHIBITS SIGNALING PATHWAYS… (3*)|(Pfizer provided support for the study through an independent research grant) Su1895. . . . TARGETING AMPKβ1 AS A NOVEL STRATEGY… (4*) Su1896. . . . RECOMBINANT RNASET2 MODULATES IFNγ SECRETION: A… (2*) Su1897. . . . INTESTINAL IMMUNE CONDITIONING WITH HELMINTHS EMPLOY… (2*) Su1898. . . . HEPATOCYTE GROWTH FACTOR AND MET, NOVEL… (4*) Su1899. . . . EXPRESSION PROFILES OF HELPER T-CELL-RELATED GENES… (5*) Su1900. . . . DIFFERENCES IN INFLAMMATION-RELATED GENE EXPRESSION IN… (3*)|(GlaxoSmithKline Investigator Initiated Grant) Su1901. . . . SPECIFIC ISOFORMS OF THE LONG NON-CODING… (4*)

Su1902. . . . PHOSPHATASE SHP2 EXACERBATES INTESTINAL INFLAMMATION BY… (2*) Su1903. . . . EARLY MEASUREMENT OF SERUM CYTOKINES AS… (4*) Su1904. . . . SELECTIN-INHIBITION BY DOUBLY GLYCOSYLATED LYSOZYME MUTANTS… (5*) Su1905. . . . B2 STRICTURING BEHAVIOR ASSOCIATED WITH TGF… (2*) Su1906. . . . MARKERS FOR SEVERE, REFRACTORY CROHN’S DISEASE… (4*) Su1907. . . . DIAGNOSTIC ACCURACY OF THE SERUM-BASED MUCOSAL… (4*)|(This study was supported in part by a collaborative grant from Prometheus Laboratories Inc, and grants to Drs. Sandborn and Dulai from the Litwin IBD Pioneers Program and American College of Gastroenterology Clinical Research Award. Serum assays for the) Su1908. . . . A VALIDATED SERUM HEADSPACE METABOLOME PROFILE… (4*) Su1909. . . . PREDICTING ENDOSCOPIC RESPONSE IN USTEKINUMAB TREATED… (4*)| Su1910. . . . A NOVEL QUANTITATIVE PROTEIN EXPRESSION PROFILE… (2*)|(nostring Technologies participated in this research under their Technology Access Program (TAP).) Su1911. . . . IDENTIFICATION OF SERUM PROTEIN BIOMARKERS FOR… (6*) Su1912. . . . A SEROLOGICAL BIOMARKER OF TYPE VIII… (3*)|(Nordic Bioscience A/S) Su1913. . . . ANTI-MAA (MALONDIALDEHYDE-ACETALDEHYDE ADDUCTS) IMMUNOGLOBULIN ISOTYPES IN… (4*) Su1914. . . . ASSOCIATION BETWEEN SEROLOGICAL MARKERS AND RATE… (5*) Su1915. . . . METABOLOMICS UNCOVERS UNIQUE DISEASE SIGNATURES IN… (2*) Su1916. . . . ABSENCE OF PERIANAL SYMPTOMS DOES NOT… (5*) Su1917. . . . CLINICAL AND ENDOSCOPIC FEATURES OF XIAP… (5*) Su1918. . . . A 1-YEAR CROSS-SECTIONAL INFLAMMATORY BOWEL DISEASE… (4*)


* = Primary Source



Su1919. . . . MONITORING VITAMIN D METABOLISM IN INFLAMMATORY… (3*)|(Immundiagnostik AG, Bensheim, Germany) Su1920. . . . PHENOTYPE CLASSIFYING CROHN'S DISEASE INTO ILEAL… (2*) Su1921. . . . VALIDATION OF SCORING SYSTEMS FOR DIFFERENTIATING… (5*) Su1922. . . . PERFORMANCE OF A NOVEL FECAL CALPROTECTIN… (3*) Su1923. . . . NOVEL ASSOCIATIONS OF PLATELETS WITH CLINICAL… (2*) Su1924. . . . THE USE OF ALVIMOPAN AS PROPHYLAXIS… (5*) Su1925. . . . NON-ADHERENCE TO MAINTENANCE MEDICATIONS IS COMMON… (2*) Su1926. . . . RISK OF INFECTIONS AND HOSPITALISATIONS IN… (5*) Su1927. . . . CONTINUING 5-ASA THERAPY IN MODERATE-TO-SEVERE ULCERATIVE… (4*) Su1928. . . . TOFACITINIB IMPROVES CLINICAL DISEASE ACTIVITY IN… (5*) Su1929. . . . OUTCOMES FOLLOWING INTRAVENOUS STEROID USE IN… (5*) Su1930. . . . SAFETY AND EFFICACY OF OLORINAB, A… (3*)|(Are Pharmaceuticals, Inc.) Su1931. . . . DOES CORTICOSTEROID THERPAY AFFECT PROGNOSIS IN… (5*) Su1932. . . . SAFETY OF RECOMBINANT ZOSTER VACCINE (RZV-SHINGRIX)… (5*) Su1933. . . . ANTI-MYCOBACTERIUM PARATUBERCULOUS THERAPY IN CROHN’S DISEASE:… (5*) Su1934. . . . SAFETY OF GRANULOCYTE AND MONOCYTE ADSORPTIVE… (3*) Su1935. . . . SAFETY AND EFFECTIVENESS OF GRANULOCYTE AND… (3*) Su1936. . . . ENDOSCOPIC EVALUATION FOR GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE:… (5*) Su1937. . . . THE MANITOBA LIVING WITH IBD STUDY:… (2*) Su1941. . . . HELICOBACTER PYLORI CAGA PROTEIN NEGATIVELY REGULATES… (5*)

Su1942. . . . CRYPTOSPORIDIUM PARVUM INFECTION INDUCES AUTOPHAGY IN… (2*) Su1943. . . . LONG-TERM EHEC INFECTION STIMULATES MUCUS PRODUCTION… (5*) Su1944. . . . METASTATIC ASSOCIATED COLON CANCER 1 (MACC1)… (2*) Su1945. . . . DIFFERENTIAL RESPONSE OF INTESTINAL EPITHELIAL CELLS… (6*) Su1946. . . . DISRUPTION OF INTESTINAL EPITHELIUM WITH THE… (2*) Su1947. . . . HYA, A METABOLITE OF LINOLEIC ACID… (5*) Su1948. . . . CHARACTERISTICS AND INFLUENCING FACTORS OF GUT… (5*) Su1949. . . . SMALL INTESTINAL ASPIRATES REQUIRE SPECIFIC TREATMENT… (4*) Su1950. . . . RISK FACTORS FOR CENTRAL LINE-ASSOCIATED BLOODSTREAM… (5*) Su1951. . . . GLOBAL DISPARITIES AND NEW INDICATIONS IN… (5*) Su1952. . . . PATIENTS’ PERSPECTIVE AND COMPLIANCE AFFECT THE… (1*) Su1953. . . . PATIENT PERCEPTIONS OF FECAL MICROBIOTA TRANSPLANTATION… (5*) Su1954. . . . LONG-TERM EFFICACY OF RIFAXIMIN TO MANAGE… (1*) Su1955. . . . CLOSTRIDIUM DIFFICILE-ASSOCIATED OUTCOMES AMONG HOSPITALIZED INFLAMMATORY… (5*) Su1956. . . . IS DIARRHEA THE ONLY SYMPTOM OF… (5*) Su1957. . . . CLOSTRIDIUM DIFFICILE SCREENING IN HOSPITALIZED PATIENTS… (5*) Su1958. . . . GEOSPATIAL DISTRIBUTION AND TRENDS IN COMMUNITY… (5*) Su1959. . . . TRENDS IN INCIDENCE, MORTALITY, AND COSTS… (5*) Su1960. . . . ASSESSMENT OF CLOSTRIDIUM DIFFICILE EPIDEMIOLOGY AMONG… (7*)|(Merck Cada) Su1961. . . . COST-EFFECTIVENESS OF TREATMENT REGIMENS FOR CLOSTRIDIUM… (2*)

Su1962. . . . DOES HIGHER SERUM PROCALCITONIN LEVELS PREDICT… (5*) Su1963. . . . AMINO ACID SENSING IS AN ESSENTIAL… (2*) Su1964. . . . THE FOOD ADDITIVE EDTA INCREASES INTESTINAL… (7*) Su1965. . . . CROHN'S LIKE LYMPHOID REACTION IS ASSOCIATED… (5*) Su1966. . . . NOVEL EVIDENCE FOR SERUM MIR-203 LEVELS… (4*) Su1967. . . . HIGH RIBOFLAVIN INTAKE PROTECTS AGAINST SESSILE… (2*) Su1968. . . . INCREASED PREVALENCE OF TYPE 2 DIABETES… (2*) Su1969. . . . PSOAS MUSCLE INDEX AFFECTS THE LONG-TERM… (5*) Su1970. . . . THE ASSOCIATION OF LACTOSE INTOLERANCE WITH… (5*) Su1971. . . . ASSOCIATION BETWEEN SARCOPENIA AND GASTRIC CARCINOGENESIS:… (5*) Su1972. . . . GASTRIC MICROBIOME IN PATIENTS WITH INTESTINAL… (2*) Su1973. . . . CAN INTRAGASTRIC BALLOON THERAPY NORMALIZE THE… (5*) Su1974. . . . FECAL MICROBIOTA TRANSPLANT IN GRAFT VERSUS… (5*) Su1975. . . . GERM-FREE C57BL/6 MICE ARE SUSCEPTIBLE TO… (4*) Su1976. . . . IMPACTS OF ADDITIVE FOOD E171 (TITANIUM… (4*) Su1977. . . . THE SAFETY AND EFFICACY OF FECAL… (5*) Su1978. . . . ASSOCIATION OF FUSOBACTERIUM NUCLEATUM IN COLORECTAL… (2*) Su1979. . . . UPREGULATED CLAUDIN-1 EXPRESSION INDUCES GUT DYSBIOSIS… (2*)| Su1980. . . . THE NETWORK CONSTRUCTION AND MODULE ORGANIZATION… (2*) Su1981. . . . INDUCTION OF SPECIFIC CARCINOGENIC MICRO-RNAS EXPRESSION… (2*)


* = Primary Source



Su1982. . . . MUCOSA-ASSOCIATED MICROBIOTA IN THE UPPER GUT… (1*) Su1983. . . . LACK OF PREVENTIVE DENTAL CARE IS… (2*) Su1984. . . . THE DIFFERENCE OF GUT MICROBIOME IN… (5*) Su1985. . . . PRELIMINARY DATA ON ORAL AND FECAL… (5*) Su1986. . . . GUT DYSBIOSIS INDUCED ABNORMAL BILE ACIDS… (5*) Su1987. . . . THE CHANGE OF THE GUT MICROBIOTA… (5*) Su1988. . . . MUCOSA-ASSOCIATED MICROBIOTA DIVERSITY SIGNIFICANTLY DIFFERS IN… (5*) Su1989. . . . ASSOCIATIONS BETWEEN GASTROESOPHAGEAL HISTOPATHOLOGY AND THE… (5*) Su1990. . . . FUSOBACTERIUM NUCLEATUM INFECTION ASSOCIATES WITH TWO… (2*) Su1991. . . . DIFFERENCES IN THE GASTROESOPHAGEAL MICROBIOME AND… (2*) Su1992. . . . INFECTION BY PATHOGENIC E. COLI INDUCES… (2*) Su1993. . . . DIET AND OBESITY RATHER THAN ETHNICITY… (4*) Su1994. . . . THE COMMON FOOD ADDITIVES SODIUM SULFITE… (6*) Su1995. . . . HIGH-FAT DIET-INDUCED GUT MICROBIOTA DYSBIOSIS PROMOTE… (2*) Su1996. . . . ALTERED GUT MICROBIOTA INDUCED BY A… (2*) Su1997. . . . COCONUT OIL DIET AS ADJUVANT FOR… (2*) Su1998. . . . EARLY LIFE SOLID FOOD INGESTION REMODELS… (5*) Su1999. . . . THE EFFECT OF DIETARY FIBER INTAKE… (2*) Su2000. . . . CROHN'S DISEASE PATIENTS IN REMISSION CONSUMING… (6*) Su2001. . . . EFFECT OF A MODIFIED AMERICAN DIET… (2*) Su2002. . . . ALTERATIONS IN THE SMALL BOWEL MICROBIOTA… (4*)

Su2003. . . . MICROENCAPSULATED SODIUM BUTYRATE SIGNIFICANTLY MODIFIES THE… (4*) Su2004. . . . DISRUPTION OF CIRCADIAN RHYTHM REDUCES THERMOGENESIS… (2*) Su2005. . . . AGE-RELATED DYSMETABOLISM IS ASSOCIATED WITH CHANGES… (2*) Su2006. . . . FUSOBACTERIUM NUCLEATUM MAY PROMOTE GLYCOLYSIS VIA… (2*) Su2008. . . . MECHANISM OF INHIBITION OF VILLUS CELL… (2*) Su2009. . . . NUTRITIONAL ASSESSMENT IN PATIENTS UNDERGOING GASTRIC… (5*) Su2010. . . . MORTALITY AND OUTCOMES IN PATIENTS WITH… (3*)|(Study funding provided by Shire) Su2011. . . . SHORT BOWEL SYNDROME PATIENTS WITH RESIDUAL… (2*) Su2012. . . . ETIOLOGY OF AND PREDICTIVE FACTORS FOR… (5*) Su2013. . . . EFFECTS OF GLEPAGLUTIDE, A NOVEL LONG-ACTING… (3*)|(The trial was sponsored by Zealand Pharma, Denmark.) Su2014. . . . HOME PARENTERAL NUTRITION PATIENTS WITH SEVERE… (5*) Su2015. . . . EFFECT OF APRAGLUTIDE, A NOVEL LONG-ACTING… (3*) Su2016. . . . ADIPOSE-DERIVED SECRETOME (ADS) MEDIATES THE STIMULATION… (2*) Su2018. . . . LONG NON-CODING RNA ZFAS1 PROMOTES PROLIFERATION… (2*) Su2019. . . . INTESTINAL GROWTH IN GLUCAGON RECEPTOR KNOCKOUT… (6*) Su2020. . . . NUTRITIONAL CARE PATHWAYS OF PATIENTS WITH… (3*)|(THIS RESEARCH WAS FUNDED BY CALEA, FRESENIUS KABI, UK.) Su2021. . . . IS HOME PARENTERAL NUTRITION BURDERSOME IN… (3*)|(Calea-Fresenius Kabi) Su2022. . . . TOLERANCE AND OUTCOME OF NUTRITION SUPPORT… (5*) Su2023. . . . A RETROSPECTIVE STUDY ON ICU ADMISSION… (5*) Su2024. . . . USE OF PREOPERATIVE TOTAL PARENTERAL NUTRITION… (5*)

Su2025. . . . SHOULD A DIAGNOSIS OF CANCER PRECLUDE… (5*) Su2026. . . . HOME PARENTERAL NUTRITION (HPN): INDICATIONS FOR… (5*) Su2027. . . . PERCUTANEOUS TRANSESOPHAGEAL GASTRO-TUBING AS AN ALTERNATIVE… (5*) Su2028. . . . NATURAL HISTORY OF PERCUTANEOUS ENTERAL GASTROSTOMY… (5*) Su2029. . . . USEFULLNESS OF BRANCHED-CHAIN AMINO ACID-ENRICHED ENTERAL… (5*) Su2039. . . . USE OF PATIENT-DERIVED TUMOR XENOGRAFT MODEL… (1*) Su2040. . . . DIVERSE TUMOR SUSCEPTIBILITY IN COLLABORATIVE CROSS… (2*) Su2042. . . . DERIVATION OF OESOPHAGEAL ORGANOIDS TO RECAPITULATE… (7*) Su2043. . . . A NOVEL CANINE INTESTINAL ORGANOID MODEL… (4*) Su2044. . . . EXOSOMES RELEASED FROM PATIENT-DERIVED ORGANOIDS CONTAIN… (2*)|(This study was supported by JSPS KAKENHI Grant number JP18K15803.) Su2045. . . . VASCULAR SHUT DOWN EFFECTS OF PHOTODYNAMIC… (5*) Su2046. . . . MORPHOLOGIC DIFFERENCE OF PATIENTS-DERIVED IMMORTAL ESOPHAGEAL… (2*) Su2047. . . . FUNCTIONAL LUMEN IMAGING PROBE IS USEFUL… (5*) Su2048. . . . ENDOSCOPIC RETEROGRADE APPENDICOGRAPY: AN EFFECTIVE DIAGNOSTIC… (5*) Su2049. . . . NONINVASIVE POINT-OF-CARE MEASUREMENT OF GUT PERMEABILTIY… (6*)|(Support received from MediBeacon Inc.) Su2050. . . . NEAR INFRARED (NIR) FLUORESCENCE READOUTS OF… (3*)|(Abbvie) Su2051. . . . INTRACOLIC MOLECULAR ULTRASOUND IMAGING FOR NON-INVASIVE… (5*)


* = Primary Source



Su2052. . . . ABILITY OF DWI TO CHARACTERIZE BOWEL… (5*) Su2053. . . . MUCOSAL INTEGRITY TESTING IS A POTENTIAL… (5*) Su2054. . . . ASSESSMENT OF ENDOSCOPIC BAND LIGATION IN… (5*) Su2055. . . . CHARACTERIZING INTESTINAL STRICTURES OF CROHN'S DISEASE… (2*) Su2056. . . . CLINICAL SIGNIFICANCE OF ROBOT CAPSULE ENDOSCOPY… (2*) Su2057. . . . DIAGNOSTIC YIELD OF VOLUMETRIC LASER ENDOMICROSCOPY… (5*) Su2058. . . . INTERPRETATION OF VOLUMETRIC LASER ENDOMICROSCOPY IN… (5*) Su2059. . . . NOVEL MULTI-VIEW IMAGING DEVICE TO IMPROVE… (2*) Su2060. . . . A NEW SECOND GENERATION ENDOSCOPE FOR… (4*)|(FUJI FILM) Su2061. . . . A MULTI-SPECTROSCOPIC APPROACH TO DISEASE DIAGNOSIS:… (4*) Su2062. . . . MEASUREMENT OF MUCOSAL MITOCHONDRIAL OXYGEN DURING… (6*) Su2063. . . . COLITIS ON CT – DOES THIS… (5*) Mo1000. . . . IMPACT OF A CITYWIDE BENCHMARKING INTERVENTION… (2*) Mo1001. . . . COLORECTAL CANCER RISK FACTORS ACCORDING TO… (5*) Mo1002. . . . THE IMPACT OF A TAILORED INTERVENTION… (5*) Mo1003. . . . BREATH ANALYSIS CAN BE USED TO… (3*)|(The eNose company supplied the eNose devices free of charge.) Mo1004. . . . IMPACT OF FIT CUT-OFF VALUES ON… (5*) Mo1005. . . . HEARTBURN AND THE AMERICAN COLLEGE OF… (5*) Mo1006. . . . OBSTRUCTION AND PERFORATION AS INITIAL PRESENTATION… (6*) Mo1007. . . . IDENTIFICATION OF RISK FACTORS FOR EARLY… (5*) Mo1008. . . . SCREENING FOR HEAD AND NECK SECOND… (5*)

Mo1009. . . . USE OF COMMUNITY HEALTH WORKERS IN… (6*) Mo1010. . . . INCREASING INCIDENCE OF STAGE I PANCREATIC… (5*) Mo1011. . . . UTILIZING SOCIAL MEDIA TO SHARE SCIENTIFIC… (4*)|(5) Mo1100. . . . HYPERURICEMIA AMELIORATES INTESTINAL INFLAMMATION ALONG WITH… (4*) Mo1101. . . . SUPERIOR MESENTERIC VEIN OCCLUSION IN RATS… (4*) Mo1102. . . . ASPIRIN AND ISCHEMIA IN THE MURINE… (4*) Mo1103. . . . RESTRICTIVE EXPRESSION OF METALLOENDOPEPTIDASE ADAM-LIKE DECYSIN… (2*) Mo1104. . . . THE TRANS-GOLGI NETWORK PROTEIN AFTIPHILIN REGULATES… (2*) Mo1106. . . . IMMUNOLOGIC DISSECTION OF COLITIS RELATED TO… (2*) Mo1107. . . . IRON PREVENTS HYPOXIA-INDUCED INFLAMMATION IN THE… (2*) Mo1108. . . . RESCUE OF RESTITUTION DEFECT IN A… (2*) Mo1109. . . . SEVERE WOUND CONTRACTION PROMOTES BARRETT'S ESOPHAGUS… (1*) Mo1110. . . . ER STRESS PATHWAY ACTIVATION AFTER DOXORUBICIN… (2*) Mo1111. . . . THE METFORMIN INHIBITS MDSC AND M2… (5*) Mo1112. . . . MICRORNA-24 IS OVEREXPRESSED IN ULCERATIVE COLITIS… (2*) Mo1113. . . . 3-OXO-C12:2 N-ACYL HOMOSERINE LACTONE, A QUORUM… (4*) Mo1114. . . . DOXORUBICIN EXPOSURE DECREASES INTESTINAL EPITHELIAL BARRIER… (2*) Mo1115. . . . PRO-INFLAMMATORY AND PRO-FIBROTIC STEM CELL VARIANTS… (2*) Mo1116. . . . MOLECULAR CHARACTERIZATION OF COLONIC MAIT CELLS… (4*)

Mo1117. . . . GAVAGE AS-MIR-214-3P REDUCES INFLAMMATION IN EXPERIMENTAL… (2*) Mo1118. . . . PRESERVATION OF JEJUNAL ACTIVE INTESTINAL STEM… (2*) Mo1119. . . . THE ROLE OF EXTRACELLULAR DNA IN… (2*) Mo1120. . . . A TRIAL FOR THE ADMINISTRATION OF… (5*) Mo1121. . . . PH-DEPENDENT G PROTEIN-COUPLED RECEPTOR GPR68 (OGR1)… (2*) Mo1122. . . . GENE EXPRESSION PROFILING AND FLOW CYTOMETRY… (4*) Mo1126. . . . RAPID RECURRENCE OF SYMPTOMS, ENDOSCOPIC FINDINGS,… (2*) Mo1127. . . . MAST CELLS IN ADDITION TO EOSINOPHILS… (3*)|(Allakos, Inc. This work was also funded in part by the Division of Intramural Research, NIAID, NIH) Mo1128. . . . VONOPRAZAN SHOWS EFFICACY SIMILAR TO THAT… (5*) Mo1129. . . . EFFICACY OF BUDESONIDE ORODISPERSIBLE TABLETS FOR… (3*)|(This study was funded by Dr. Falk Pharma GmbH, Freiburg, Germany) Mo1130. . . . BUDESONIDE ORODISPERSIBLE TABLETS CAN EFFECTIVELY INDUCE… (3*)|(This study was funded by Dr. Falk Pharma GmbH, Freiburg, Germany.) Mo1131. . . . CLINICAL AND ENDOSCOPIC CHARACTERISTICS ACCURATELY PREDICT… (2*) Mo1132. . . . DIETARY ELIMINATION THERAPY IS EFFECTIVE FOR… (2*) Mo1133. . . . HIGH PATIENT-REPORTED DISEASE BURDEN FOR EOSINOPHILIC… (2*) Mo1134. . . . ESOPHAGEAL LICHEN PLANUS: DIAGNOSTIC CRITERIA AND… (5*) Mo1135. . . . ROLE OF REFLUX IN THE PATHOGENESIS… (5*) Mo1136. . . . EOSINOPHIL COUNT ON BASELINE ENDOSCOPY PREDICTS… (5*) Mo1137. . . . QUALITY IMPROVEMENT IN THE MANAGEMENT OF… (5*) Mo1138. . . . A COMPREHENSIVE ASSESSMENT OF EOSINOPHILIC OESOPHAGITIS… (5*)


* = Primary Source



Mo1139. . . . CAN IGG4 BE USED AS AN… (5*) Mo1140. . . . EOSINOPHILIC OESOPHAGITIS IN CHILDREN AND ADULTS:… (5*) Mo1141. . . . FECAL EOSINOPHIL CATIONIC PROTEIN AS POTENTIAL… (5*) Mo1142. . . . ACHALASIA IS A COMMON FINDING IN… (5*) Mo1143. . . . ESOPHAGEAL MOTILITY DISORDERS IN EOSINOPHILIC ESOPHAGITIS… (5*) Mo1144. . . . EOSINOPHILIC GASTROINTESTINAL DIESEASE FOLLOWING INTESTINAL TRANSPLANT… (5*) Mo1145. . . . EOSINOPHILIC ESOPHAGITIS IS ASSOCIATED WITH A… (5*) Mo1146. . . . CLINICAL MANIFESTATION, COURSE OF DISEASE AND… (5*) Mo1147. . . . ASSOCIATION OF ALLERGENIC HOUSING COMPOUNENTS AND… (2*) Mo1148. . . . ESOPHAGEAL LAMINA PROPRIA FIBROSIS OCCURS IN… (4*) Mo1149. . . . PREVALENCE OF EOSINOPHILIC ESOPHAGITIS IN CROHN'S… (5*) Mo1150. . . . SUBSTANTIAL BURDEN OF PSYCHIATRIC COMORBIDITIES AND… (5*) Mo1151. . . . PSYCHIATRIC COMORBIDITY IS ASSOCIATED WITH DEMOGRAPHIC… (5*) Mo1152. . . . VALIDATION OF A MODEL TO PREDICT… (2*) Mo1153. . . . BIOMARKERS OF DISEASE ACTIVITY AND TREATMENT… (5*) Mo1154. . . . PREVALENCE AND CHARACTERISTICS OF EOSINOPHILIC ESOPHAGITIS… (3*)|(This study was funded by Shire Human Genetic Therapies, Inc.) Mo1155. . . . PATTERNS OF CARE IN THE MANAGEMENT… (5*) Mo1156. . . . ENDOSCOPIC FEATURES OF GERD PREDICT PARTIAL… (2*) Mo1157. . . . THE ASSOCIATION OF EOSINOPHILIC ESOPHAGITIS AND… (5*) Mo1158. . . . CLINICAL FEATURES AND TREATMENT OUTCOMES ACCORDING… (5*)

Mo1159. . . . LYMPHOCYTIC ESOPHAGITIS: A CASE SERIES OF… (5*) Mo1160. . . . EATING BEHAVIOR IN PATIENTS WITH EOSINOPHILIC… (6*) Mo1161. . . . THE ENDOSCOPIC BURDEN OF EOSINOPHILIC ESOPHAGITIS… (5*) Mo1162. . . . THE ENDOSCOPICALLY NORMAL ESOPHAGUS IN EOSINOPHILIC… (2*) Mo1163. . . . EG AND EOE PATIENT BIOPSIES HAVE… (3*)|(Allakos, Inc.) Mo1164. . . . THE UTILITY OF EPITHELIAL EOSINOPHILIC DERIVED… (1*) Mo1165. . . . THE THIAZOLIDINEDIONES AS POTENTIAL THERAPEUTIC AGENTS… (2*) Mo1166. . . . DISRUPTION OF ESOPHAGEAL EPITHELIAL BARRIER FUNCTION… (5*) Mo1167. . . . EFFECT OF VARYING TIME INTERVALS ON… (4*) Mo1168. . . . SERUM MILK-SPECIFIC IGG4 LEVELS ARE ASSOCIATED… (2*) Mo1169. . . . AUTOMATED ANALYSIS OF EOSINOPHIL PEROXIDASE FOR… (2*) Mo1249. . . . INVESTIGATING THE ROLE OF INTEGRINS IN… (2*) Mo1250. . . . CONTRIBUTION OF THE INTESTINAL EPITHELIUM IN… (2*) Mo1251. . . . NATIONAL TRENDS AND OUTCOMES OF GASTROINTESTINAL… (5*) Mo1252. . . . A COMPARISON OF LOGISTIC REGRESSION AND… (5*) Mo1253. . . . THE RISK OF GASTROINTESTINAL BLEEDIND OF… (5*) Mo1254. . . . GASTROINTESTINAL BLEEDING DURING DIRECT ORAL ANTICOAGULANT… (5*) Mo1255. . . . GUIDELINE ADHERENCE AND EFFECTS OF ASPIRIN… (5*) Mo1256. . . . PREVALENCE AND PREDICTORS OF GASTROINTESTINAL BLEEDING… (5*) Mo1257. . . . RISK OF GASTROINTESTINAL BLEEDING HOSPITALIZATION IN… (5*) Mo1258. . . . ONLINE SYMPTOM CHECKERS FOR GASTROINTESTINAL BLEEDING:… (5*)

Mo1259. . . . ANTEGRADE DEEP ENTEROSCOPY SHOULD BE CONSIDERED… (5*) Mo1260. . . . MANAGEMENT OF ACUTE GASTROINTESTINAL BLEEDING IN… (5*) Mo1261. . . . ENDOSCOPIC AND CLINICAL MANAGEMENT OF GASTROINTESTINAL… (5*) Mo1262. . . . ADHERENCE TO LOWER GASTROINTESTINAL HEMORRHAGE GUIDELINES… (5*) Mo1263. . . . ACUTE UPPER GASTROINTESTINAL BLEEDING: EVALUATING PHYSICIAN… (2*) Mo1264. . . . HELICOBACTER PYLORI INFECTION DECREASES NA,K-ATPASE EXPRESSION… (2*) Mo1265. . . . DYSBIOSIS OF THE GASTRIC MICROBIOTA IN… (2*) Mo1266. . . . SOCIO-ENVIRONMENTAL FACTORS AND COLOMBIAN HOST GENE… (2*) Mo1267. . . . ROLE OF IL-22 IN HELICOBACTER PYLORI-INDUCED… (2*) Mo1268. . . . VITAMIN K DEFICIENCY IN ANTIBIOTIC-TREATED, H.… (2*) Mo1269. . . . DEVELOPMENT OF NEOPLASIA IN THE ABSENCE… (2*) Mo1270. . . . PARACRINE LOOPS BETWEEN HELICOBACTER PYLORI, FIBROBLASTS… (4*)|(This study receives funding from Jagiellonian University Medical College (statutory grant).) Mo1271. . . . THE INFLUENCE OF H. PYLORI INFECTION… (5*) Mo1272. . . . SHORT-TERM EFFECTS OF AMBIENT FINE PARTICULATE… (4*) Mo1273. . . . A SYSTEMATIC REVIEW AND META-ANALYSIS. ANALYSING… (5*) Mo1274. . . . NON-VITAMIN K ORAL ANTICOAGULANTS HAVE LOWER… (1*) Mo1275. . . . THE EFFECT OF LOW-DOSE ASPIRIN ON… (3*)|(This study was funded by Bayer AG) Mo1276. . . . NO DIFFERENCES IN GI BLEEDING RISK… (5*)


* = Primary Source



Mo1277. . . . ANTIPLATELET VERSUS ANTICOAGULANT EFFECTS IN NON-VARICEAL… (5*) Mo1278. . . . UPPER GASTROINTESTINAL BLEEDING IN THE PRESENCE… (5*) Mo1279. . . . PREDICTION OF DIEULAFOY’S LESION OR PEPTIC… (2*)|(Supported by VA Clinical Merit Review Grant (CLIN – 013-07F) and NIH CURE: DDRC Grant (NIH-NIDDK 41301) Human Studies CORE.) Mo1280. . . . DEMAND ISCHEMIA IS ASSOCIATED WITH INCREASED… (5*) Mo1281. . . . THE IMPACT OF URGENT UPPER ENDOSCOPY… (4*) Mo1282. . . . CHARACTERISTICS OF PATIENTS WITH NON-HELICOBACTER PYLORI… (4*) Mo1283. . . . ACUTE KIDNEY INJURY IS ASSOCIATED WITH… (5*) Mo1284. . . . COMPARING OUTCOMES IN UPPER GASTROINTESTINAL BLEEDING… (2*) Mo1285. . . . RECENT TRENDS IN BLEEDING LOCATION AND… (5*) Mo1286. . . . CAN CLINICAL FACTORS AND DEMOGRAPHICS DETERMINE… (5*) Mo1287. . . . CHARLSON COMORBIDITY INDEX, HEMOGLOBIN LEVEL AND… (5*) Mo1288. . . . THALIDOMIDE IS AN EFFECTIVE TREATMENT FOR… (1*) Mo1289. . . . INTERMITTENT DOSING OF PROTON PUMP INHIBITOR… (5*) Mo1290. . . . COMPARISON OF RISK SCORING SYSTEMS IN… (5*) Mo1291. . . . FACTORS AFFECTING REBLEEDING AND MORTALITY IN… (5*) Mo1292. . . . END- STAGE RENAL DISEASE IS ASSOCIATED… (5*) Mo1293. . . . CLINICAL OUTCOMES IN PATIENTS WITH ACUTE… (5*) Mo1294. . . . RISK FACTORS OF POOR PROGNOSIS AND… (5*) Mo1295. . . . MANAGEMENT OF ANTITHROMBOTIC THERAPY AFTER GASTROINTESTINAL… (6*) Mo1296. . . . PROTON PUMP INHIBITOR TREATMENT INITIATED PRIOR… (5*)

Mo1297. . . . SARCOPENIA IS INDEPENDENTLY ASSOCIATED WITH AN… (5*) Mo1298. . . . DIAGNOSTIC YIELD OF ISOLATED DEAMIDATED GLIADIN… (5*) Mo1362. . . . PANCREATIC TRIGLYCERIDE LIPASE (PNLIP) MEDIATED UNSATURATED… (4*) Mo1363. . . . GABA INHIBITED NERVE-ACTIVITY-MEDIATED INSULIN SECRETION: A… (2*) Mo1364. . . . ECT2 IS REGULATED BY YAP AND… (2*) Mo1365. . . . SENSITIVITY OF COMPUTERIZED TOMOGRAPHY DURING PRE-DIAGNOSTIC… (5*) Mo1366. . . . DETECTION AND CHARACTERIZATION OF EARLY DUCT… (2*) Mo1367. . . . MICRORNA-296-5P PROMOTES EMT PROCESS AND CELL… (2*) Mo1368. . . . SUCCESSFUL GROWTH OF RECOMBINANT CO-CULTURED PANCREATIC… (5*) Mo1369. . . . ROLE OF IL-18R AND IL-1R SIGNALING… (2*) Mo1370. . . . PANCREATIC CANCER DETECTION BY PLASMA ASSAY… (4*)|(Exact Sciences) Mo1371. . . . SURVIVAL OF RESECTABLE PANCREATIC CANCER: THE… (5*) Mo1372. . . . GENETIC SUSCEPTIBILITY TO CHRONIC INFLAMMATORY INTESTINAL… (2*) Mo1373. . . . IS THERE AN ASSOCIATION BETWEEN PREVIOUSLY-IDENTIFIED… (5*) Mo1374. . . . 12 YEARS OF PROSPECTIVE PANCREATIC CANCER… (4*) Mo1375. . . . CLINICAL COURSE AND RISK FACTORS OF… (5*) Mo1376. . . . FAMILIAL PANCREATIC CANCER PATIENTS HAVE BETTER… (5*) Mo1377. . . . THE CLINICOPATHOLOGIC CHARACTERISTICS OF MUCINOUS CYST… (5*) Mo1378. . . . AUTOPHAGY INHIBITION ENHANCES ANTIPROLIFERATIVE EFFECT OF… (5*)

Mo1379. . . . NOTABLE FINDINGS FOR EARLY DIAGNOSIS OF… (5*) Mo1380. . . . THE RELATIONSHOP BETWEEN THE PD-L1 EXPRESSION… (5*) Mo1381. . . . ANTIOXIDANTS AS POSSIBLE ANTI-PROLIFERATIVE AGENTS FOR… (4*) Mo1382. . . . SUCCESSFUL ESTABLISHMENT OF PANCREATIC CANCER PATIENT-DERIVED… (4*) Mo1383. . . . DIAGNOSTIC YIELD OF EUS-FNA FOR SOLID… (5*) Mo1384. . . . ADULT MOUSE MODEL OF PANCREATIC CANCER… (2*) Mo1385. . . . IGF-1 (INSULIN LIKE GROWTH FACTOR 1)… (2*) Mo1386. . . . STATINS INHIBIT PROLIFERATION OF PANCREATIC DUCTAL… (2*) Mo1387. . . . STATINS INHIBIT YAP ACTIVATION IN RESPONSE… (2*) Mo1388. . . . TARGETED NEXT GENERATION SEQUENCING FOR PREDICTING… (5*) Mo1389. . . . DETECTION SYSTEM OF CIRCULATING TUMOR DNA… (6*)|(This study was funded by The Osaka Foundation for The Prevention of Cancer and Life-style related Diseases (Public Interest Incorporated Foundation).) Mo1390. . . . SYNERGISTIC EFFECT OF VERTEPORFIN-PDT WITH GEMCITABINE… (2*) Mo1391. . . . CIRCULATING EXTRACELLULAR VESICLE LNCRNA LINC02280 IS… (2*) Mo1392. . . . THE UTILITY OF HIGH INTENSITY FOCUSED… (5*) Mo1393. . . . THE AUTOPHAGY-RELATED-PROTEIN VMP1 IS SECRETED IN… (4*) Mo1394. . . . ROLE OF GENETIC EVALUATION IN CHILDREN… (5*) Mo1395. . . . METABOLIC REPROGRAMMING AND SUBSEQUENT AUTOPHAGY TRIGGERED… (2*) Mo1396. . . . THE EXPRESSION OF GNAS IN PANCREATIC… (2*) Mo1397. . . . DYSFUNCTION OF RAB PROTEINS AND ENDO-LYSOSOMAL… (2*)


* = Primary Source



Mo1398. . . . ACTIVATION OF P21-ACTIVATED KINASE 4 (PAK4)… (2*) Mo1399. . . . HIGH LEVELS OF AMINO ACIDS (AA)… (2*) Mo1400. . . . CALCIUM/ CALCINEURIN SIGNALING PATHWAY MEDIATES AUTOPHAGY… (2*) Mo1401. . . . FLAGELLIN INHIBITS THIAMIN UPTAKE BY PANCREATIC… (2*) Mo1402. . . . PREVENTIVE AND THERAPEUTIC EFFECT OF TRAILPEG… (2*) Mo1403. . . . DNA PROFILING OF MAIN PANCREATIC DUCT… (5*) Mo1404. . . . CONCENTRATION CHANGES OF GEMCITABINE METABOLITES COMBINED… (5*) Mo1405. . . . MICRO-RNA ANALYSIS OF CYST FLUID FOR… (2*) Mo1406. . . . THE CORRELATIONS OF ADIPONECTIN WITH SEVERITY… (5*) Mo1407. . . . PANCREATIC SENESCENT STROMA INFLUENCE ON PROGNOSIS… (5*) Mo1433. . . . CHOLESTATIC JAUNDICE IN NEONATES: HOW COMMON… (5*)|(The study requires no funding.) Mo1434. . . . CHARACTERIZATION OF PEDIATRIC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY… (5*) Mo1491. . . . NOVEL PREOPERATIVE NOMOGRAMS PREDICT MICROVASCULAR INVASION… (5*) Mo1492. . . . TRANSCUTANEOUS ELECTRICAL ACUSTIMULATION IMPROVES GASTROINTESTINAL DISTURBANCES… (5*) Mo1493. . . . EUS-GUIDED BILIARY DRAINAGE IS NON-INFERIOR TO… (5*) Mo1494. . . . THE CHANGING HISTOLOGICAL FACE OF GALLBLADDER… (5*) Mo1495. . . . ASPARTATE-β-HYDROXYLASE REGULATES METABOLIC REPROGRAMMING IN HEPATOCELLUAR… (4*) Mo1496. . . . TRENDS IN CURE RATES AMONG MEDICARE… (5*) Mo1497. . . . PREDICTIVE VALUES OF MUSCLE VOLUME AND… (5*)

Mo1498. . . . A NOVEL APPROACH FOR THE GENETIC… (5*) Mo1499. . . . DEOXYCHOLIC ACID-INDUCED SENESCENT HEPATIC STELLATE CELLS… (2*)| Mo1500. . . . NRF2 ACTIVATION PROMOTES MUTANT K-RAS/P53 DRIVEN… (5*) Mo1501. . . . THE RISK OF DEVELOPING PRIMARY HEPATOCELLULAR… (5*) Mo1502. . . . THE ASSOCIATION OF HEPATOCELLULAR CARCINOMA AND… (5*) Mo1503. . . . COMPARISON OF SELF-EXPANDING METAL STENTS IN… (5*) Mo1504. . . . LONG NON-CODING RNA LINC00152 REGULATES CELL… (2*) Mo1505. . . . MALIGNANT HILAR STRICTURES WITH BISMUTH IV… (5*) Mo1506. . . . MISCLASSIFICATION OF KLATSKIN TUMORS: DID THE… (5*) Mo1507. . . . INCREASED SUSCEPTIBILITY TO BET INHIBITION IN… (2*) Mo1508. . . . EXTRAHEPATIC MANIFESTATIONS OF NON-ALCOHOLIC FATTY LIVER… (5*) Mo1509. . . . NONALCOHOLIC FATTY LIVER DISEASE IS ASSOCIATED… (5*) Mo1510. . . . PREVALENCE AND RISK FACTORS FOR ADVANCED… (4*) Mo1511. . . . ASSOCIATIONS BETWEEN WEIGHT LOSS METHOD, PATIENT… (4*) Mo1539. . . . ASSESSING THE RISK FOR ACUTE ISCHEMIC… (5*) Mo1540. . . . DETERMINANTS OF QUALITY OF LIFE IMPACT… (5*) Mo1541. . . . PLECANATIDE IMPROVED PATIENT GLOBAL RATING OF… (3*)|(Synergy Pharmaceuticals, Inc., New York, NY) Mo1542. . . . PRIMARY BILE ACIDS IN A SINGLE… (4*) Mo1543. . . . THE EFFECT OF LOW FODMAP DIET… (5*) Mo1544. . . . ASSOCIATION OF CANNABIS AND HEALTH CARE… (5*)

Mo1545. . . . CHARACTERIZATION OF ABDOMINAL PAIN RESPONSE TO… (3*)|(Funded by Salix Pharmaceuticals.) Mo1546. . . . TIME TO ONSET OF TEGASEROD EFFECT… (3*)|(US WorldMeds provided funding for this realysis.) Mo1547. . . . IMPACT OF TRANSANAL IRRIGATION (TAI) DEVICE… (5*) Mo1548. . . . EFFICACY, FEASIBILITY, AND SAFETY OF THE… (4*) Mo1549. . . . INFANT COLIC MIGHT PREDISPOSE TO BEHAVIORAL… (5*) Mo1550. . . . INITIAL EXPERIENCE WITH ABDOMINAL MASSAGE DURING… (5*) Mo1551. . . . LIFESTYLE, PSYCHOLOGICAL STRESS, AND INCIDENCE OF… (2*) Mo1552. . . . COMPLICATIONS OF ANAL SPHINCTER BOTULINUM TOXIN… (5*) Mo1553. . . . COMPARISON OF ROME III AND ROME… (2*) Mo1554. . . . CHARACTERIZATION OF THE COLONIC RESPONSE TO… (5*) Mo1555. . . . PROTON PUMP INHIBITORS REDUCE DUODENAL HYPERPERMEABILITY,… (5*) Mo1556. . . . OPIOID USE DISORDER IS ASSOCIATED WITH… (5*) Mo1557. . . . NATIONAL ESTIMATES OF 30-DAY READMISSIONS AMONG… (5*) Mo1558. . . . FUNCTIONAL DYSPEPSIA AND DUODENAL EOSINOPHILIA ARE… (4*) Mo1559. . . . GENERAL POPULATION PREVALENCE AND CLINICAL CHARACTERISTICS… (5*) Mo1560. . . . APPLYING NUTRIENT DRINK TEST AS A… (4*) Mo1561. . . . PREVALENCE OF CYCLIC VOMITING SYNDROME IN… (5*) Mo1562. . . . EARLY-LIFE ADVERSITY INDUCESD SEX-DEPENDENT GASTRIC HYPRSENSITIVITY… (4*) Mo1563. . . . REGONAL GASTRIC RETENTION DURING GASTRIC EMPTYING… (5*) Mo1564. . . . WHICH ANTI-NAUSEA THERAPIES DO PATIENTS BELIEVE… (5*)


* = Primary Source



Mo1565. . . . CONFOCAL LASER ENDOMICROSCOPY IN PATIENTS WITH… (2*)|(Study supported by Michigan Institute for Clinical and Health Research (MICHR) grant number UL1TR000433) Mo1566. . . . CHARACTERISTICS OF THE HOT-WATER BATHING PATTERN… (4*)| Mo1567. . . . IMPACT OF GENETIC VARIATION IN GLP-1… (2*) Mo1568. . . . CORRELATION BETWEEN SLEEP DISTURBANCE IN FUNCTIONAL… (5*) Mo1569. . . . EXOSOMAL HSA-MIR-933 IN GASTRIC JUICE AS… (2*)|(Japan Society for the Promotion of Science(JSPS) KAKENHI Grant Number JP16K09252) Mo1570. . . . A NOVEL COMBINED NONINVASIVE MULTIPLE GASTRIC… (5*) Mo1571. . . . COMPARISON OF GASTRIC SLOW WAVES AND… (5*) Mo1572. . . . DELAYED GASTRIC EMPTYING BY WIRELESS MOTILITY… (3*)|(This study was supported by a grant from Medtronic.) Mo1573. . . . 3D MRI IMAGING OF THE STOMACH… (2*) Mo1574. . . . GASTRIC ELECTRICAL NEUROSTIMULATION COMBINED WITH PYLOROPLASTY… (5*) Mo1575. . . . ASSESSMENT OF GASTRIC EMPTYING MOTILITY UTILIZING… (5*) Mo1576. . . . GASTRIC EMPTYING RESULTS FROM WIRELESS MOTILITY… (5*) Mo1577. . . . ADVANCED GASTRIC EMPTYING SCINTIGRAPHY TO EVALUATE… (4*) Mo1578. . . . SURGICAL INTERVENTIONS FOR REFRACTORY GASTROPARESIS: GASTRIC… (5*) Mo1579. . . . CLINICAL AND GASTRIC MOTILITY FEATURES IN… (5*) Mo1580. . . . EFFECT OF DIETARY INTERVENTION ON PATIENTS… (4*) Mo1581. . . . EVALUATION OF THE SAFETY, TOLERABILITY, PHARMACOKINETIC… (3*)|(The study was funded by Theravance Biopharma US, Inc., while medical writing assistance was provided by Colin Glen of Oxford PharmaGenesis, Oxford, UK and supported by Takeda Pharmaceutical Company Ltd.)

Mo1582. . . . TRANSCUTANEOUS VAGAL NERVE STIMULATION IMPROVES SYMPTOMS… (4*) Mo1583. . . . GHRELIN AND MOTILIN DERANGEMENTS DURING WIRELESS… (7*)| Mo1584. . . . EFFECTIVENESS OF LANREOTIDE IN THE TREATMENT… (3*)|(This study was sponsored by Ipsen Pharmaceuticals.) Mo1585. . . . ROLE OF SEX HORMONES AND THEIR… (2*) Mo1586. . . . OPIOID USE DISORDER IS ASSOCIATED WITH… (5*) Mo1587. . . . PRUCALOPRIDE VERSUS PLACEBO IN DIABETIC GASTROPARESIS:… (3*)|(Janssen Inc.) Mo1588. . . . INCREASED SYMPTOM SEVERITY ASSOCIATED WITH THE… (3*)|(Takeda Pharmaceuticals) Mo1589. . . . GASTRIC RETENTION IN GASTROPARESIS: RELATIONSHIP OF… (2*) Mo1590. . . . BODY WEIGHT AND BODY WEIGHT CHANGES… (2*) Mo1591. . . . DOES OTHER END-ORGAN DAMAGE CORRELATE WITH… (2*) Mo1592. . . . MARIJUANA USE IN PATIENTS WITH SYMPTOMS… (2*) Mo1593. . . . DOCUMENTATION OF PYLORIC SMOOTH MUSCLE DYSFUNCTION… (5*) Mo1594. . . . MODELING DELAYED GASTRIC EMPTYING USING WNT1CRE-IDTR… (2*) Mo1595. . . . THE IMPACT OF RISK FACTORS ON… (5*) Mo1596. . . . A PILOT CHRONIC ANIMAL STUDY OF… (2*) Mo1597. . . . THE VIPUN BALLOON CATHETER REVEALS A… (4*) Mo1598. . . . THE DIAGNOSIS AND MANAGEMENT OF GASTROPARESIS:… (5*) Mo1599. . . . COMBINED GASTRIC ELECTRICAL STIMULATION PYLOROPLASTY IMPROVES… (5*) Mo1600. . . . ASSESSING PYLORUS DISTENSION WITH IMPEDANCE PLANIMETRY… (5*)

Mo1601. . . . GASTROINTESTINAL SYMPTOMS IN CHILDREN DURING GASTRIC… (5*) Mo1602. . . . SCINTIGRAPHIC METHODOLOGY USING MID-ANTRUM REGIONS OF… (5*) Mo1603. . . . PREVALENCE AND INCIDENCE OF GASTROPARESIS IN… (3*)|(This study was supported by Takeda Pharmaceuticals Intertiol Inc,. All authors are employees of Takeda Pharmaceuticals Intertiol Inc,.) Mo1604. . . . COMPARISON OF SYMPTOM AND QUALITY OF… (3*)|(The parent investigation supporting this study was funded by Medtronic (grant MA501).) Mo1605. . . . CLINICAL CHARACTERISTICS AND GUT PHYSIOLOGY IN… (4*) Mo1606. . . . AUTONOMIC AND ENTERIC FUNCTION PROFILING CAN… (5*) Mo1607. . . . BASELINE PREDICTIVE FACTORS FOR FORE AND… (5*) Mo1608. . . . ALTERED INTESTINAL PERMEABILITY AND EFFECT OF… (5*) Mo1609. . . . CAREGIVER BURDEN IN GASTROPARESIS: CORRELATION WITH… (5*) Mo1610. . . . CHARACTERIZING SYMPTOMS OF BRAIN FOGGINESS AND… (5*) Mo1611. . . . SYMPTOMS OF AVOIDANT/RESTRICTIVE FOOD INTAKE DISORDER… (5*) Mo1612. . . . SYMPTOM VARIABILITY THROUGHOUT THE DAY IN… (5*) Mo1613. . . . WIRELESS MOTILITY CAPSULE EVALUATION OF REGIONAL… (5*) Mo1614. . . . COMPARISON OF GASTRIC ACCOMMODATION MEASUREMENTS BY… (5*) Mo1615. . . . FAT-SOLUBLE VITAMINS, B12, AND IRON DEFICIENCY… (3*)|(Progenity, Inc) Mo1616. . . . CARDIAC SAFETY AND CLINICAL EFFICACY OF… (5*) Mo1617. . . . DIFFERENCES IN PYLORIC DISTENSIBILITY IN PATIENTS… (5*) Mo1618. . . . PER-ORAL ENDOSCOPIC PYLOROMYOTOMY FOR SEVERE REFRACTORY… (5*)


* = Primary Source



Mo1619. . . . AN INTERNATIONAL SURVEY ON THE DIAGNOSIS… (5*) Mo1620. . . . DISTENSION-INDUCED GASTRIC SLOW WAVE DYSRHYTHMIAS DEFINED… (2*) Mo1622. . . . WHICH COMBO WORKS BEST? A COMPARISON… (5*) Mo1623. . . . THE ROLE OF SOCIAL MEDIA ON… (5*) Mo1624. . . . ARE PATIENTS WITH NON-COLORECTAL CANCER AT… (5*) Mo1625. . . . ETHNIC DISPARITIES AND BODY MASS INDEX… (5*) Mo1626. . . . EFFECT OF DYNAMIC POSITION CHANGES ON… (5*) Mo1627. . . . COLON CANCER IN YOUNG AMERICANS… (5*) Mo1628. . . . PROSPECTIVE PRE-COLONOSCOPY BOWEL PREPARATION STUDY COMPARING… (1*) Mo1629. . . . EVALUATION OF THE DISSEMINATION AND IMPLEMENTATION… (2*) Mo1630. . . . HISTOLOGY, TOTAL NUMBER OF POLYPS, AND… (5*) Mo1631. . . . AGE AND GENDER DEPENDENT REDUCTIONS IN… (2*) Mo1632. . . . INTERVAL COLORECTAL CANCER RATES IN VETERANS… (5*) Mo1633. . . . SCREENING AND MANAGEMENT OF LYNCH SYNDROME… (5*) Mo1634. . . . NO INCREASED RISK OF COLORECTAL ADENOMAS… (5*) Mo1635. . . . REAL-LIFE EXPERIENCE WITH MORE THAN 20000… (5*) Mo1636. . . . THE ADDITION OF OTHER FAECAL BIOMARKERS… (5*) Mo1637. . . . SCREENING AND TREATING HELICOBACTER PYLORI INTEGRATED… (2*) Mo1638. . . . ARE NEGATIVE FECAL IMMUNOCHEMICAL TEST HEMOGLOBIN… (3*)|(Fecal immunochemical tests were provided by Eiken Chemical Company.) Mo1639. . . . USE OF FECAL IMMUNOCHEMICAL TESTS IN… (3*)|(Fecal

immunochemical tests for this study were provided by Eiken Chemical Company.) Mo1640. . . . DIFFERENT CUT-OFF LEVELS OF FECAL IMMUNOCHEMICAL… (5*) Mo1641. . . . REPEAT FECAL OCCULT BLOOD TESTS FOR… (2*) Mo1642. . . . PATIENTS ARE OFTEN UNAWARE OF ABNORMAL… (5*) Mo1643. . . . CORRELATING QUANTITATIVE FECAL IMMUNOCHEMICAL TEST (FIT)… (5*) Mo1644. . . . INAPPROPRIATE OUTPATIENT USE OF FECAL IMMUNOCHEMICAL… (5*) Mo1645. . . . THE FECAL OCCULT BLOOD TEST POSITIVE… (5*) Mo1646. . . . ASSOCIATION BETWEEN CONCENTRATIONS OF FECAL HEMOGLOBIN… (5*) Mo1647. . . . FACTORS ASSOCIATED WITH COMPLETION OF MAILED… (2*) Mo1648. . . . IMPROVING ACCESS TO COLONOSCOPY FOR UNINSURED… (1*) Mo1708. . . . COMPARISON OF PRESENTING DIAGNOSES AND SYMPTOMS… (2*) Mo1709. . . . RISK OF COLORECTAL CANCER INCIDENCE AND… (7*) Mo1710. . . . PREVALENCE OF COLORECTAL NEOPLASIA AMONG PATIENTS… (4*) Mo1711. . . . REDUCTION OF INCIDENT COLORECTAL CANCER AFTER… (2*) Mo1712. . . . SURVEILLANCE OF HIGH-RISK POLYPS IN THE… (5*) Mo1713. . . . SIGNIFICANCE OF FECAL HEMOGLOBIN CONCENTRATION FOR… (5*) Mo1714. . . . EFFECTIVENESS OF PHONE PROMPT PRIOR TO… (2*) Mo1715. . . . THE ISRAELI MULTI CENTER SWALLOW AND FORGET STUDY:… (3*)|(Check-Cap Ltd, Isfiya, Israel) Mo1716. . . . INCIDENCE OF METACHRONOUS SESSILE SERRATED ADENOMAS… (5*) Mo1717. . . . TRENDS IN EARLY-ONSET COLORECTAL CANCER INCIDENCE… (5*) Mo1718. . . . RACIAL AND GEOGRAPHIC DISPARITIES IN PANCREATIC… (7*)

Mo1719. . . . ASSOCIATION BETWEEN HEPATITIS C VIRUS INFECTION… (4*) Mo1720. . . . INVESTIGATION OF RECOMMENDED ALCOHOL INTAKES AND… (5*) Mo1721. . . . INCREASING INCIDENCE OF ADVANCED NON-CARDIA GASTRIC… (5*) Mo1722. . . . ABDOMINAL OBESITY IS ASSOCIATED WITH ESOPHAGEAL… (5*) Mo1723. . . . PREDICTORS OF STAGE III/IV COLORECTAL CANCER… (5*) Mo1724. . . . METABOLIC SYNDROME IS ASSOCIATED WITH INCREASED… (5*) Mo1725. . . . HELICOBACTER PYLORI INFECTION DOES NOT MODIFY… (2*) Mo1726. . . . CHROMOENDOSCOPY LEADS TO A HIGHER SPIGELMAN-STAGE… (4*) Mo1727. . . . GENETIC COUNSELING AND GERMLINE TESTING AMONG… (5*) Mo1728. . . . GENETIC VARIANTS IN DPF3 ARE ASSOCIATED… (5*) Mo1729. . . . FEASIBILITY OF UTILIZING PREMM SCORE FOR… (5*) Mo1730. . . . BUTYRATE-TREATED COLON ORGANOIDS FROM FAP SUBJECTS… (4*) Mo1731. . . . CANCER RISK IN PATIENTS AND FAMILIES… (4*) Mo1732. . . . GENETIC RISK SCORE TO IDENTIFY INDIVIDUALS… (4*) Mo1733. . . . PREVALENCE OF GERMLINE MUTATIONS IN PATIENTS… (5*) Mo1734. . . . COMPARISON OF UNIVERSAL SCREENING YIELD IN… (5*) Mo1735. . . . LOW RATES OF GENETIC COUNSELING AND… (5*) Mo1736. . . . MOLECULAR CHARACTERISTICS OF THE DEPRESSED COLORECTAL… (5*) Mo1737. . . . ALDH2 AND AUTOPHAGHY-MEDIATED REDOX HOMEOSTASIS LIMIT… (2*) Mo1738. . . . NOTCHLESS HOMOLOG1(NLE1), A STEPWISELY UPREGULATED GENE… (2*)


* = Primary Source



Mo1739. . . . MOLECULAR MARKERS, MLH1 AND MSI STATUS… (2*) Mo1740. . . . ALCOHOL AND COLON CANCER: DOES TIME… (2*) Mo1741. . . . INDUCTION OF WHOLE GENOME DOUBLING WITH… (2*) Mo1742. . . . PROXIMAL VERSUS DISTAL COLON ADENOCARCINOMA WITH… (5*) Mo1743. . . . KNOCK-DOWN OF GRANULIN, A NOVEL STAT3-INTERACTING… (5*) Mo1744. . . . NLRP6 TARGETING SUPPRESSES COLONIC TUMORIGENESIS VIA… (2*) Mo1745. . . . PATHOLOGICAL IMPACT OF TRANSANAL COLORECTAL TUBE… (5*) Mo1746. . . . 12-LIPOXYGENASE PROMOTES EPITHELIAL-MESENCHYMAL TRANSITION THROUGH THE… (2*) Mo1764. . . . SERUM N-GLYCOMIC BIOMARKERS PREDICT TREATMENT ESCALATION… (2*) Mo1765. . . . REAL-LIFE EXPERIENCE WITH LONG-TERM MAINTENANCE OF… (5*) Mo1766. . . . MULTIDISCIPLINARY TEAM CARE AT THE EMERGENCY… (5*) Mo1767. . . . PEDIATRIC ONSET INFLAMMATORY BOWEL DISEASE IS… (5*) Mo1768. . . . ELEVATED RISK OF METACHRONOUS NEOPLASIA WITH… (5*) Mo1769. . . . OPIOID USAGE AND PATIENT-REPORTED PAIN SCORES… (5*) Mo1770. . . . ADHERENCE TO GUIDELINES REMAINS POOR AMONG… (5*) Mo1771. . . . THE FACTORS ASSOCIATED WITH THE LEVELS… (7*) Mo1772. . . . INCREASED HEALTHCARE UTILIZATION BY MEDICAID PATIENTS… (5*) Mo1773. . . . COST DRIVERS AND TRENDS IN INFLAMMATORY… (6*)|(Funding for this initiative is made possible through a grant from the Leo M. and Harry B. Helmsley Charitable Trust and United Health Group.) Mo1774. . . . HEALTHCARE UTILISATION COSTS MAY BE REDUCED… (3*)|(This work was supported by a peer reviewed grant from the Gastroenterological Society of Australia funded by Janssen: “Inflammatory

Bowel Disease Centre of Excellence Award”.) Mo1775. . . . PREVALENCE OF FINANCIAL CONFLICTS OF INTEREST… (5*) Mo1776. . . . SUSTAINED IMPROVEMENTS IN FATIGUE AND QUALITY… (3*)|(AMAG Pharmaceuticals, Inc.) Mo1777. . . . A PROSPECTIVE MULTI-CENTER STUDY ON THE… (4*) Mo1778. . . . FEMALE GENDER ASSOCIATED WITH LESS-SEVERE CROHN’S… (5*) Mo1779. . . . TRENDS IN EMERGENCY DEPARTMENT VISITS AND… (3*)|(Sponsorship: Janssen Scientific Affairs, LLC) Mo1780. . . . GENDER BIAS IN REFERRAL AND DIAGNOSIS… (2*) Mo1781. . . . ROLE OF G PROTEIN-COUPLED RECEPTOR 15… (4*) Mo1782. . . . THE ROLE OF CYCLOOXYGENASE IN COLITIS-ASSOCIATED… (2*) Mo1783. . . . H. PYLORI-INDUCED PRDX2 PROTECTS AGAINST OXIDATIVE… (4*) Mo1784. . . . THE ROLE OF FOXM1 IN HELICOBACTER… (2*) Mo1785. . . . CELLULAR SENESCENCE OF CD4+ T CELLS… (5*) Mo1786. . . . AGE- AND CANCER-ASSOCIATED OPLAH METHYLATION IS… (5*) Mo1787. . . . THE FUNCTIONAL ROLE OF VEGFR-2 IN… (5*) Mo1788. . . . PREVALENCE AND RISK FACTORS OF FIRST-EVER… (5*) Mo1789. . . . INFLAMMATORY REACTION PATTERNS AND MOLECULAR GENETICS… (5*) Mo1790. . . . MUCOSAL HEALING IS ACHIEVABLE WITH METHOTREXATE… (5*) Mo1791. . . . BIOLOGIC AND IMMUNOMODULATOR WITHDRAWAL IN PEDIATRIC… (2*)|(This Tobacco Formula grant is under the Commonwealth Universal Research Enhancement (C.U.R.E) program with the grant number SAP # 4100068710.)

Mo1792. . . . SELF-REPORTED DIETARY BEHAVIORS FOR SYMPTOM MANAGEMENT… (4*) Mo1793. . . . DRIVERS OF HEALTHCARE COST FOR CHILDREN… (5*) Mo1794. . . . INCREASING TRENDS IN DIAGNOSTIC PREVALENCE AND… (3*) Mo1795. . . . THREE YEAR OUTCOMES OF A COHORT… (5*) Mo1796. . . . VEDOLIZUMAB EXPERIENCE IN CHILDREN AND ADOLESCENTS… (5*) Mo1797. . . . IMPACT OF PREMEDICATION AND OTHER VARIABLES… (5*) Mo1798. . . . INFLAMMATORY MICROHETEROGENEITY IN UC: IMPLICATIONS FOR… (5*) Mo1799. . . . UTILITY OF A SIMPLE BLOOD TEST… (5*)|(Testing of patient samples was provided by Prometheus Laboratories Inc.) Mo1800. . . . A SIMPLE SCORING TOOL PREDICTS EXPOSURE-RESPONSE… (3*)|(Takeda Pharmaceuticals U.S.A., Inc.) Mo1801. . . . INCORPORATING FECAL CALPROTECTIN IN CLINICAL PRACTICE… (5*) Mo1802. . . . TRANSMURAL HEALING ASSESSED USING MRI IS… (5*) Mo1803. . . . THE MODIFIED HARVEY-BRADSHAW INDEX AND PARTIAL… (5*) Mo1804. . . . THE ROLE OF FECAL CALPROTECTIN IN… (5*) Mo1805. . . . INFLAMMATORY BOWEL DISEASE PATIENTS WITH ILEAL… (5*) Mo1806. . . . ENDOSCOPIC POUCH ACTIVITY IN ASYMPTOMATIC PATIENTS… (5*) Mo1807. . . . MAGNETIC RESONANCE FINGERPRINTING (MRF) IS A… (2*)|(Siemens Health) Mo1808. . . . RAID-MONITOR TEST IS UNAFFECTED BY GEOGRAPHICAL… (2*) Mo1809. . . . DIAGNOSTIC ACCURACY OF FECAL LACTOFERRIN AND… (4*)|(Repha GmbH biologische Arzneimittel TechLab Inc) Mo1810. . . . FAECAL CALPROTECTIN CONCENTRATION IN INFLAMMATORY BOWEL… (5*)


* = Primary Source



Mo1811. . . . RAPID POINT-OF-CARE ANTI-DRUG ANTIBODIES MEASUREMENT CORRELATES… (2*)|(1) Mo1812. . . . CONSIDERATION OF SERUM IGA IN PATIENTS… (5*) Mo1813. . . . BOTH FECAL IMMUNOCHEMICAL BLOOD TEST AND… (3*) Mo1814. . . . A COMBINED SET OF FOUR SERUM… (5*) Mo1815. . . . MODIFIED GLASGOW PROGNOSTIC SCORE IS USEFUL… (5*) Mo1816. . . . PREDICTION OF ENDOSCOPIC ACTIVITY IN PATIENTS… (5*) Mo1817. . . . RESPONDER DEFINITIONS FOR THE ULCERATIVE COLITIS… (3*)|(Genentech, Inc.) Mo1818. . . . TARGETED LIPIDOMIC ANALYSIS OF THE PLASMA… (5*) Mo1819. . . . PERFORMANCE OF NOVEL MYCOBACTERIAL DETECTION TEST… (5*) Mo1820. . . . MONITORING INFLAMMATORY ACTIVITY IN CROHN’S DISEASE:… (5*) Mo1821. . . . THE UTILITY OF MONITR TEST AS… (5*) Mo1822. . . . ELEVATED ECTODOMAIN OF TYPE 23 COLLAGEN… (5*)|(S. Sun, J.H. Mortensen, M.L. Olesen, M.A. Karsdal and T. Manon-Jensen are employed at Nordic Bioscience A/S which is a company involved in discovery and development of biochemical biomarkers. M.A. Karsdal and T. Manon-Jensen owns stocks at Nordic Bioscien) Mo1823. . . . ENDOSCOPIC PATTERNS AND LOCATION OF POST-OPERATIVE… (2*) Mo1824. . . . HISTOLOGIC HEALING RATES OF MEDICAL THERAPIES… (5*)|(Statistical alyses performed by Robarts Clinical Trials Inc.) Mo1825. . . . FECAL CALPROTECTIN (FCAL) MONITORING IN ASYMPTOMATIC… (5*) Mo1826. . . . HOLD THE MAYO, ARE ENDOSCOPISTS TAKING… (5*) Mo1827. . . . CUMULATIVE HISTOLOGIC INFLAMMATION PREDICTS COLORECTAL NEOPLASIA… (5*)

Mo1828. . . . HISTOLOGIC DISEASE ACTIVITY AT SURGICAL RESECTION… (5*) Mo1829. . . . DEGRADATION AND FORMATION OF TYPE III,… (5*) Mo1830. . . . SEROLOGICAL BIOMARKERS OF TYPE VI COLLAGEN… (3*)|(Nordic Bioscience A/S) Mo1831. . . . MMP-2 AND -8 DEGRADED AND CITRULLINATED-VIMENTIN… (2*)|(The assessment of VICM is done by and at the expense of Nordic Bioscience.) Mo1832. . . . AN INVERSE CORRELATION OF SERUM FIBROBLAST… (4*) Mo1833. . . . CAPSULE ENDOSCOPY IMPACT ON THERAPEUTIC DECISIONS… (5*) Mo1834. . . . VALIDATION OF AN INTEGRAL DISEASE INDEX… (4*) Mo1835. . . . THE DEVELOPMENT OF A NON-INVASIVE ULTRASONOGRAPHIC… (5*) Mo1836. . . . CAN CROHN'S PATIENTS BE ACCURATELY PHENOTYPED… (2*) Mo1837. . . . EFFECT OF UPADACITINIB ON EXTRA-INTESTINAL MANIFESTATIONS… (3*)|(The authors and AbbVie scientists designed the study, and alysed and interpreted the data. AbbVie funded the research and provided writing support. All authors contributed to the development of the content. The authors and AbbVie reviewed and approved the) Mo1838. . . . CROHN’S DISEASE HAS AN INCREASED RISK… (5*) Mo1839. . . . RISK FACTORS FOR ACUTE VENOUS THROMBOEMBOLISM… (5*) Mo1840. . . . INCIDENCE OF ADVERSE PSYCHIATRIC EFFECTS OF… (2*) Mo1841. . . . SAFETY AND EFFICACY OF ENDOSCOPIC DILATION… (5*) Mo1842. . . . RELATIVE HAZARD OF CHRONIC KIDNEY DISEASE… (2*) Mo1843. . . . A SIGNIFICANT DECLINE IN COLECTOMY RATES… (5*) Mo1844. . . . LONG-TERM FATE OF THE EXCLUDED RECTUM… (5*) Mo1845. . . . INCREASED RISK OF ADVANCED NEOPLASIA IN… (5*)

Mo1846. . . . ULCERATIVE COLITIS (UC) PATIENTS WITH PRIMARY… (4*) Mo1847. . . . NUTRITIONAL INDICATORS AND POSTOPERATIVE OUTCOMES IN… (5*) Mo1848. . . . EXTRAINTESTINAL MANIFESTATIONS AND THEIR IMPACT ON… (3*)|(Pfizer Inc) Mo1849. . . . LONG-TERM OUTCOMES OF STEROID-RESPONSIVE AND NON-RESPONSIVE… (5*) Mo1850. . . . PREOPERATIVE ANTI-TNFS ARE ASSOCIATED WITH A… (5*) Mo1851. . . . THE TREATMENT OF PERIANAL FISTULAS BY… (5*) Mo1852. . . . INVESTIGATION OF CORRELATION BETWEEN POUCH WALL… (5*) Mo1853. . . . OPPORTUNISTIC INFECTIONS IN INFLAMMATORY BOWEL DISEASE:… (5*) Mo1854. . . . WEEKEND DISCHARGES AND HOSPITAL READMISSIONS FOR… (5*) Mo1855. . . . HOSPITALIZATION OUTCOMES FOR INFLAMMATORY BOWEL DISEASE… (5*) Mo1856. . . . BIG DATA ANALYTICS IDENTIFIES ULCERATIVE COLITIS… (2*) Mo1857. . . . 7ALPHA-HYDROXY-4-CHOLESTEN-3-ONE FOR DIAGNOSIS AND MANAGEMENT OF… (5*) Mo1858. . . . OUTCOMES OF ACUTE PANCREATITIS IN INFLAMMATORY… (5*) Mo1859. . . . DOES A POSITIVE CLOSTRIDIODES DIFFICILE RESULT… (6*) Mo1860. . . . PREGNANT WOMEN WITH IBD HAVE WORSE… (5*) Mo1861. . . . THE RISK OF ECTOPIC PREGNANCY IN… (5*) Mo1862. . . . NO INCREAED RATES OF ADVERSE IBD-RELATED… (5*) Mo1863. . . . EXTRAINTESTINAL MANIFESTATIONS AND QUALITY OF LIFE… (3*)|(The authors & AbbVie scientists designed the study, & alysed & interpreted the data. AbbVie funded the research & provided writing support. All authors contributed to the development of the content. The authors & AbbVie reviewed & approved the abstract; t)


* = Primary Source



Mo1864. . . . INCREASING RATES OF INFECTIVE ENDOCARDITIS IN… (5*)|(There are no industry or commercial sources of funding.) Mo1865. . . . PREDICTORS OF 30-DAY READMISSION ASSOCIATED WITH… (5*) Mo1866. . . . PREDICTORS OF 30 DAYS READMISSIONS AFTER… (5*) Mo1867. . . . THE IMPORTANCE OF MONITORING THE POSTPARTUM… (3*)|(UCB Sponsored) Mo1868. . . . METHYLATION PATTERNS IN DYSPLASIA IN INFLAMMATORY… (7*) Mo1869. . . . SCREENING, PREVALENCE AND INAPPROPRIATE IRON SUPPLEMENTATION… (5*) Mo1870. . . . ABDOMINAL PAIN IN PATIENTS WITH INFLAMMATORY… (4*)|(5) Mo1871. . . . THE ASSOCIATION BETWEEN INFLAMMATORY BOWEL DISEASE… (5*) Mo1872. . . . THE REGULATORY ROLE OF POLYCOMB REPRESSIVE… (2*) Mo1873. . . . THE CONSTITUTIVE ANDROSTANE RECEPTOR (CAR) ACTS… (2*) Mo1874. . . . INCREASED NCR+ ILC3 LEVELS AFTER BIOLOGICAL… (2*) Mo1875. . . . IDENTIFICATION AND VALIDATION OF NOVEL CROHN'S… (2*) Mo1876. . . . EXPRESSION OF CD69 ON PERIPHERAL LYMPHOCYTES… (4*)|(Unrestricted research grant from Janssen Cilag) Mo1877. . . . TUMOR NECROSIS FACTOR α AND IL-17A… (4*) Mo1878. . . . LYMPHOCYTE ACTIVATION GENE (LAG)-3 ON T… (3*)|(This project is funded by GlaxoSmithKline.) Mo1879. . . . METHYLTRANSFERASE G9A AS AN EPIGENOMIC REGULATOR… (2*) Mo1880. . . . ULCERATIVE COLITIS PATIENTS ARE CHARACTERIZED BY… (2*) Mo1881. . . . MULTIOMICS ANALYSIS OF IBD ENDOSCOPIC BIOPSIES… (3*)|(Interl funding by Bristol Myers Squibb) Mo1882. . . . IMMUNE CELL AND CHECKPOINT SIGNATURES IN… (3*)|(Study was performed in collaboration with Roche Pharma Research and Early Development,

Immunology, Inflammation and Infectious Diseases (I3) Discovery and Translatiol Area, Roche Innovation Center Basel, Basel, Switzerland. No specific funding was receive) Mo1883. . . . CLINICAL RESPONSE TO USTEKINUMAB IN CROHN'S… (5*) Mo1884. . . . DIETARY WHEAT ALPHA-AMYLASE/TRYPSIN INHIBITORS INDUCE SYSTEMIC… (2*) Mo1885. . . . CHRONIC INFLAMMATION PROMOTES INTESTINAL MACROPHAGES TO… (4*) Mo1886. . . . FLAGELLIN-ACTIVATED CD4 CELLS IN REMISSION CROHN… (2*) Mo1887. . . . USTEKINUMAB ENDOSCOPIC RESPONSE AT WEEK 16… (3*)|(Truvion Healthcare (Preventis)) Mo1888. . . . IMPROVEMENT IN RADIOGRAPHIC SMALL BOWEL INFLAMMATION… (5*) Mo1889. . . . YOUNG PATIENTS WITH INFLAMMATORY BOWEL DISEASE… (2*) Mo1890. . . . USING THERAPEUTIC DRUG MONITORING TO PREDICT… (5*) Mo1891. . . . POST-MARKETING SAFETY EXPERIENCE OF VEDOLIZUMAB IN… (3*)|(Medical writing assistance was provided by Alex Kisbey of Oxford PharmaGenesis, Oxford, UK and was supported by Takeda Pharmaceutical Company Ltd.) Mo1892. . . . NON-MEDICAL REVERSE SWITCH BETWEEN THE ORIGINATOR… (4*)|(Fincial Support: This work was supported by NKFIH-OTKA (Hungarian Scientific Research Fund) Research Grant (Grant ID: K115345). This work was supported by the ÚNKP-18-3-I New tiol Excellence Program of the Ministry of Human Capacities, Hungary.) Mo1893. . . . PERIPHERAL BLOOD EOSINOPHILIA FUNCTIONS AS A… (2*) Mo1894. . . . EARLY VEDOLIZUMAB TROUGH LEVELS ARE NOT… (6*) Mo1895. . . . EFFICACY OF INTRAVENOUS USTEKINUMAB RE-INDUCTION IN… (5*) Mo1896. . . . VEDOLIZUMAB INDUCED ENDOSCOPIC REMISSION IN ANTI-TNF… (5*)

Mo1897. . . . BIOLOGICAL THERAPIES IN CHRONIC ANTIBIOTIC-REFRACTORY POUCHITIS:… (5*) Mo1898. . . . EVALUATION OF BODY MASS INDEX AND… (5*) Mo1899. . . . PROGNOSTIC FACTORS FOR LONG-TERM ADALIMUMAB TREATMENT… (5*) Mo1900. . . . TNF-α INHIBITORS AND RISK OF TYPE… (6*) Mo1901. . . . ANTI-TNF DOSE AUGMENTATION INCIDENCE AND PERSISTENCE… (5*) Mo1902. . . . MOOD AND ANXIETY DISORDERS AND PERSISTANCE… (6*)|(Crohn's and Colitis Cada, CIHR) Mo1903. . . . THE RATES OF ANTI-TNF DOSE AUGMENTATION… (6*)|(Crohn's and Colitis Cada) Mo1904. . . . CONCOMITANT STEROID THERAPY WITH ANTI-TNF THERAPY… (4*) Mo1905. . . . A RETROSPECTIVE STUDY TO EXAMINE THE… (3*)|(AbbVie Pharmaceuticals S.A. (Greece)) Mo1906. . . . COMBINATION THERAPY OF VEDOLIZUMAB AND TOFACITINIB… (5*) Mo1907. . . . EVALUATION OF USTEKINUMAB TREATMENT PATTERNS AMONG… (3*)|(Funded by Janssen Scientific Affairs, LLC.) Mo1908. . . . NONBIOLOGIC DRUG USE BEFORE AND AFTER… (3*)|(Funded by Janssen Scientific Affairs, LLC, Horsham, PA, USA) Mo1909. . . . EVALUATION OF HEALTH CARE UTILIZATION, HOSPITALIZATION/… (3*)|(Funded by Janssen Scientific Affairs, LLC.) Mo1910. . . . LONG-TERM CLINICAL EFFICACY OF USTEKINUMAB IN… (5*)|(No industry or commercial sources to report) Mo1911. . . . SERUM BILE ACIDS PROFILING IN IBD… (5*) Mo1912. . . . VEDOLIZUMAB IN ELDERLY PATIENTS WITH INFLAMMATORY… (5*) Mo1913. . . . TWO YEAR EXPERIENCE WITH VEDOLIZUMAB IN… (4*) Mo1914. . . . USTEKINUMAB IS EFFECTIVE FOR THE TREATMENT… (5*)


* = Primary Source



Mo1915. . . . LONG-TERM OUTCOMES OF INFLIXIMAB THERAPY FOR… (5*) Mo1916. . . . EFFECTIVENESS AND SAFETY OF USTEKINUMAB FOR… (5*) Mo1917. . . . USTEKINUMAB: EARLY EXPERIENCE AND MEDIUM-TERM OUTCOMES… (5*) Mo1918. . . . CAN WE STOP ANTI-TUMOUR NECROSIS FACTOR… (5*) Mo1919. . . . USTEKINUMAB EFFICIENCY AS A HIGHER-LINE THERAPY… (5*) Mo1920. . . . RESULTS OF INTERIM ANALYSIS OF A… (5*) Mo1921. . . . TNF-α INHIBITORS HAVE SIMILAR EFFECTIVENESS IN… (5*) Mo1922. . . . SUPPLEMENTATION WITH BUTYRATE PRODUCING BACTERIA REDUCES… (4*) Mo1923. . . . LONG-TERM SAFETY OF FECAL MICROBIOTA TRANSPLANTATION… (5*) Mo1924. . . . CLOSTRIDIUM BUTYRICUM PROMOTES LIGANDS RELEASE FROM… (5*) Mo1925. . . . TRANSGENERATIONAL IMPACTS OF ORAL PROBIOTICS ADMINISTRATION… (5*) Mo1926. . . . A SINGLE CENTER EXPERIENCE: FECAL MICROBIOTA… (5*) Mo1927. . . . CITROBACTER RODENTIUM INDUCES CD4+ TISSUE RESIDENT… (4*) Mo1928. . . . TOLL-LIKE RECEPTOR2-MEDIATED ACCLERATION OF INTESTINAL MUCOSAL… (2*) Mo1929. . . . CANDIDA ALBICANS SC5314 INHIBITS NLRP3/NLRP6 INFLAMMASOME… (2*) Mo1930. . . . HARNESSING ANTI-INFLAMMATORY GUT BIOACTIVES TO MODULATE… (4*) Mo1931. . . . URINE METABOLOMIC SIGNATURES DIFFERENTIATE PREGNANCY FROM… (5*) Mo1932. . . . MECHANISTIC INSIGHT INTO BACTERIAL HTPG-HOST INTERACTIONS… (2*) Mo1933. . . . ASSOCIATION BETWEEN PRENATAL ANTIBIOTICS EXPOSURE AND… (5*)

Mo1934. . . . UNEXPLAINED CHRONIC ABDOMINAL PAIN IN 50-YEAR-OLD… (5*) Mo1939. . . . PERIPARTUM CLOSTRIDIOIDES DIFFICILE INFECTION AND ITS… (5*) Mo1940. . . . CLOSTRIDIUM DIFFICILE INFECTION MIMICS INTESTINAL ACUTE… (5*) Mo1941. . . . TREATMENT FOR REDUCING RECURRENCE OF C.… (5*) Mo1942. . . . CLOSTRIDIUM DIFFICILE OF THE ILEAL POUCH… (5*) Mo1943. . . . COLONOSCOPY-BASED FECAL MICROBIOTA TRANSPLANTATION IS HIGHLY… (5*) Mo1944. . . . ADHERENCE TO THE TESTING GUIDELINES FOR… (5*) Mo1945. . . . THE INFLUENCE OF PETS ON RISK… (1*) Mo1946. . . . RECONSTITUTION OF PREBIOTIC-DRIVEN HOST-MICROBE SYNTROPHY IN… (4*) Mo1947. . . . TAXONOMIC AND FUNCTIONAL INTESTINAL DYSBIOSIS IN… (7*) Mo1948. . . . GUT MICROBIOTA COMPOSITION AT DIAGNOSIS PREDICTS… (2*) Mo1949. . . . DECREASED COMPLEXITY OF SERUM N-GLYCAN STRUCTURES… (4*) Mo1950. . . . POSITIVE ENZYME IMMUNOASSAY (EIA) TOXIN TESTING… (4*) Mo1951. . . . FECAL MICROBIOTA TRANSPLANT DECREASES MORTALITY IN… (5*) Mo1952. . . . EFFICACY OF ORAL VANCOMYCIN PROPHYLAXIS FOR… (5*) Mo1953. . . . GROWTH INHIBITION OF CLOSTRIDIOIDES DIFFICILE BY… (4*) Mo1954. . . . FECAL MICROBIOTA TRANSPLANTATION IS SAFE AND… (5*) Mo1955. . . . VE303, A LIVE BIOTHERAPEUTIC PRODUCT FOR… (3*)|(Vedanta Biosciences Inc.) Mo1956. . . . CONSTIPATION IS A COMPLICATION OF ORAL… (5*)

Mo1957. . . . EEFFECT OF LYOPHILIZED STERILE FECAL FILTRATE… (6*) Mo1958. . . . TOXIN A AND B COMBINED WITH… (5*) Mo1959. . . . A META-ANALYSIS OF THE SAFETY AND… (5*) Mo1960. . . . CORTICOSTEROIDS AND ADVERSE OUTCOMES IN INFLAMMATORY… (5*) Mo1961. . . . INPATIENT MANAGEMENT OF SEVERE CLOSTRIDIUM INFECTION… (2*) Mo1962. . . . MORBID OBESITY INCREASES 30-DAY READMISSION AND… (5*) Mo1963. . . . DOES ADDITION OF METRONIDAZOLE TO ORAL… (5*) Mo1964. . . . COMPARISON OF IN-VITRO PHOTODYNAMIC BACTERICIDAL EFFECT… (2*)|(Small Grant Exploratory Research, Korea) Mo1965. . . . EVIDENCE FOR CELLULAR ENGRAFTMENT IN GI… (4*) Mo1966. . . . INSTITUTIONAL EXPERIENCE WITH CAPSULE FECAL MICROBIOTA… (5*) Mo1967. . . . DISPARITIES IN MANAGEMENT OF CLOSTRIDIOIDES DIFFICILE… (5*) Mo1968. . . . FECAL MICROBIOTA TRANSPLANTATION FOR TREATMENT OF… (5*) Mo1969. . . . GASTROSTOMY TUBE PLACEMENT (GTP) AND ITS… (5*) Mo1970. . . . EFFICACY OF COLONOSCOPY, NASOGASTRIC TUBE, ENEMA,… (5*) Mo1971. . . . IN VITRO AND IN VIVO VIRULENCE… (2*)|(Nil) Mo1972. . . . AN ANALYSIS OF LONG-TERM EFFICACY AND… (5*) Mo1973. . . . PREDICTORS OF TREATMENT FAILURE IN FECAL… (5*) Mo1974. . . . CLOSTRIDIUM DIFFICILEMINFECTION (CDI) IS ASSOCIATED WITH… (5*) Mo1975. . . . INPATIENT COSTS ASSOCIATED WITH C. DIFFICILE… (5*) Mo1976. . . . RACIAL DISPARITIES IN CLOSTRIDIOIDES DIFFICILE MORTALITY… (4*)


* = Primary Source



Mo1977. . . . THE EFFECT OF ANTI-INFLAMMATORY PROPERTIES OF… (5*) Mo1978. . . . OUTCOMES OF FECAL MICROBIOTA TRANSPLANTATION FOR… (5*) Mo1979. . . . HOSPITAL - ONSET CLOSTRIDIUM DIFFICILE INFECTION… (5*) Mo1980. . . . VOLUME OF FECAL FILTRATE FOR FECAL… (5*) Mo1981. . . . ETIOLOGIES, TRENDS AND SHORT-TERM OUTCOMES OF… (5*) Mo1982. . . . GENDER DIFFERENCES IN FECAL BACTERIOME AND… (4*) Mo1983. . . . THE UTILITY OF IGA BASED SEROLOGIC… (5*) Mo1984. . . . SYMPTOM PROFILES, GLUTEN FREE DIET ADHERENCE,… (5*) Mo1985. . . . MINIMALLY-INVASIVE MONITORING OF INTESTINAL VILLOUS HEALTH… (3*) Mo1986. . . . LATIGLUTENASE IMPROVES QUALITY OF LIFE IN… (3*)|(Immunogenics LLC (dba ImmunogenX)) Mo1987. . . . RESPONDER ANALYSIS FOR LATIGLUTENASE REDUCTION IN… (3*) Mo1988. . . . USE OF CLADRIBINE FOR ULCERATIVE JEJUNITIS… (5*) Mo1989. . . . ASSESSMENT OF NOVEL CANDIDATE BIOMARKERS OF… (4*) Mo1990. . . . ADHERENCE TO THE GLUTEN-FREE DIET AND… (3*)|(Takeda Pharmaceutical Company) Mo1991. . . . CO-LOCALISATION OF IGA AND IGG ANTI-TISSUE… (4*) Mo1992. . . . SOLVING THE STAIN DILEMMA: COMPUTATIONAL IMAGE… (4*)| Mo1993. . . . HEALTHCARE UTILIZATION AND COMORBIDITIES AMONG PEOPLE… (5*) Mo1994. . . . IS THE INCREASE IN CELIAC DISEASE… (5*) Mo1995. . . . THE POSITIVE AND NEGATIVE RIPPLE-EFFECT OF… (4*)

Mo1996. . . . ASSESSING SEVERITY AND HEALTHCARE RESOURCE UTILIZATION… (3*)|(Takeda Pharmaceuticals Intertiol Co.) Mo1997. . . . ACUTE PANCREATITIS WITH CELIAC DISEASE: HAS… (5*) Mo1998. . . . CELIAC AUTOIMMUNITY AND PREGNANCY OUTCOMES… (5*) Mo1999. . . . PREVALENCE OF CELIAC DISEASE (CD) IN… (5*) Mo2000. . . . INCIDENCE OF CELIAC DISEASE IS INCREASING… (6*) Mo2001. . . . EPIDEMIOLOGY OF PATIENTS ADMITTED FOR CELIAC… (5*) Mo2002. . . . CELIAC DISEASE: ENHANCING EDUCATIONAL SUPPORT FOR… (5*) Mo2003. . . . COMPARISON OF QUALITY OF CELIAC DISEASE… (5*) Mo2004. . . . HOW ARE CELIAC DISEASE PATIENTS FOLLOWED… (5*) Mo2005. . . . ASSESSMENT OF PARENTAL GLUTEN-FREE DIET KNOWLEDGE… (6*) Mo2006. . . . AN EDUCATIONAL APP TO SUPPORT THE… (6*) Mo2007. . . . COMPARISON OF CELIAC DISEASE PATIENT SATISFACTION… (5*) Mo2008. . . . BLENDERIZED DIETS ARE ASSOCIATED WITH IMPROVED… (5*) Mo2009. . . . ASSOCIATION BETWEEN COLORECTAL ADENOMA AND NONALCOHOLIC… (2*) Mo2010. . . . THE IMPACT OF ADJUSTABLE INTRAGASTRIC BALLOON… (2*) Mo2011. . . . SMALL INTESTINAL MICROBIAL SHIFTS TOWARDS BILE-TOLERANT-ASSOCIATED-MICROBIOTA… (2*)|(NIDDK r01 21769 NIDDK r01 29867) Mo2012. . . . HIGH-FAT DIET REDUCES BROWN ADIPOSE TISSUE… (2*) Mo2013. . . . HEPATIC AGO2 IS INDISPENSABLE FOR NASH… (2*) Mo2014. . . . COMPARATIVE EFFECTS OF BAR502, A DUAL… (5*) Mo2015. . . . THE ROLE OF SMALL INTESTINAL BACTERIA… (5*) Mo2016. . . . THE TGF-β/SMAD3 ADAPTOR SPTBN1 AND ALDH2… (2*)

Mo2017. . . . ANTIMICROBIAL PEPTIDE ELAFIN REVERSES OBESITY, INSULIN… (2*) Mo2018. . . . HEPATOCYTE-SPECIFIC OVEREXPRESSION OF FADS1 ATTENUATED DIETARY… (2*) Mo2019. . . . DEFINING CLINICALLY SIGNIFICANT WEIGHT REGAIN AFTER… (5*) Mo2020. . . . CHARACTERISTICS OF A CASH-PAY GI-BASED MEDICAL… (5*) Mo2021. . . . NUMBER OF FOLLOW-UP VISITS IS INDEPENDENTLY… (5*) Mo2022. . . . WEIGHT LOSS ADVICE FOR FATTY LIVER… (5*) Mo2023. . . . ASSOCIATION BETWEEN OBESITY AND RISK OF… (5*) Mo2024. . . . OBESITY PROLONGS HOSPITALIZATION IN CHRONIC PANCREATITIS… (5*) Mo2025. . . . COLORECTAL CANCER SCREENING RATES ARE LOWER… (4*) Mo2026. . . . EFFECTIVENESS OF ANTI-OBESITY MEDICATIONS IN “REAL… (2*) Mo2027. . . . HIGH STRESS LEVEL IS ASSOCIATED WITH… (5*) Mo2028. . . . A STRUCTURED, COMPREHENSIVE LIFESTYLE INTERVENTION PROGRAM… (5*) Mo2029. . . . OCTREOTIDE AMELIORATES OBESITY-INDUCED PANCREATIC STEATOSIS VIA… (5*) Mo2030. . . . COST-EFFECTIVENESS OF EARLY INITIATION AND/OR MORE… (4*) Mo2031. . . . A FUNCTIONAL SCREENING APPROACH FOR ANIT-OBESITY… (4*)| Mo2032. . . . INTESTINAL ELECTRICAL STIMULATION ALTERS HYPOTHALAMIC EXPRESSIONS… (2*) Mo2041. . . . ARTIFICIAL INTELLIGENCE AUGMENTS REAL-TIME HISTOLOGY OF… (2*) Mo2042. . . . CHROMOENDOSCOPY REDUCES THE SUBSEQUENT RISK OF… (4*) Mo2043. . . . IMAGE ENHANCED ENDOSCOPY DOES NOT IMPROVE… (5*) Mo2044. . . . 0.02 VITAMIN C SOLUTION SPRAY FOR… (2*)


* = Primary Source



Mo2045. . . . MACHINE-LEARNING-BASED AUTOMATIC DIAGNOSTIC SYSTEM USING LINKED… (5*) Mo2046. . . . AUTOMATED REAL TIME ENDOSCOPIC SCORING BASED… (5*) Mo2047. . . . AUTOMATED DETECTION OF ABDOMINAL FREE FLUID… (5*) Mo2048. . . . UNSUPERVISED MACHINE LEARNING BASED AUTOMATIC DEMARCATION… (5*) Mo2049. . . . AUGMENTING GASTROINTESTINAL HEALTH: A DEEP LEARNING… (5*) Mo2050. . . . NOVEL COMPUTER-ASSISTED DETECTION SYSTEM OF COLORECTAL… (3*) Mo2051. . . . AUTOMATED COMPUTER DETECTION OF COLONOSCOPY COMPLETION… (5*) Mo2052. . . . APPLICATION OF MACHINE LEARNING AND ARTIFICIAL… (7*) Mo2053. . . . PRE-PROCEDURAL ASSESSMENT OF THE FASTING STATE… (5*)|(The eNose Company, Zutphen, NL, provided Aeonose device for study but no funding.) Mo2054. . . . A SEMI-SUPERVISED BLEEDING DETECTION METHOD IN… (3*)| Mo2055. . . . A NATURAL LANGUAGE BASED TOOL IMPROVES… (5*) Mo2056. . . . PERORAL ENDOSCOPIC MYOTOMY: EFFECTS OF THE… (5*) Mo2057. . . . INITIAL NORTH AMERICAN EXPERIENCE WITH ENDOSCOPIC… (4*) Tu1000. . . . CHRONIC LIVER DISEASE IS ASSOCIATED WITH… (5*) Tu1001. . . . PERFORMANCE OF THE VETERAN'S CHOICE PROGRAM… (5*) Tu1002. . . . WEEKEND ADMISSIONS FOR ACUTE CHOLANGITIS: IMPORTANCE… (5*) Tu1003. . . . CHARACTERIZING LOW-VALUE PPI USE AMONG OLDER… (4*) Tu1004. . . . FRAGMENTED CARE IS PREVALENT AMONG PATIENTS… (5*) Tu1005. . . . ANESTHESIA ROLE IN HOSPITALIZATION FOR PNEUMONIA… (3*)|(Medivators)

Tu1006. . . . DEVELOPMENT OF AN EVIDENCE-BASED STRATEGY INCORPORATING… (4*) Tu1007. . . . PATIENT-INITIATED ELECTRONIC MESSAGING WITH PHYSICIANS IS… (5*) Tu1008. . . . PROXIMAL NEOPLASIA YIELD AMONG SUBJECTS REFERRED… (2*) Tu1009. . . . TRANSCRIPTOMIC PROFILING IDENTIFIES A NOVEL, NON-INVASIVE,… (2*) Tu1010. . . . VALIDATION OF A STOOL-DERIVED EUKARYOTIC RNA… (3*)|(Geneoscopy) Tu1011. . . . CHARACTERISTICS OF INDIVIDUALS UNDERGOING FIT FOR… (5*) Tu1012. . . . LOW RATES OF METACHRONOUS ADVANCED NEOPLASIA… (4*) Tu1013. . . . ARE OUT-OF-POCKET COSTS UNDER MEDICARE A… (1*) Tu1014. . . . ABERRANT CRYPT FOCI PREDICT RISK OF… (5*) Tu1015. . . . MULTI-TARGET STOOL DNA TESTING: YIELD AS… (4*) Tu1016. . . . COLORECTAL CANCER SCREENING: HOLES AND HOPE… (5*) Tu1017. . . . PREVALENCE OF COLONIC POLYPS IN END-STAGE… (5*) Tu1018. . . . SHOULD SCREENING FOR COLORECTAL CANCER START… (5*) Tu1019. . . . INCREASING PREVALENCE OF SESSILE SERRATED POLYPS… (5*) Tu1020. . . . UNDERUTILISATION OF RESOURCES FOR COLORECTAL CANCER… (5*) Tu1021. . . . DISTANCE OF TRAVEL TO THE SITE… (5*) Tu1022. . . . QUALITY OF BOWEL PREPARATION AMONG PATIENTS… (5*) Tu1023. . . . ADDITIONAL INTESTINAL MUCOSAL BIOPSY SAMPLING FOR… (5*) Tu1027. . . . ESOPHAGEAL MANOMETRY COMPETENCY PROGRAM IMPROVES PERFORMANCE… (5*) Tu1028. . . . FACTORS CONTRIBUTING TO ENTRUSTMENT DECISIONS IN… (7*)

Tu1029. . . . IMPACT OF SPECIFIC TEACHING STRATEGIES ON… (5*) Tu1030. . . . A LOOK AT HOW ENDOCUFF AFFECTS… (5*) Tu1031. . . . BEST PRACTICES IN TEACHING ENDOSCOPY: A… (5*) Tu1032. . . . DOES MENTORSHIP IMPACT TRAINEE PARTICIPATION IN… (5*) Tu1033. . . . A SNAPSHOT OF WOMEN IN GASTROENTEROLOGY… (5*) Tu1034. . . . PROXIMAL SERRATED POLYP DETECTION RATE IS… (5*) Tu1035. . . . IMPACT OF PATIENT EDUCATION ON SWITCH… (1*) Tu1036. . . . ENSURING JUDICIOUS PPI USE THROUGH AN… (5*) Tu1037. . . . ADDRESSING THE GENDER DIVIDE: FEMALE GASTROENTEROLOGISTS… (5*) Tu1038. . . . SOCIAL INFLUENCES ON CAREER CHOICES IN… (4*) Tu1039. . . . WHY NOT BE A LEADER? CHARACTERISTICS… (5*) Tu1040. . . . EXPERIENCED ENDOSCOPY TEACHERS USE TEACHING STRATEGIES… (5*) Tu1041. . . . ELECTRONIC CASE-BASED GI BLEEDING MODULE IMPROVES… (5*) Tu1042. . . . INNOVATIVE INSTRUCTIONAL STRATEGIES FOR INCORPORATING THE… (5*) Tu1043. . . . GASTROENTEROLOGY FELLOWS HAVE SIMILAR POLYP, ADENOMA… (5*) Tu1044. . . . WORK-LIFE CONFLICT AND ITS HEALTH EFFECTS… (4*) Tu1045. . . . TEACHING THE “FOUR-POSITION METHOD” MAKES BEGINNER… (5*) Tu1046. . . . KNOWLEDGE AND PRESCRIBING PATTERNS OF INTERNAL… (5*) Tu1047. . . . FOOD FOR THOUGHT: GASTROENTEROLOGY FELLOW AND… (5*) Tu1144. . . . CELLULAR SIGNALING CASCADES FOR ACTIVATION OF… (2*)


* = Primary Source



Tu1145. . . . INDUCTION OF LIVER AUTOPHAGY AMELIORATES IMPAIRED… (3*)|(Tsumura & Co.) Tu1146. . . . SCHLAFEN 3 KNOCKOUT MICE DISPLAY GENDER-SPECIFIC… (5*) Tu1147. . . . NPT2B, A TYPE II SODIUM-PHOSPHATE COTRANSPORTER,… (2*) Tu1148. . . . MICROFLUIDIC ORGANOTYPIC SYSTEM FOR THE ANALYSIS… (4*) Tu1149. . . . IDENTIFYING FUNCTIONAL PATHWAY ASSOCIATIONS BETWEEN GENE… (2*) Tu1150. . . . INSULIN PROMOTES THE INVASION AND MIGRATION… (2*) Tu1151. . . . HUMAN MYOFIBROBLASTS SUPPORT PROLIFERATION OF INTESTINAL… (5*) Tu1152. . . . CORDYCEPIN INDUCES G2/M PHASE ARREST AND… (2*) Tu1153. . . . REGULATION OF KETOGENESIS BY WNT/β-CATENIN/PPARγ SIGNALING… (2*) Tu1154. . . . TROP2 UPREGULATION IN MOUSE PRE-NEOPLASTIC STOMACH… (2*) Tu1155. . . . EXPRESSION OF GCRG213, LINE-1 ENDONUCLEASE VARIANT,… (2*) Tu1156. . . . EVALUATION OF SERUM TFF3 LEVELS IN… (5*) Tu1157. . . . ANALYSIS OF GASTRIC POLYPS FROM WESTERN… (5*)|(NIL) Tu1158. . . . GENOME-WIDE ANALYSIS FOR GASTRIC ADENOCARCINOMA-SPECIFIC H.PYLORI… (2*) Tu1159. . . . BLOOD MQTL EFFECTS ARE CONSISTENT DURING… (6*) Tu1160. . . . GENE EXPRESSION SIGNATURE OF THE “POINT… (4*) Tu1161. . . . A PROTOCOL FOR LIVE-FACS FROM CRYOPRESERVED… (2*) Tu1162. . . . USING TRANSCRIPTOMICS TO SUBCLASSIFY ULCERATIVE COLITIS… (6*) Tu1163. . . . HISTONE DESACETYLASE 2 FAVORS AIEC INVASION… (4*) Tu1164. . . . SHARED GENETIC MUTATIONS ARE FOUND IN… (2*)

Tu1169. . . . SEX MODERATES THE RELATION BETWEEN NAUSEA… (2*) Tu1170. . . . HOSPITAL ADMISSIONS AND TREATMENT COST OF… (5*) Tu1171. . . . IS THE CONCLUSIVE EVIDENCE FOR GERD… (5*) Tu1172. . . . INCOMPLETE RESPONSE OF SYMPTOMS OF GASTROESOPHAGEAL… (2*) Tu1173. . . . ESOPHAGEAL MUCOSAL INTEGRITY IS UNCHANGED IN… (5*) Tu1174. . . . RECLASSIFICATION OF PATIENTS WITH GASTROESOPHAGEAL REFLUX… (5*) Tu1175. . . . EVALUATION OF MINIMAL CHANGE LESION USING… (5*) Tu1176. . . . SHORTER (48-HOUR) BRAVO PH MONITORING MAY… (5*)

Tu1177. . . . ESOPHAGEAL BASELINE

IMPEDANCE FROM HIGH RESOLUTION… (5*) Tu1178. . . . ASSOCIATION BETWEEN GASTROESOPHAGEAL JUNCTION MORPHOLOGY AND… (5*) Tu1179. . . . A DISTINCT PATTERN OF RUMINATION SYNDROME… (4*) Tu1180. . . . HIGH RESOLUTION MANOMETRY (HRM) EVALUATION OF… (5*) Tu1181. . . . PROSPECTIVE STUDY OF A COHORT OF… (1*) Tu1182. . . . HIGH RESOLUTION ESOPHAGEAL MANOMETRY RESULTS AFFECT… (5*) Tu1183. . . . MEASUREMENT OF ESOPHAGEAL BASELINE IMPEDANCE: A… (1*) Tu1184. . . . MUCOSAL IMPEDANCE PREDICTS ABILITY TO DISCONTINUE… (2*) Tu1185. . . . PROLONGED (96 H) WIRELESS AMBULATORY ESOPHAGEAL… (5*) Tu1186. . . . E-CADHERIN AND EPIDERMAL GROWTH FACTOR (EGF)… (4*) Tu1187. . . . SYMPTOM RECOGNITION DURING AMBULATORY PH-IMPEDANCE MONITORING:… (5*)

Tu1188. . . . REFLUX PATTERN AND ROLE OF IMPEDANCE-PH… (5*) Tu1189. . . . A BRIEF MANOMETRIC INDEX FOR COMPREHENSIVE… (5*) Tu1190. . . . POSTREFLUX SWALLOW-INDUCED PERISTALTIC WAVE INDEX INDEPENDENTLY… (5*) Tu1191. . . . BASELINE IMPEDANCE ON HIGH-RESOLUTION ESOPHAGEAL IMPEDANCE-MANOMETRY… (5*) Tu1192. . . . CLINICAL UTILITY OF ADVANCED IMPEDANCE METRICS… (5*) Tu1193. . . . IMPACT OF CHRONIC OPIATES ON ESOPHAGEAL… (5*) Tu1194. . . . ESOPHAGOGASTRIC JUNCTION DISTENSIBILITY IS NEARLY ALWAYS… (2*) Tu1195. . . . 3D-PRESSURE TOPOGRAPHY OF THE ESOPHAGOGASTRIC JUNCTION… (2*) Tu1196. . . . IMPAIRED SWALLOW-INDUCED AXIAL ESOPHAGEAL SHORTENING/ LES… (2*) Tu1197. . . . ENDOSCOPIC INTRASPHINCTERIC INJECTION OF BOTOX IN… (2*) Tu1198. . . . INEFFECTIVE ESOPHAGEAL MOTILITY IS ASSOCIATED WITH… (5*) Tu1199. . . . ENDOSCOPIC MANAGEMENT OF ESOPHAGEAL SOFT FOOD… (5*) Tu1200. . . . UTILIZING FUNCTIONAL LUMINAL IMAGING PROBE (FLIP)… (2*) Tu1201. . . . CODEINE INDUCES MAJOR MOTILITY DISORDERS IN… (5*) Tu1202. . . . KEY PARAMETERS OF ESOPHAGOGASTRIC JUNCTION (EGJ)… (5*) Tu1203. . . . PHARMACOLOGIC INTERROGATION OF PATIENTS WITH ESOPHAGEAL… (4*) Tu1204. . . . MUSCLE LAYER FIBROSIS DO NOT REDUCE… (5*) Tu1205. . . . EOSINOPHILS EXPRESSING TGF-Β1 IN THE MUSCLE… (5*) Tu1206. . . . DYSPHAGIA IS A COMMON CONSEQUENCE OF… (5*) Tu1207. . . . THE CHICAGO CLASSIFICATION FREQUENTLY IDENTIFIES MANOMETRIC… (5*)


* = Primary Source



Tu1208. . . . NORMAL PARAMETERS OF DISTENSION-INDUCED CONTRACTILITY ASSESSED… (2*) Tu1209. . . . CLINICAL, MANOMETRIC AND PSYCHOLOGICAL PROFILE OF… (5*) Tu1210. . . . ESOPHAGEAL PATHOLOGY IS THE LIKELY ETIOLOGY… (5*) Tu1211. . . . ESOPHAGOGASTRIC JUNCTION MEASURES FOLLOWING PER ORAL… (2*) Tu1212. . . . HIGH PREVALENCE OF DYSPHAGIA AND ASSOCIATED… (2*) Tu1213. . . . ACUTE ADMINISTRATION OF CODEINE HAS NO… (5*) Tu1214. . . . FUNCTIONAL LUMEN IMAGING PROBE TOPOGRAPHY (FLIP)… (5*) Tu1215. . . . COMPARISON OF SAFETY OF TREATMENT OPTIONS… (5*) Tu1216. . . . RAPID SEQUENCE CT SCAN IMAGING TO… (2*) Tu1217. . . . COEXISTING ABNORMAL ESOPHAGEAL BODY MOTILITY PREDICTS… (5*) Tu1218. . . . ABERRANT STRIATED MUSCLE CONTRACTILITY IN SYMPTOMATIC… (2*) Tu1219. . . . MONTE CARLO SIMULATION CONFIRMS AGE-RELATED GROUP… (2*) Tu1220. . . . ACID EXPOSURE AND DYSMOTILITY IN SYMPTOMATIC… (5*) Tu1221. . . . LOW CLINICAL RELEVANCE OF CERVICAL INLET… (5*) Tu1222. . . . ESOPHAGEAL DYSMOTILITY OF ASIAN PEOPLE WITH… (5*) Tu1223. . . . EFFECTIVENESS OF N-ACETYLCYSTEINE ON THE TREATMENT… (5*) Tu1224. . . . DEPRESSION OF HYDROGEN SULFIDE SYNTHESIS ENZYMES… (5*) Tu1225. . . . HYPERCONTRACTILE MOTILITY DISORDERS OF THE ESOPHAGUS:… (5*) Tu1226. . . . FACTORS ASSOCIATED WITH SPASTIC ESOPHAGEAL DISORDERS… (5*) Tu1227. . . . EFFICACY OF PER-ORAL ENDOSCOPIC MYOTOMY FOR… (5*) Tu1228. . . . ACHALASIA QUALITY OF LIFE SCORE AND… (5*)

Tu1229. . . . IMPAIRED ESOPHAGOGASTRIC JUNCTION RECESSIVE RELAXATION PLAYS… (5*) Tu1230. . . . CLINICAL OUTCOME AFTER SINGLE HYDRAULUC ESOFLIP… (1*) Tu1231. . . . DIFFERENCES IN TRANSABDOMINAL ULTRASONOGRAPHIC PARAMETERS AMONG… (4*) Tu1232. . . . DISTAL ESOPHAGEAL DYSMOTILITY AND BOLUS CLEARANCE… (5*) Tu1233. . . . RAPID DRINKING CHALLENGE MAY HELP DISTINGUISH… (2*) Tu1234. . . . CROSS-SECTIONAL IMAGING IN PATIENTS WITH ESOPHAGOGASTRIC… (4*) Tu1235. . . . CLINICAL UTILITY OF HIGH-RESOLUTION ESOPHAGEAL MANOMETRY… (5*) Tu1236. . . . PATHOPHYSIOLOGICAL MECHANISMS ASSOCIATED WITH SUPRAGASTRIC BELCHING.… (5*) Tu1237. . . . ESOPHAGEAL ACID SENSITIVITY IN PATIENTS WITH… (4*) Tu1238. . . . THE TRANSITION ZONE AND DYSPHAGIA: A… (2*) Tu1239. . . . ESOPHAGEAL HYPERVIGILANCE AND VISCERAL ANXIETY ARE… (2*) Tu1240. . . . ASSESSMENT OF ESOPHAGEL BOLUS TRANSIT AND… (5*) Tu1241. . . . EFFECTS OF STRENGTH TRAINING ON DEGLUTITIVE… (2*) Tu1242. . . . DEGLUTITIVE STRIATED MUSCLE ENSEMBLE CONTRACTILITY INDICES:… (2*) Tu1243. . . . SUSTAINED ESOPHAGEAL CONTRACTIONS ON FUNCTION LUMINAL… (5*) Tu1244. . . . SWALLOWING AGAINST LARYNGEAL RESTRICTION (SALR) EXERCISE… (2*) Tu1245. . . . INITIAL GAINS BY SWALLOWING AGAINST LARYNGEAL… (2*) Tu1246. . . . HIGH RESIDUAL UPPER ESOPHAGEAL SPHINCTER PRESSURE… (5*) Tu1247. . . . ASSOCIATION OF NON-DYSPHAGIA SYMPTOMS AND UPPER… (5*)

Tu1248. . . . THE EFFICACY OF FLUOXETINE FOR TREATMENT… (5*) Tu1249. . . . AUTOLOGOUS HAEMATOPOETIC STEM CELL TRANSPLANT (HSCT)… (5*) Tu1250. . . . TOTAL DAILY OPIOID DOSE IS ASSOCIATED… (2*) Tu1251. . . . EFFECT OF ACUTE ESOPHAGEAL ACID EXPOSURE… (2*) Tu1252. . . . TOPOGRAPHICAL PLOTS OF ESOPHAGEAL DISTENSION AND… (2*) Tu1253. . . . VASCULAR PRESSURE BANDS ON HIGH RESOLUTION… (5*) Tu1254. . . . ASSOCIATION BETWEEN MEDICATION USE AND GERD… (5*) Tu1255. . . . THE EFFICACY OF TOPICAL LIDOCAINE IN… (5*) Tu1256. . . . DEEP LEARNING FOR ESOPHAGEAL MANOMETRY –… (5*) Tu1257. . . . ESOPHAGEAL HISTOPATHOLOGIC PATTERNS IN PATIENTS UNDERGOING… (5*) Tu1258. . . . MAST CELL INFILTRATION ASSOCIATED WITH LOSS… (2*)|(declared.) Tu1259. . . . YIELD OF ENDOSCOPIC ULTRASOUND AND COMPUTED… (5*) Tu1260. . . . UPRIGHT AND SUPINE INTEGRATED RESIDUAL PRESSURE… (5*) Tu1261. . . . PHARYNGEAL PRESSURIZATION SEEN ON PHARYNGEAL SCREENING… (5*) Tu1262. . . . THE EFFECT OF AGING ON ESOPHAGO-UES… (2*) Tu1263. . . . VARIATION OF BASAL UES PRESSURE WITHIN… (2*) Tu1264. . . . INTER-OBSERVER AGREEMENT FOR ANALYSIS OF FUNCTIONAL… (5*) Tu1265. . . . COMPARING REAL-TIME VS POST-PROCESSING DATA IN… (5*) Tu1266. . . . PROSPECTIVE EVALUATION OF THE CLINICAL RESPONSE… (5*) Tu1267. . . . RELATIONSHIP BETWEEN UPPER ESOPHAGEAL PRESSURES AND… (5*)


* = Primary Source



Tu1268. . . . INCOMPLETE ESOPHAGEAL BOLUS CLEARANCE IS ASSOCIATED… (5*) Tu1269. . . . INCOMPLETE BOLUS CLEARANCE CONTRIBUTES TO SEVERITY… (5*) Tu1270. . . . CONTROL OF ESOPHAGEAL SECONDARY PERISTALSIS BY… (4*) Tu1271. . . . APPLICATION OF A NOVEL LEG ELEVATION… (4*) Tu1272. . . . IMPACT OF GABA-B AGONIST BACLOFEN ON… (4*) Tu1273. . . . ELEVATION OF BASAL EGJ PRESSURE IS… (5*) Tu1274. . . . IMPACT OF PATIENT POSITION ON ESOPHAGEAL… (5*) Tu1275. . . . HEMATOLOGICAL INDICES IN ACHALASIA PATIENTS AND… (4*) Tu1276. . . . DIAGNOSTIC ACCURACY OF AN ESOPHAGEAL SWEEP… (5*) Tu1277. . . . ESOPHAGOGASTRIC JUNCTION OUTFLOW OBSTRUCTION: DETERMINATION OF… (4*) Tu1278. . . . UTILITY OF ESOPHAGEAL DUAL PH SENSORS-IMPEDANCE… (1*) Tu1279. . . . CORRELATION OF NOVEL INFLAMMATORY-NUTRITIONAL BIOMARKERS WITH… (5*) Tu1280. . . . PERFORMING MORE THAN TEN SWALLOWS DURING… (5*) Tu1281. . . . UPPER ESOPHAGEAL SPHINCTER IS HYPOTENSIVE IN… (5*) Tu1282. . . . CLINICAL CHARACTERISTICS AND TREATMENT RESPONSE OF… (5*) Tu1283. . . . ESOPHAGOGASTRIC JUNCTION OUTFLOW OBSTRUCTION ASSOCIATED WITH… (5*) Tu1284. . . . SWALLOW-TO-SWALLOW VARIATION IN ESOPHAGEAL MOTOR PATTERNS… (5*) Tu1285. . . . MANOMETRIC CHARACTERISTICS OF UPPER ESOPHAGEAL SPHINCTER… (2*) Tu1286. . . . DURATION OF SYMPTOMS AND MANOMETRIC PARAMETERS… (5*) Tu1287. . . . ESOPHAGEAL MOTILITY AND ANTI-REFLUX BARRIER FUNCTION… (5*)

Tu1288. . . . THE PREVALENCE OF DISACCHARIDASE DEFICIENCY IN… (5*) Tu1289. . . . PILL ESOPHAGRAM CAN IDENTIFY PEDIATRIC PATIENTS… (5*) Tu1290. . . . RELATIONSHIPS BETWEEN CLINICAL CHARACTERISTICS, TREATMENT, AND… (5*) Tu1291. . . . VARIATIONS IN PRACTICE PATTERNS IN THE… (2*) Tu1292. . . . ABNORMAL 24-HOUR PH-IMPEDANCE TESTING IS NOT… (4*)| Tu1305. . . . ASSOCIATION OF PHENOTYPES OF LOW MUCOSAL… (5*) Tu1306. . . . PREVALENCE OF CANNABINOID USE DISORDER HAS… (5*) Tu1307. . . . PHYSICAL ACTIVITY AND ITS IMPACT ON… (5*) Tu1308. . . . POOR SLEEP QUALITY AND DYSPEPSIA:ITS NOT… (5*) Tu1309. . . . EFFECT OF RIKKUNSHITO ON GASTROINTESTINAL MOTILITY… (3*)|(TSUMURA & CO. (Japan) provided study medication for this trial.) Tu1310. . . . EFFICACY AND SAFETY OF SOYO-SAN FOR… (2*)|(This study was supported by grants from the Korea Evaluation Institute of Industrial Technology (No.10060251, The project of 'Development of the diagnostic device for functiol dyspepsia based on Korean-Western medicine fusion abdomil diagnosis').) Tu1311. . . . ENDOSCOPIC GASTRIC FUNCTION TEST: THE RELATIONSHIP… (4*) Tu1312. . . . CAMOSTAT MESILATE, PANCRELIPASE AND RABEPRAZOLE COMBINATION… (1*) Tu1313. . . . EATING AND PSYCHIATRIC DISORDERS ARE INDEPENDENT… (5*) Tu1314. . . . CLASSIFYING FUNCTIONAL DYSPEPSIA USING A NOVEL… (5*) Tu1315. . . . ACYLATED GHRELIN LEVELS WERE ASSOCIATED WITH… (1*) Tu1316. . . . DOES MEASUREMENT OF SYMPTOMS DURING A… (5*) Tu1318. . . . TOOSENDANIN EXERTS ANTITUMOR ACTIVITY IN GASTRIC… (2*) Tu1319. . . . PREDICTIVE FACTORS OF LYMPH NODE METASTASIS… (5*)

Tu1320. . . . PROGNOSIS OF GASTRIC DYSPLASIA AFTER COMPLETE… (5*) Tu1321. . . . STRATIFICATION OF CT SURVEILLANCE BASED ON… (5*) Tu1323. . . . IMPLICATION OF MOLECULAR SUBTYPE OF GASTRIC… (1*) Tu1324. . . . IMPACT OF AGE ON STAGE-SPECIFIC MORTALITY… (2*) Tu1325. . . . COMPARISON OF GASTRIC CANCER PATIENTS BEFORE… (5*) Tu1326. . . . HIGH PREVALENCE OF DISTANT METASTASIS AND… (4*) Tu1327. . . . RISK FACTORS OF EARLY AND ADVANCED… (1*) Tu1328. . . . OUTCOMES OF GI POLYPS RESECTED USING… (5*) Tu1329. . . . OUTCOMES IN PATIENTS UNDERGOING GASTRECTOMY FOR… (5*) Tu1330. . . . FACTORS ASSOCIATED WITH DEGREE OF DUODENAL… (4*) Tu1331. . . . EMERGENCY PRESENTATIONS FOR GASTROSTOMY COMPLICATIONS IN… (5*) Tu1415. . . . MANAGEMENT OF ACUTE PANCREATITIS IN CHILDREN:… (5*) Tu1416. . . . PROLONGED HYPERAMYLASEMIA IN PATIENTS WITH ACUTE… (5*) Tu1417. . . . ACUTE PANCREATITIS IN PATIENTS WITH CYSTIC… (5*) Tu1418. . . . THE EPIDEMIOLOGY OF ACUTE PANCREATITIS IN… (5*) Tu1419. . . . SAFETY AND EFFICACY OF AN ED… (5*) Tu1420. . . . SAME ADMISSION CHOLECYSTECTOMY FOR MODERATE TO… (5*) Tu1421. . . . MORE ABOUT NPO IN ACUTE PANCREATITIS… (5*) Tu1422. . . . DEVELOPMENT AND VALIDATION OF RISK PREDICTION… (2*) Tu1423. . . . ROLE OF INFLAMMATORY MARKERS IN STEP-UP… (5*) Tu1424. . . . MARKED SERUM LIPASE ELEVATIONS ARE ASSOCIATED… (5*)


* = Primary Source



Tu1425. . . . ARE OPIATE NAIVE PATIENTS WITH ACUTE… (5*) Tu1426. . . . ADMITTING ACUTE PANCREATITIS PATIENTS WHO REQUIRE… (5*) Tu1427. . . . ACUTE PANCREATITIS AND BMI: MORTALITY RATES… (5*) Tu1428. . . . GASTROINTESTINAL FISTULISATION IN WALLED OFF PANCREATIC… (5*) Tu1429. . . . LEFT VENTRICULAR ASSIST DEVICE (LVAD), HEART… (5*) Tu1430. . . . THE PREVALENCE OF VITAMIN D DEFICIENCY,… (5*) Tu1431. . . . FACTORS PREDICTING FAILURE OF PERCUTANEOUS DRAINAGE… (5*)|(Nil) Tu1432. . . . COMPARISON OF OUTCOME IN ACUTE PANCREATITIS… (5*) Tu1433. . . . RISK FACTORS AND INCIDENCE FOR 30-DAY… (5*) Tu1434. . . . TRENDS IN EARLY VS LATE MORTALITY… (5*) Tu1435. . . . MATRIX METALLOPROTEINASES AND THEIR TISSUE INHIBITORS… (4*) Tu1436. . . . OBESITY BUT NOT NAFLD IS A… (5*) Tu1437. . . . DEPLETION OF GRAM-POSITIVE BACTERIA IN THE… (2*) Tu1438. . . . ACCURACY OF ENDOSCOPIC ULTRASOUND TO ASSESS… (5*) Tu1439. . . . GROWTH FACTOR RECEPTOR SIGNALING IN MEN1… (4*) Tu1440. . . . PREOPERATIVE C-REACTIVE PROTEIN/ALBUMIN RATIO PREDICTS CANCERIZATION… (5*) Tu1441. . . . ANALYSIS OF PANCREAS CYST GROWTH RATES… (7*) Tu1442. . . . ASSOCIATION OF DIABETES MELLITUS FOR LONG… (5*) Tu1443. . . . PERFORMANCE CHARACTERISTICS OF DNA ANALYSIS IN… (5*) Tu1444. . . . THE RELATIONSHIP BETWEEN OBSERVATION INTERVAL AND… (5*)

Tu1445. . . . COMPARISON OF ONSITE, GLUCOMETER-MEASURED, CYST FLUID… (5*) Tu1446. . . . CLINICOPATHOLOGICAL FEATURES OF PANCREATIC DUCTAL ADENOCARCINOMA… (5*) Tu1447. . . . EFFICACY OF LUMEN-APPOSING METAL STENT INSERTION… (5*) Tu1448. . . . ALCOHOL-INDUCED EXPERIMENTAL PANCREATITIS: THERAPEUTIC BENEFITS BY… (2*) Tu1449. . . . PIRFENIDONE AMELIORATES WELL-ESTABLISHED CHRONIC PANCREATITIS IN… (2*) Tu1450. . . . COMBINATION OF HEPARANASE INHIBITORS AND ASPIRIN… (5*) Tu1451. . . . CLINICAL CHARACTERISTICS AND OUTCOMES OF IMMUNE… (5*) Tu1452. . . . EPITHELIAL PROLIFERATION OF THE INTRAPANCREATIC DUCTS… (4*) Tu1453. . . . TEDUGLUTIDE AMERIORATES EXTRA-PANCREATIC INFLAMMATION BY REDUCTION… (2*)|(Shire Pharmaceuticals) Tu1454. . . . USEFULNESS OF TRANSABDOMINAL SHEAR WAVE ELASTOGRAPHY… (5*) Tu1455. . . . CARBOXYL ESTER LIPASE DOES NOT MEDIATE… (2*) Tu1456. . . . MORPHINE TREATMENT IN ACUTE PANCREATITIS AFFECTS… (2*) Tu1457. . . . ELEVATED BODY MASS INDEX INCREASES RISK… (5*) Tu1458. . . . IMPACT OF PATIENT’S WEIGHT ON PERFORMING… (5*) Tu1459. . . . A PAIN IN THE GUT: A… (5*) Tu1473. . . . THERAPEUTIC EFFICACY OF CHEMORADIOTHERAPY WITH MIRIPLATIN… (2*) Tu1474. . . . UTILITY OF ENDOSCOPIC ULTRASOUND IN THE… (5*) Tu1475. . . . SYSTEMIC INFLAMMATORY RESPONSE MARKERS AS PROGNOSTIC… (5*) Tu1476. . . . AFATINIB COMBINED WITH GEMCITABINE/CISPLATIN IN CHEMOTHERAPY… (3*)|(Boehringer Ingelheim)

Tu1535. . . . SEX, RACE AND INSURANCE DISPARITIES IN… (5*) Tu1536. . . . ASSESSING THE SURVIVAL OUTCOME RELATIONSHIP BETWEEN… (5*) Tu1537. . . . DEMOGRAPHICS FOR DO-NOT RESUSCITATE STATUS AND… (5*) Tu1538. . . . ETIOLOGY OF CIRRHOSIS CHANGING TRENDS OVER… (5*) Tu1539. . . . PREVALENCE OF LIVER DISEASE IN PATIENTS… (5*) Tu1540. . . . HEPATOBILIARY-SPECIFIC DELETION OF POLYMERIC IMMUNOGLOBULIN RECEPTOR… (6*) Tu1541. . . . VALIDATION OF NON-INVASIVE BIOMARKERS OF LIVER… (2*) Tu1542. . . . THE EFFECT OF LOW-ENERGY EXTRACORPOREAL SHOCK… (5*) Tu1543. . . . REVERSAL OF IMMUNE EXHAUSTION FOLLOWING SVR… (3*)|(The Bristol-Myers Squibb Virology Fellows Research Program for 2015-2017, (EA).) Tu1544. . . . ACCURACY OF NON-INVASIVE TESTS TO DETECT… (5*) Tu1545. . . . SHEAR WAVE ELASTOGRAPHY USE FOR SCREENING… (5*) Tu1546. . . . GPBAR1 IS A MODULATOR OF LIVER… (5*) Tu1547. . . . GAUCHER DISEASE PRESENTING AS NEONATAL CHOLESTASIS… (5*) Tu1548. . . . STATIN-ASSOCIATED AUTOIMMUNE MYOPATHY: AN UNUSUAL CAUSE… (5*) Tu1549. . . . SKYROCKETING LIVER ENZYMES: A REMARKABLE CASE… (5*) Tu1550. . . . INFLAMMATION, ARTERIAL STIFFNESS AND DIRECTLY-ACTING ANTIVIRALS… (4*) Tu1551. . . . HEPATITIS C PATIENTS WITH ADVANCED AGE,… (5*) Tu1552. . . . PREVALENCE OF HEPATITIS E VIRUS INFECTION… (4*)|(5) Tu1553. . . . HEPATITIS B VIRUS PATIENTS WITH MEDICAID… (3*)|(Research funding: Gilead Sciences)


* = Primary Source



Tu1554. . . . HEPATITIS B REACTIVATION IN INDIVIDUALS WITH… (5*) Tu1555. . . . RISKY ALCOHOL CONSUMPTION IS COMMON AMONG… (5*) Tu1593. . . . VIRULENCE PHENOTYPES OF ATYPICAL ENTEROPATHOGENIC ESCHERICHIA… (5*) Tu1594. . . . TETHERED CAPSULE OCT IMAGING OF THE… (6*)| Tu1595. . . . INFLAMMATORY POTENTIAL OF DIET, CIRCULATING INFLAMMATORY… (2*) Tu1596. . . . MULTIPLEX GASTROINTESTINAL PATHOGEN PCR TESTING IN… (5*) Tu1597. . . . THE ROLE OF ANTIBIOTICS IN ACUTE… (5*) Tu1598. . . . EXAMINING THE UTILITY OF GASTROINTESTINAL PATHOGEN… (5*) Tu1599. . . . AQUAPORIN-5 EXPRESSION IS REDUCED IN LYMPHOCYTIC… (4*) Tu1600. . . . AIR OR CARBON DIOXIDE INSUFFLATION IN… (5*) Tu1601. . . . DIARRHEA IN TUBE-FED HOSPITALIZED PATIENTS: FEEDING… (4*) Tu1602. . . . MEASUREMENT OF STRESS AND ANXIETY AND… (7*) Tu1603. . . . GASTROINTESTINAL COMPLICATIONS IN PATIENTS WITH CLOCAL… (5*) Tu1604. . . . EFFICACY AND SAFETY OF ANAL SPHINCTER… (5*) Tu1605. . . . CHRONIC INTESTINAL PSEUDO-OBSTRUCTION IN CHILDREN: EPIDEMIOLOGY… (5*) Tu1606. . . . PREVALENCE OF CHILD ABUSE IN CHILDREN… (5*) Tu1607. . . . SOMATIC AND PSYCHOSOCIAL FACTORS ASSOCIATED WITH… (2*) Tu1608. . . . LONG-TERM FOLLOW-UP OF GUT-DIRECTED HYPNOTERAPY SELF-EXERCISES… (5*) Tu1609. . . . HOW OFTEN DO GASTROENTEROLOGIST'S SCREEN FOR… (5*)

Tu1610. . . . RESILIENCE IN IRRITABLE BOWEL SYNDROME IS… (2*) Tu1611. . . . PSYCHOLOGICAL FLEXIBILITY AS AN IMPORTANT FEATURE… (2*) Tu1612. . . . CENTRALIZED SENSITIVITY PHENOTYPE AS A PREDICTOR… (2*) Tu1613. . . . GLOBAL IBS SYMPTOM IMPROVEMENT IN COGNITIVE-BEHAVIORAL… (2*) Tu1614. . . . VIRTUAL REALITY MINDFULNESS THERAPY REDUCES PAIN… (4*) Tu1615. . . . IS IT ARFID, A GASTROINTESTINAL DISORDER… (5*) Tu1616. . . . INTEGRATED INFLAMMATORY BOWEL DISEASE- BEHAVIORAL MEDICINE… (5*) Tu1617. . . . PREDICTING SUCCESSFUL OUTCOMES OF ANORECTAL BIOFEEDBACK… (5*) Tu1618. . . . PATIENTS WITH FUNCTIONAL GASTROINTESTINAL DISORDERS (FGIDS)… (2*) Tu1619. . . . SELF-PERCEIVED STRESS IS ASSOCIATED WITH CHEST… (5*) Tu1620. . . . WHAT IS COGNITIVE IN/FLEXIBILITY IN IRRITABLE… (4*) Tu1621. . . . ATTENTIONAL BIAS IN PEDIATRIC INFLAMMATORY BOWEL… (4*) Tu1623. . . . EPIDEMIOLOGY OF CYCLIC VOMITING SYNDROME: ANALYSIS… (3*)|(Takeda Pharmaceuticals) Tu1624. . . . SEASONAL VARIATIONS IN THE INCIDENCE AND… (5*) Tu1625. . . . INCIDENCE AND RISK FACTORS OF DIVERTICULITIS… (5*) Tu1626. . . . NATIONAL TRENDS, OUTCOMES AND PREDICTORS OF… (5*) Tu1627. . . . BUDD CHIARI SYNDROME: A STUDY FROM… (5*) Tu1628. . . . SHOULD ORIGINAL RESEARCH BE SHARED ON… (5*) Tu1629. . . . INCREASING BODY MASS INDEX, MALE GENDER,… (5*) Tu1630. . . . HEPATOCELLULAR CARCIOMA INCIDENCE IS DECREASING AMONG… (5*)

Tu1631. . . . CHARACTERIZATION OF SYMPTOMATIC UNCOMPLICATED DIVERTICULAR DISEASE… (4*) Tu1632. . . . ASSOCIATION BETWEEN BOWEL MOVEMENTS AND DIVERTICULITIS… (2*)|(R01 DK101495, K24 DK 098311 and UM1 CA186107 from the tiol Institutes of Health) Tu1633. . . . HIGH PROPORTION OF DIFFUSE TYPE GASTRIC… (5*) Tu1634. . . . THE PREVALENCE OF CARCINOID TUMORS OF… (5*) Tu1635. . . . EPIDEMIOLOGY AND MANAGEMENT OF ACHALASIA IN… (5*) Tu1636. . . . THE USE OF WEB FORUMS DATA… (3*)|(Da Nutricia Research) Tu1637. . . . CARDIAC RISK OF PROKINETICS: A POPULATION-BASED,… (5*) Tu1638. . . . CHANGING TRENDS IN US HOSPITALIZATIONS WITH… (5*) Tu1639. . . . QUANTIFYING RISK FACTORS FOR ISCHEMIC COLITIS:… (5*) Tu1640. . . . A LEFT-TO-RIGHT SHIFT REEVALUATION OF COLORECTAL… (5*) Tu1641. . . . ANALYSIS OF UC COLECTOMY RATES IN… (5*) Tu1642. . . . VALIDATION OF THE BRISTOL STOOL CHART… (2*) Tu1643. . . . RISING INCIDENCE OF SMALL INTESTINAL CANCER… (5*) Tu1644. . . . GASTRIC CANCER SCREENING AT 2 U.S.… (5*) Tu1645. . . . KILLING TWO BIRDS WITH ONE STONE:… (5*) Tu1646. . . . VARIATION IN RURAL COLORECTAL CANCER SCREENING… (6*) Tu1647. . . . STATE-LEVEL HEALTH INSURANCE STATUS IS ASSOCIATED… (5*) Tu1648. . . . LOW YIELD OF ENDOSCOPIC SURVEILLANCE FOR… (5*) Tu1649. . . . GALLBLADDER POLYP IS ASSOCIATED WITH PROXIMAL… (5*) Tu1650. . . . ACCURACY OF ELECTRONIC HEALTH RECORD BILLING… (2*)


* = Primary Source



Tu1651. . . . TELEPHONE COUNSELING INTERVENTION IMPROVES UPTAKE OF… (4*) Tu1652. . . . COLORECTAL CANCER SCREENING AND PATIENT NAVIGATION:… (2*) Tu1653. . . . ACCURACY OF INITIAL RECOMMENDED COLONOSCOPY SURVEILLANCE… (2*) Tu1654. . . . THE EFFECT OF GENDER AND RACE… (5*) Tu1655. . . . THE LONG TERM IMPACT OF ROUX-EN-Y… (5*) Tu1656. . . . GASTRIC CANCER AND GEOGRAPHICAL/ETHNIC SHIFTS IN… (5*) Tu1657. . . . REGIONAL AND RACIAL DISPARITIES IN GASTRIC… (4*) Tu1658. . . . MECKEL’S DIVERTICULUM- A NIDUS FOR ILEAL… (4*) Tu1659. . . . ENDOMETRIAL POLYPS ARE MORE LIKELY TO… (2*) Tu1660. . . . INCREASING INPATIENT ADMISSIONS, COSTS, AND MORTALITY… (5*) Tu1661. . . . PREVALENCE, IN-HOSPITAL OUTCOMES AND RESOURCE UTILIZATION… (5*) Tu1662. . . . THE EPIDEMIOLOGY OF GASTRIC CANCER IN… (5*) Tu1663. . . . ANATOMICAL DISTRIBUTION OF GASTRIC CANCER IN… (5*) Tu1664. . . . DOES THE GEOGRAPHIC DISTRIBUTION OF THE… (5*) Tu1665. . . . TRISOMY 21 DOES NOT INCREASE THE… (5*) Tu1666. . . . ANALYSIS OF THE ASSOCIATION BETWEEN POVERTY… (5*) Tu1667. . . . RACIAL/ETHNIC DISPARITIES IN GASTRIC CANCER INCIDENCE,… (5*) Tu1668. . . . WHAT IS THE PREVALENCE OF SERRATED… (2*) Tu1669. . . . CHROMOENDOSCOPY LEADS TO A HIGHER INSIGHT-STAGE… (4*) Tu1670. . . . EXOGENOUS AND ENDOGENOUS ASSOCIATED FACTORS TO… (5*)

Tu1671. . . . SMALL BOWEL NEOPLASIA DETECTION IN LYNCH… (5*) Tu1672. . . . PREVALENCE OF GENE MUTATIONS IN PATIENTS… (4*) Tu1673. . . . SINGLE-GENE VS. MULTI-GENE PANEL TESTING IN… (5*) Tu1691. . . . PLATINUM BASED THERAPY IN PATIENTS WITH… (5*) Tu1692. . . . CLINICAL CHARACTERISTICS OF TAXANE-BASED CHEMOTHERAPY-INDUCED COLITIS… (5*) Tu1693. . . . POTENTIATION OF CALCIUM-ACTIVATED CHLORIDE SECRETION AND… (4*) Tu1694. . . . CLINICAL FEATURES OF RITUXIMAB-INDUCED GASTROINTESTINAL TOXICITIES… (5*) Tu1695. . . . ANTI-ANGIOGENESIS CANCER THERAPY-RELATED GASTROINTESTINAL INJURY CAN… (5*) Tu1696. . . . NEUTROPENIC COLITIS - CLINICAL FEATURES, TREATMENT… (5*) Tu1697. . . . COMPARISON OF RISK FACTORS BETWEEN INTESTINAL… (5*) Tu1698. . . . FLUOROPYRIMIDINE-INDUCED INTESTINAL MUCOSAL INJURY IS ASSOCIATED… (1*) Tu1699. . . . BIFIDOBACTERIUM ANIMALIS SUBSPECIES LACTIS ENGINEERED TO… (5*) Tu1700. . . . ANTI-INFLAMMATORY AND ANTI-OXIDATIVE EFFECTS OF 17-β… (5*) Tu1701. . . . EFFECTS OF 17β-ESTRADIOL ON COLORECTAL CANCER… (5*) Tu1702. . . . ELEVATED O-GLCNACYLATION INCREASES FOXM1 PROTEIN VIA… (4*) Tu1703. . . . CYSTATHIONINE-GAMMA-LYASE EXPRESSING BONE MARROW-DERIVED CELLS INHIBIT… (2*) Tu1704. . . . THE PREVELANCE OF PRIMARY MALIGNANT NEOPLASM… (5*) Tu1705. . . . COLONOSCOPY IS INDICATED AFTER AN EPISODE… (5*) Tu1706. . . . EARLY ENDOSCOPIC EVALUATION ASSOCIATED WITH SHORTER… (5*) Tu1707. . . . PATIENT REPORTED MEASURES OF HEALTH STATUS… (3*)|(This

study was conducted with unrestricted funding from Celgene Corporation.) Tu1708. . . . EARLY CHILDHOOD INFLAMMATORY BOWEL DISEASE IS… (2*) Tu1710. . . . USTEKINUMAB TO TREAT PEDIATRIC PATIENTS WITH… (2*) Tu1711. . . . EXTENDED TREATMENT WITH MIRIKIZUMAB IN PATIENTS… (3*)|(Eli Lilly and Company) Tu1712. . . . REDUCTION IN INFLAMMATORY BIOMARKERS IN A… (3*)|(Eli Lilly and Company) Tu1713. . . . EFFICACY AND SAFETY OF 2 OR… (3*)|(Takeda) Tu1714. . . . IMPACT OF UPADACITINIB ON THE GENERAL… (3*)|(AbbVie funded the study, contributed to its design, and was involved in the collection, alysis, and interpretation of the data, and in the writing, review, and approval of the publication. Medical writing support was provided by Maria Hovenden, PhD, Compl) Tu1715. . . . A NOVEL FORMULATION OF CT-P13 (INFLIXIMAB… (3*) Tu1716. . . . HIGHLY BIOAVAILABLE CURCUMIN (THERACURMIN®) FOR CROHN’S… (5*) Tu1717. . . . TOFACITINIB FOR THE TREATMENT OF ULCERATIVE… (3*)|(Pfizer Inc) Tu1718. . . . IMMUNOGENICITY OF USTEKINUMAB IN PATIENTS WITH… (3*)|(This study was funded by Janssen Research & Development, LLC) Tu1719. . . . CLINICAL REMISSION BY LEGACY VERSUS FDA… (3*)|(This study was funded by Janssen Research & Development, LLC) Tu1720. . . . EFFICACY OF TOFACITINIB MAINTENANCE THERAPY FOR… (3*)|(Pfizer Inc) Tu1721. . . . MAINTENANCE OF EFFICACY FOLLOWING TOFACITINIB DOSE… (3*)|(Pfizer Inc) Tu1722. . . . DARVADSTROCEL TREATMENT OUTCOMES IN CROHN'S DISEASE… (3*)|(Takeda Pharmaceutical Company) Tu1723. . . . IDENTIFICATION OF RISK FACTORS ASSOCIATED WITH… (3*)|(This study was funded by Janssen Research & Development, LLC)


* = Primary Source



Tu1724. . . . ASSOCIATION OF USTEKINUMAB SERUM CONCENTRATIONS AND… (3*)|(Janssen Research & Development, LLC funded this study.) Tu1725. . . . CHARACTERIZATION OF PATIENTS WITH DELAYED RESPONSE… (3*)|(This study was funded by Janssen Research & Development, LLC) Tu1726. . . . THE IMPACT OF EARLY DISEASE CONTROL… (3*)|(Takeda) Tu1727. . . . RAPIDITY OF SYMPTOMATIC AND INFLAMMATORY BIOMARKER… (3*)|(The authors and AbbVie scientists designed the study, and alysed and interpreted the data. AbbVie funded the research and provided writing support. All authors contributed to the development of the content. The authors and AbbVie reviewed and approved the) Tu1728. . . . LONG-TERM EFFICACY AND PHARMACODYNAMICS OF THE… (3*)|(The OPERA II study was funded by Pfizer. These alyses were funded by Pfizer and Shire. Medical writing support was provided by Emma Saxon PhD of PharmaGenesis London and funded by Shire.) Tu1729. . . . LONG-TERM EFFICACY OF TOFACITINIB IN PATIENTS… (3*)|(Pfizer Inc) Tu1730. . . . IMPROVEMENT IN PATIENT-REPORTED INFLAMMATORY BOWEL DISEASE… (3*)|(Pfizer Inc) Tu1731. . . . EARLY HISTOLOGIC IMPROVEMENT DEMONSTRATED WITH ORAL… (3*)|(This study is sponsored by Celgene Corporation.) Tu1732. . . . CHANGES IN SIMPLIFIED ENDOSCOPIC SCORE FOR… (3*)|(AbbVie funded the study, contributed to its design, and was involved in the collection, alysis, and interpretation of the data, and in the writing, review, and approval of the publication. Medical writing support was provided by Maria Hovenden, PhD, Compl) Tu1733. . . . CLINICAL REMISSION DEMONSTRATED WITH ORAL OZANIMOD… (3*)|(This study is sponsored by Celgene Corporation.) Tu1734. . . . EFFECT OF VEDOLIZUMAB ON SURGICAL RATES… (3*)|(Takeda Pharmaceuticals U.S.A., Inc.) Tu1735. . . . EFFECTS OF USTEKINUMAB INDUCTION THERAPY ON… (3*)|(This study

was funded by Janssen Research & Development, LLC) Tu1736. . . . MOLECULAR RESPONSE TO USTEKINUMAB IN MODERATE-TO-SEVERE… (3*)|(This study was funded by Janssen Research & Development, LLC) Tu1737. . . . EFFICACY OF THE ANTI-MUCOSAL ADDRESSIN CELL… (3*)|(The TURANDOT II study was funded by Pfizer and Shire. These alyses were funded by Shire. Medical writing support was provided by PharmaGenesis London and funded by Shire.) Tu1738. . . . BIOMARKER AND PHARMACOKINETIC DATA FROM THE… (3*)|(The TURANDOT II study was funded by Pfizer and Shire. These alyses were funded by Shire. Medical writing support was provided by PharmaGenesis London and funded by Shire.) Tu1739. . . . EFFICACY AND SAFETY OF USTEKINUMAB THROUGH… (3*)|(This study was funded by Janssen Research & Development, LLC) Tu1740. . . . SUSTAINED REMISSION IN PATIENTS WITH MODERATE… (3*)|(The study was funded by Janssen Research & Development, LLC) Tu1741. . . . A NOVEL ORAL FORMULATION OF BUDESONIDE… (3*)|(Dr. Falk Pharma GmbH) Tu1742. . . . LONG-TERM IMMUNOGENICITY OF INTRAVENOUS VEDOLIZUMAB IN… (3*)|(Takeda) Tu1743. . . . IV IRON TREATMENT OF IRON DEFICIENCY… (3*)|(AMAG Pharmaceuticals, Inc.) Tu1744. . . . TARGETED RELEASE ORAL CYCLOSPORINE (ST-0529) AS… (3*) Tu1745. . . . CORRELATION OF FECAL CALPROTECTIN AND C-REACTIVE… (3*)|(Are Pharmaceuticals, Inc.) Tu1746. . . . A PHASE 3 STUDY OF VEDOLIZUMAB… (3*)|(Takeda Pharmaceutical Company, Ltd.) Tu1747. . . . EFFECT OF TELEMEDICINE FOR INFLAMMATORY BOWEL… (2*)|(This research was supported by the Agency for Healthcare Research and Quality (1R01HS018975-01A1) and the University of Maryland General Clinical Research Centers Program. Zaid Bilgrami was supported by the Program for Research Initiated by Students and)

Tu1748. . . . ORAL CURCUMIN IS NOT MORE EFFECTIVE… (2*) Tu1749. . . . PHARMACOKINETICS AND EXPOSURE-RESPONSE RELATIONSHIPS OF INTRAVENOUSLY… (3*)|(This study was funded by Janssen Research & Development, LLC) Tu1750. . . . NOVEL RIFAMYCIN SV MULTI-MATRIX FORMULATION FOR… (3*)|(Clinical study was funded by Dr. Falk Pharma GmbH.) Tu1751. . . . THE EFFECT OF REMOTE ISCHEMIC CONDITIONING… (3*)|(Novo Nordisk Foundation) Tu1752. . . . ANALYSIS OF HEMATOLOGICAL CHANGES IN TOFACITINIB-TREATED… (3*)|(Pfizer Inc) Tu1753. . . . ANALYSIS OF THE IMPACT OF BODY… (3*)|(Pfizer Inc) Tu1754. . . . SAFETY AND TOLERABILITY OF BT-11, A… (3*)|(Study was funded by Landos Biopharma, Inc.) Tu1755. . . . EFFICACY OF COMBINATION THERAPY OF FECAL… (2*) Tu1756. . . . THE TREATMENT NAIVE RECTAL TRANSCRIPTOME IDENTIFIES… (2*) Tu1757. . . . FUNCTIONAL REGULATORY ANNOTATION OF FINE-MAPPED IBD… (2*) Tu1758. . . . INFLAMMATORY BOWEL DISEASE TRANSCRIPTOMES REVEAL REDUCED… (4*) Tu1759. . . . NEW METHYLATION BIOMARKER PANEL OF INFLAMMATORY… (5*) Tu1760. . . . ALTERATIONS IN EXPRESSION QUANTITATIVE TRAIT LOCI… (2*) Tu1761. . . . POLYGENIC RISK SCORES ARE ASSOCIATED WITH… (2*) Tu1762. . . . GENETIC BACKGROUND OF THIOPURINE-INDUCED PANCREATITIS IN… (2*) Tu1763. . . . SYSTEMIC AND TISSUE MODULATION OF IL-23… (3*)|(Boehringer Ingelheim and AbbVie funded the study and research. AbbVie provided medical writing support. All authors contributed to the development of the content. The authors and AbbVie reviewed and approved the abstract. The authors maintained control ov)


* = Primary Source



Tu1764. . . . INHIBITION OF MYELOID DIFFERENTIATION 1 SPECIFICALLY… (2*) Tu1765. . . . HISTONE 3 LYSINE 27 ACETYLATION PROFILING… (2*) Tu1766. . . . DYSREGULATED LNCRNAS IN INFLAMMATORY BOWEL DISEASE… (2*) Tu1767. . . . MULTI-ALLELES POLYMORPHISMS PREDICT PRIMARY NON-RESPONSE TO… (5*) Tu1768. . . . IDENTIFYING MOLECULAR FEATURES CONTRIBUTING TO DISEASE… (4*) Tu1769. . . . DNA METHYLATION SIGNATURES IN CROHN’S DISEASE-RELATED… (2*) Tu1770. . . . TLR7 AGONIST INDUCED DERMATITIS EXACERBATED COLITIS… (2*)|(This work is supported by the Yakult bio science foundation. Author was the employee of Takeda pharm. Co-author was the employee of Miyarisan, Tabe mitsubishi, Ezaki pharm.) Tu1771. . . . PRENATAL MATERNAL STRESS INDUCES GUT DYSBIOSIS… (5*) Tu1772. . . . ‘INDIGO NATURALIS’ AMELIORATES ULCERATIVE COLITIS VIA… (5*) Tu1773. . . . CHARACTERISTICS AND PATHOGENIC ROLE OF ADHERENT-INVASIVE… (2*) Tu1774. . . . MICROBIOME FUNCTIONALGENOMICS REVEALS NOVEL BACTERIAL STRAINS… (3*)|(Biomica Ltd. Rehovot, Israel, www.biomicamed.com) Tu1775. . . . THE NOD2 ASSOCIATION WITH CD-ASSOCIATED SEROLOGICAL… (2*) Tu1776. . . . CLOSTRIDIUM DIFFICILE DIAGNOSIS BY TOXIN ENZYME… (5*) Tu1777. . . . THE GUT MICROBIOME MODULATES COLORECTAL TUMORIGENESIS… (2*)| Tu1778. . . . THE GUT MICROBIAL PROFILE OF PRECLINICAL… (4*) Tu1779. . . . CINNAMON EXTRACT AMELIORATES EXPERIMENTAL COLITIS VIA… (4*) Tu1780. . . . DIETARY WHEAT AMYLASE TRYPSIN INHIBITORS MODIFY… (2*)

Tu1781. . . . SEASONAL VARIATION OF FECAL MICROBIOTA IN… (1*) Tu1782. . . . COMPOSITIONAL CHANGES IN THE GUT MICROBIOTA… (2*) Tu1783. . . . IN VITRO EFFECTS OF XYLO-OLIGOSACCHARIDE ON… (2*) Tu1784. . . . ABNORMALITIES IN THE FECAL MICROBIOME OF… (4*) Tu1785. . . . EB8018 IS ABLE TO DECREASE TNFα… (3*)|(ENTEROME S.A.) Tu1786|BSQS5. . . . CHARACTERIZATION OF THE FISTULA-ASSOCIATED MICROBIOME IN… (4*)|(The Tobacco Formula grant is under the Commonwealth Universal Research Enhancement (C.U.R.E) program with the grant number SAP # 4100068710.) Tu1787. . . . POTENTIAL PROTECTIVE EFFECT OF PD-1 INHIBITOR… (5*) Tu1788. . . . COMPLETE ENGRAFTMENT OF THE HUMAN GUT… (2*) Tu1789. . . . TREATMENT RESPONSE TO USTEKINUMAB AND VEDOLIZUMAB… (5*) Tu1790. . . . BACTERIA DERIVED TRYPTAMINE PRODUCTION ALTERS HOST… (2*) Tu1791. . . . INSIGHTS INTO ALTERATION OF GUT MICROBIOTA… (4*) Tu1792. . . . GUT MICROBIOME DIVERSITY IN ACUTE SEVERE… (2*) Tu1793. . . . EUKARYOTIC MICROBIAL DYSBIOSIS IN TREATMENT-NAÏVE PATIENTS… (6*)|(This work was supported by the Leo M. and Harry B. Helmsley Charitable Trust) Tu1794. . . . ADHERENT-INVASIVE ESCHERICHIA COLI COLONIZATION PROMOTES INTESTINAL… (2*) Tu1795. . . . CHANGES IN SMALL INTESTINAL MICROBIOME DURING… (4*) Tu1796. . . . MANAGEMENT OF INFLAMMATORY BOWEL DISEASE PATIENTS… (2*)|(Promoting Access and Care through Centers of Excellence (PACE) Network, Crohn's and Colitis Cada.) Tu1797. . . . HERPES ZOSTER VIRUS IN INFLAMMATORY BOWEL… (5*) Tu1798. . . . LOW MOLECULAR WEIGHT HEPARIN (LMWH) COMPARED… (5*)

Tu1799. . . . A NATIONAL, RETROSPECTIVE, OBSERVATIONAL STUDY ON… (3*)|(Ferring Pharmaceuticals) Tu1800. . . . A PROSPECTIVE MULTICENTER OBSERVATIONAL COHORT STUDY… (3*)|(This study is supported by Ferring Pharmaceuticals.) Tu1801. . . . PRESCRIBING PATTERNS AND LONG-TERM CONTINUATION RATES… (5*) Tu1802. . . . PERCEIVED QUALITY OF CARE IS ASSOCIATED… (1*)|(The study was supported by the McGill CAS Research Support Program, the Kimberly Sue McGall Award in IBD Research and the Nesbitt-McMaster Award and the WI230654 Pfizer unrestricted research grant.) Tu1803. . . . IDENTIFICATION OF PATIENTS WITH INFLAMMATORY BOWEL… (6*) Tu1804. . . . EFFECTIVENESS OF A REMOTE PATIENT MONITORING… (3*)|(Abbvie Cada) Tu1805. . . . REGIONAL IBD SURVEILLANCE ENDOSCOPY NORTH WEST… (6*) Tu1806. . . . KNOWLEDGE AND ATTITUDES TOWARDS PREGNANCY IN… (5*) Tu1807. . . . THE COMPARISON OF DISEASE-RELATED KNOWLEDGE OF… (5*) Tu1808. . . . SIGNIFICANT REDUCTION OF ADMISSION TIME AT… (5*) Tu1809. . . . INFREQUENT COUNSELING BY PHYSICIANS ON IBD… (5*) Tu1810. . . . FRAGILITY INDEX OF RANDOMIZED CONTROLLED TRIALS… (5*) Tu1811. . . . THE CONCERT INITIATIVE: IMPROVING COMMUNITY CARE… (3*)|(Financial support for this study is being provided by AbbVie; AbbVie participated in the design of the study and approval of the abstract; all authors contributed to the development of the abstract and maintained control over the fil content.) Tu1812. . . . USE OF ADVANCED PRACTICE NURSING TO… (5*) Tu1813. . . . WHAT ARE THE MOST CHALLENGING ASPECTS… (5*) Tu1814. . . . INFLAMMATORY BOWEL DISEASE, THE EMERGENCY DEPARTMENT,… (5*)


* = Primary Source



Tu1815. . . . CONCENTRATION OF INFLIXIMAB IN THE NON-INFLAMED… (2*)|(This study was partly supported by AMED (Japan Agency for MedicalResearch and Development) (J160705148).) Tu1816. . . . COMBINATION OF BIOMARKERS REFLECTING TYPE IV… (5*) Tu1817. . . . INCREASING SUBCUTANEOUS FAT AND WEIGHT ARE… (2*) Tu1818. . . . ULTRA-PROACTIVE THERAPEUTIC DRUG MONITORING INCORPORATING INFLIXIMAB… (5*)|(Mundipharma) Tu1819. . . . SERUM MARKER PANEL FOR DETECTION OF… (3*)|(Kepler Diagnostics, Inc. purchased all alyzed ELISA kits) Tu1820. . . . PROACTIVE INFLIXIMAB DRUG MONITORING IS SUPERIOR… (5*) Tu1821. . . . PHARMACOKINETIC AND PHARMACODYNAMIC EVALUATION OF RADIOLOGICAL… (5*) Tu1822. . . . IFX SERUM LEVELS AT TROUGH DO… (5*) Tu1823. . . . THERAPEUTIC DRUG MONITORING-BASED OPTIMIZATION SHOULD BE… (5*) Tu1824. . . . TROUGH LEVELS OF INFLIXIMAB BETTER CORRELATE… (5*) Tu1825. . . . USTEKINUMAB THERAPEUTIC DRUG MONITORING IN CROHN’S… (5*) Tu1826. . . . EVALUATION OF PREDICTORS OF DURABLE CLINICAL… (5*) Tu1827. . . . MAINTENANCE LEVELS OF VEDOLIZUMAB DO NOT… (4*)|(Prometheus Laboratories) Tu1828. . . . ENHANCING UTILIZATION OF THERAPEUTIC DRUG MONITORING… (2*)| Tu1829. . . . COMPARISON OF SERUM CONCENTRATIONS OF USTEKINUMAB… (5*) Tu1830. . . . INFLIXIMAB AND ADALIMUMAB CONCENTRATIONS MAY VARY… (3*)|(This study was funded by Inform Diagnostics.) Tu1831. . . . USE OF DRUG-TOLERANT ASSAYS IN INFLAMMATORY… (3*)|(Prometheus Laboratories (who performed the drug/antibody assays))

Tu1832. . . . ASSOCIATION OF VEDOLIZUMAB LEVELS WITH CLINICAL… (5*) Tu1833. . . . WEEK 2 ADALIMUMAB LEVEL PREDICTS SHORT-TERM… (5*) Tu1834. . . . A PROTOCOL FOR SAFE REINTRODUCTION OF… (5*) Tu1835. . . . ASSOCIATION BETWEEN VEDOLIZUMAB TROUGH CONCENTRATION AND… (5*) Tu1836. . . . INFLIXIMAB TROUGH LEVELS ARE NOT PREDICTIVE… (2*) Tu1837. . . . DEVELOPING A NOVEL MEDICATION ADHERENCE INDEX… (5*) Tu1838. . . . DOES SWITCHING BETWEEN 5-AMINOSALICYLATES AFFECT THIOPURINE… (5*) Tu1839. . . . IMPACT OF USTEKINUMAB TDM ON CLINICAL… (3*) Tu1840. . . . LOW DRUG LEVELS DURING INFLIXIMAB MAINTENANCE… (5*) Tu1841. . . . COMPARATIVE ANALYSIS OF BLOOD AND MUCOSAL… (4*) Tu1842. . . . NOVEL POPULATION SUBSETS OF TCRΒHI TH17,… (5*) Tu1843. . . . ACETYLCHOLINE SECRETING T-CELLS CONTRIBUTE TO INNATE… (3*)|(Galvani Bioelectronics unrestricted research grant) Tu1844. . . . DETERMINING PREDICTORS OF GASTROINTESTINAL DISEASE IN… (5*) Tu1845. . . . IDENTIFICATION OF A UNIQUE POPULATION OF… (4*)|(This work was supported by the Gatorade Trust through funds distributed by the University of Florida, Department of Medicine.) Tu1846. . . . HIGHER TNFα AND MIP-1β EXPRESSION IN… (4*) Tu1847. . . . UREASE-POSITIVE PROTEOBACTERIA IN CROHN'S DISEASE IDENTIFIED… (6*) Tu1848. . . . ESCHERICHIA COLI SIDEROPHORE PRODUCTION INDUCES INTESTINAL… (2*) Tu1849. . . . ROSEBURIA INTESTINALIS FLAGELLIN ALLEVIATES EXPERIMENTAL COLITIS… (2*)

Tu1850. . . . ADHERENT-INVASIVE ESCHERICHIA COLI IN INFLAMMATORY BOWEL… (2*) Tu1851. . . . STUDY ON THE INFLAMMATORY MECHANISMS OF… (2*) Tu1852. . . . METFORMIN AMELIORATED INFLAMMATORY BOWEL DISEASE BY… (2*) Tu1853. . . . FAECALIBACTERIUM PRAUSNITZII PRODUCES BUTYRATE TO DECREASE… (2*) Tu1854. . . . ASSOCIATION BETWEEN QPCR ASSAYS TARGETING FIMS/FIMH… (3*)|(Enterome was the sponsor of the study) Tu1855. . . . MICROBIOTA EXPOSURE IN EARLY LIFE IMPACTS… (2*) Tu1856. . . . THE SIDEROPHORE YERSINIABACTIN POTENTIATES INFLAMMATORY BOWEL… (4*) Tu1857. . . . NEONATAL SUPPLEMENTATION WITH A LACTOBACILLUS RHAMNOSUS… (2*) Tu1858. . . . SEGMENTED FILAMENTOUS BACTERIA INDUCE ALTERNATIVE TH17… (2*) Tu1859. . . . ALTERING DIETARY FERMENTABLE CARBOHYDRATE (FODMAP) CONTENT… (2*) Tu1860. . . . THE OCCURRENCE OF UPPER GASTROINTESTINAL DISEASE… (5*) Tu1861. . . . UNIDENTIFIED COCCOID BACTERIA (UCB) ARE ASSOCIATED… (5*) Tu1862. . . . HISTAMINE IS IMPORTANT FOR MACROPHAGES ACTIVITIES… (2*) Tu1863. . . . DIFFERENCES AMONG LUMINAL AND MUCOSAL MICROBIOTA… (4*) Tu1867. . . . LNCRNAS TARGETED BY ENTERIC BACTERIAL INFECTION… (2*) Tu1868. . . . THERAPEUTIC FECAL MICROBIOTA TRANSPLANTATION CONTROLS INTESTINAL… (6*) Tu1869. . . . CHARACTERIZATION OF CROHN'S DISEASE MUCOSA-ASSOCIATED MICROBIOTA… (6*) Tu1870. . . . ENDOBARRIER® IMPLANTATION IS ASSOCIATED WITH MARKED… (2*)|(NIDDK rO1 21769 NIDDK rO1 29867)


* = Primary Source



Tu1871. . . . THE ASSOCIATION BETWEEN ANTIBIOTICS EXPOSURE DURING… (4*) Tu1872. . . . THE HUMAN INTESTINAL PROTEOME IN CHILDREN… (7*) Tu1873. . . . BOWEL CLEANSING MAY AFFECT DIAGNOSTIC YIELD… (5*) Tu1874. . . . DETECTION OF ENTERIC INFECTIONS IN THE… (5*) Tu1875. . . . CHRONIC ANTIBIOTIC USE AND SUBSEQUENT DEVELOPMENT… (2*) Tu1876. . . . FECAL MICROBIOTA TRANSPLANTATION FOR IMMUNE CHECKPOINT… (4*) Tu1877. . . . FECAL MICROBIOTA TRANSPLANTATION (FMT) FOR IRRITABLE… (5*) Tu1878. . . . FECAL MICROBIOTA TRANSPLANTATION (FMT) IN IRRITABLE… (5*) Tu1879. . . . RAPID AND DURABLE ENGRAFTMENT OF DONOR… (4*)|(the funding source from Gut Microbiome Research Center provided by the Faculty of Medicine, The Chinese University of Hong Kong) Tu1880. . . . DURABLE FREEDOM FROM CLOSTRIDIUM DIFFICILE INFECTION… (3*)|(This alysis was funded by Rebiotix Inc., Roseville, MN, USA.) Tu1881. . . . ECONOMIC EVALUATION OF A FECAL MICROBIOTA… (4*) Tu1882. . . . FECAL VIRUS-LIKE PARTICLES REDUCE BACTERIAL DENSITY… (6*) Tu1883. . . . SELECTIVE MICROBIOTA TRANSPLANTATION INDUCES RADIATION PROCTITIS… (1*)| Tu1884. . . . PRE-TREAT WITH FAECALIBACTERIUM PRAUSNITZII PREVENT THE… (2*) Tu1885. . . . PROTECTIVE EFFECT OF SMT (SELECTIVE MICROBIOTA… (2*) Tu1886. . . . COMMENSAL DERIVED BIOPRODUCTS CONTRIBUTE TO MODULATE… (2*) Tu1887. . . . PATIENTS WITH APPENDECTOMY HAVE SIGNIFICANTLY LESS… (4*)

Tu1888. . . . THE UTILITY OF MULTIPLEX GI PCR… (5*) Tu1889. . . . THE PROTECTIVE ANTIMICROBIAL ACTIVITY OF VSL#3… (5*) Tu1890. . . . GASTRIC MICROBIOTA IN HELICOBACTER PYLORI-NEGATIVE AND… (2*)| Tu1891. . . . AUTOMATED MOLECULAR DETECTION OF HELICOBACTER PYLORI… (3*)|(This study was funded by AutoGenomics inc.) Tu1892. . . . COMPARISON OF HIGH AND LOW MOLECULAR… (2*)|(Small Grant Exploratory Research, korea) Tu1893. . . . SPANISH SPECIALYST CARE SURVEY ON THE… (3*)|(Laboratorios Casen Recordati, Spain.) Tu1894. . . . COLONIC MUCOSAL MICROBIOME IS ASSOCIATED WITH… (4*) Tu1895. . . . COLONIC MUCOSAL MICROBIOME CORRELATES WITH DIETARY… (2*) Tu1896. . . . ASTAXANTHIN ATTENUATED INTESTINAL HYPERMOTILITY INDUCED BY… (2*) Tu1897. . . . ENTERIC METHANE OR HYDROGEN PRODUCTION IN… (2*) Tu1898. . . . A COMPARISON OF PATIENTS WITH UNEXPLAINED… (2*) Tu1899. . . . MICROBIAL FECALIZATION OF THE SMALL INTESTINE… (2*)|(NIDDK r01 21769 NIDDK r01 29867) Tu1900. . . . DOSE RESPONSE FOR ARGON PLASMA COAGULATION… (5*) Tu1901. . . . LOW FREQUENCY VAGAL NERVE STIMULATION USING… (2*) Tu1902. . . . PROSPECTIVE STUDY INVESTIGATING CHANGES IN GASTRIC… (2*) Tu1903. . . . A COMPARISON OF GASTRIC PLICATION ALONE… (5*) Tu1904. . . . BARIATRIC SURGERY IS ASSOCIATED WITH INCREASED… (5*) Tu1905. . . . CHANGES IN METABOLIC AND INFLAMMATORY BIOMARKERS… (5*) Tu1906. . . . 30 DAY READMISSION AFTER ROUX-EN Y… (5*)

Tu1907. . . . LIVER FIBROSIS STAGE AT BASELINE PREDICTS… (2*) Tu1908. . . . EFFICACY OF PHARMACOTHERAPY IN THE TREATMENT… (5*) Tu1909. . . . ROUX-EN-Y GASTRIC BYPASS IMPROVES ESOPHAGEAL SYMPTOMS… (5*) Tu1910. . . . ESOPHAGITIS AFTER BARIATRIC SURGERY: LARGE CROSS-SECTIONAL… (4*) Tu1911. . . . BARIATRIC SURGERY IS ASSOCIATED WITH REDUCED… (5*) Tu1912. . . . WEIGHT LOSS AND METABOLIC IMPROVEMENTS ONE… (2*)|(GI Dymics provided training for the clinical staff.) Tu1913. . . . ‘TO DELAY OR NOT TO DELAY:… (5*) Tu1914. . . . BODY COMPOSITION AS FOLLOW UP OF… (5*) Tu1915. . . . FEASIBILITY OF SERUM LIPIDOMICS AND FECAL… (2*) Tu1916. . . . ASSESSMENT OF NOVEL PLICATION TECHNIQUE IN… (5*) Tu1917. . . . IMPACTS OF LIRAGLUTIDE USE IN WEIGHT… (5*) Tu1918. . . . SEVERE NUTRITIONAL COMPLICATIONS AFTER BARIATRIC SURGERY… (4*) Tu1919. . . . COMPLIANCE WITH EARLY POST-OPERATIVE FOLLOW-UP REDUCES… (4*) Tu1920. . . . CHANGES IN QUALITY OF LIFE, BODY… (5*) Tu2026. . . . MIR-23B-3P PROMOTES CARCINOGENICITY THROUGH PETN/PI3K/AKT PATHWAY… (2*) Tu2027. . . . GREATER LINE-1 HYPOMETHYLATION IN TUBULAR ADENOMAS… (4*) Tu2028. . . . IDENTIFICATION OF 5-FLUOROURACIL (5-FU) RESISTANCE-RELATED MICRORNA… (4*)|(5) Tu2029. . . . ESOPHAGEAL ADENOCARCINOMA WITH INTESTINAL METAPLASIA PHENOTYPE… (5*) Tu2030. . . . NOVEL CIRCULAR RNA NF1 ACTS AS… (2*)


* = Primary Source



Tu2031. . . . ITGBL1 PROMOTES EPITHELIAL-MESENCHYMAL TRANSITION VIA THE… (4*) Tu2032. . . . ADDITION OF PRESERVATIVE BUFFER IMPROVES DNA… (4*)|(Exact Sciences The Champions for Hope Foundation Florida Pancreatic Cancer Coalition) Tu2033. . . . QUANTITATION OF METHYLATION LOAD OF TUMOR… (2*) Tu2034. . . . FACTORS ASSOCIATED WITH PATHOLOGICAL COMPLETE RESPONSE… (4*) Tu2035. . . . NEUROTENSIN PROMOTES EPITHELIAL-MESENCHYMAL TRANSFORMATION VIA ERK… (2*) Tu2036. . . . A PATIENT SELF-MADE ONE STEP QUICK… (5*) Tu2037. . . . NOVEL GENOMIC ANALYSIS OF CENTRAL AMERICA… (2*) Tu2038. . . . LAPAROSCOPY-ASSISTED VERSUS ENTEROSCOPY-ASSISTED ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY… (5*) Tu2039. . . . GASTRIC PERORAL ENDOSCOPIC PYLOROMYOTOMY (G-POEM) FOR… (5*) Tu2040. . . . PROSPECTIVE ASSESSMENT OF THE USE OF… (5*) Tu2041. . . . THE OUTCOME OF ENDOSCOPIC MUCOSAL RESECTION… (5*) Tu2042. . . . INVESTIGATION OF POLYETHYLENE GLYCOL RECOVERY RATE… (5*) Tu2043. . . . EFFICACY AND SAFETY OF PERCUTANEOUS RENDEZ-VOUS… (5*) Tu2044. . . . SMALL BOWEL PREPARATION PRIOR TO VIDEO… (5*) Tu2045. . . . EFFICACY AND SAFETY OF NOVEL, DISPOSABLE… (5*) Tu2046. . . . CHOLEDOCHOSCOPE WITH STENT PLACEMENT FOR TREATMENT… (5*) Tu2047. . . . A TRANSNASAL IMAGING TUBE FOR UNSEDATED… (4*) Tu2051. . . . CANDIDATE AND EXPLORATORY GENETIC ASSOCIATION STUDY… (2*)

Tu2052. . . . POTENTIAL NOVEL SEROLOGICAL MICRO-RNA MARKERS OF… (4*) Tu2053. . . . INFLAMMATORY BOWEL DISEASE IN CYSTIC FIBROSIS:… (5*) Tu2054. . . . ACUTE PANCREATITIS IN PATIENTS WITH DOWN… (4*)|(5) Tu2055. . . . CHARACTERIZATION OF GASTROINTESTINAL SYMPTOMS IN FABRY… (3*)|(Sanofi Genzyme) Tu2056. . . . THE IMPACT OF METABOLIC SYNDROME (MS)… (5*)

Documents

Abstract Funding Sources* AGA Oral and Poster ... · Abstract Funding Sources* AGA Oral and Poster Presentations at DDW® 2019 AGA Institute 4930 Del Ray Avenue Bethesda, MD 20814